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ABSTRACT 
 
This thesis aims to address a major knowledge gap in understanding the epidemiology of HIV 
infection among people who inject drugs (PWID) in the Middle East and North Africa (MENA) by 
1) assessing HIV epidemic state, 2) estimating HIV epidemic potential using hepatitis C virus 
(HCV) prevalence, and 3) estimating HIV incidence and impact of interventions on incidence. 
Methods included systematic review and data synthesis, mathematical modelling, and 
ecological analysis of systematic review data.  
 
There was evidence of HIV epidemics among PWID in at least one-third of countries, most being 
emerging concentrated epidemics with HIV prevalence of about 10-15%. The overall high 
injecting risk environment suggests potential for further spread.  
 
Mathematical modelling indicated, across a range of HCV prevalence, overall acceptable 
precision in predicting endemic HIV prevalence among PWID. Ecological analysis on PWID 
MENA data also indicated a positive, statistically significant association between HCV and HIV 
endemic prevalence. Of nine MENA countries with data, five have high and three medium HIV 
epidemic potential, based on current HCV prevalence.  
 
The estimated HIV incidence rate among PWID ranged between 0.7% per person-year (ppy) and 
7.8% ppy. Further, substantial number of HIV infections in the general population were 
estimated to be due to the dynamics of injecting drug use, namely among ex-PWID and sexual 
partners of current/ex-PWID. It was predicted that scale-up of antiretroviral therapy and harm 
reduction services could avert up to 90% and 70% of incident infections among PWID and their 
sexual partners, respectively.  
 
In conclusion, this thesis identified recent emerging HIV epidemics with high HIV incidence rates 
among PWID in multiple MENA countries. A novel method for estimating HIV epidemic 
potential using current HCV prevalence was demonstrated. In MENA, further HIV epidemic 
growth among PWID is predicted in most countries. Scale-up of HIV/drug interventions is 
needed to halt the growing epidemics.  
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1. INTRODUCTION 
 
1.1. MENA DEFINITION 
 
The definition of the boundaries of the Middle East and North Africa (MENA) varies between 
different regional and international organizations. In this thesis, MENA includes countries that 
are part of the MENA definitions of all three United Nations agencies leading most HIV/AIDS 
efforts in the region; the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Eastern 
Mediterranean Region Office of the World Health Organization (WHO/EMRO), and the World 
Bank. Since the goal of this research is to impact policymaking and facilitate evidence-informed 
HIV prevention and intervention programming in the region, having an operational definition of 
MENA that falls into the mandates and catchment areas of these organizations is essential. The 
definition includes the following 23 countries that share historical, socio-cultural, or linguistic 
similarities:   
 
Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, 
Morocco, Oman, Pakistan, Qatar, Saudi Arabia, Somalia, Sudan (including South Sudan), Syria, 
Tunisia, United Arab Emirates, West Bank and Gaza (Occupied Palestinian Territories (OPT)), 
and Yemen. 
 
 
 
Figure 1.1. Map of the Middle and North Africa.  
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1.2. OVERALL AIM AND OBJECTIVES 
 
Rationale 
 
MENA is one of the region where knowledge of the HIV epidemic continues to be limited. Yet, 
based on scattered available data, the region is thought to have one of the fastest growing HIV 
epidemics despite overall low HIV prevalence [1, 2]. Much remains to be known about HIV 
epidemic dynamics in MENA, particularly among key populations at increased risk (KPs) where 
most HIV infections appear to be happening [3]. One of these KPs is people who inject drugs 
(PWID), who bear a disproportionate burden of HIV infections globally.  
 
Emerging HIV epidemics have been recently documented among men who have sex with men 
(MSM) in MENA [4]. There could be similar epidemic trends among the other KPs, namely PWID 
in a region that is at the centre of major drug production and trade routes. MENA has also a 
number of social and structural drivers of risk and vulnerability for injecting drug use and HIV 
such as a political instability, refugee population movements, a large youth population, high 
unemployment rates, and high levels of stigma and non-supportive policy responses, among 
others. Fortunately, the recent nature of the documented epidemics in the region means that 
there is a window of opportunity for prevention that should not be missed to halt the growing 
epidemics.  
 
Following investments by global donors such as the Global Fund, there has been a remarkable 
increase in the number of integrated bio-behavioural surveillance surveys (IBBSS) in MENA, 
particularly among KPs. This large volume of data that became available in the last few years is 
yet to be analysed and synthesized within a country-specific or a regional context to 
characterize the HIV epidemics in this region. A critical understanding of the status, scale, and 
epidemic potential of the epidemic in MENA is critical for evidence-informed political advocacy 
to control the epidemic and increase commitment to HIV surveillance, prevention, and 
treatment. 
 
Aims and objectives 
 
The overall aim of this thesis is to address a major gap in knowledge and understanding of the 
epidemiology of HIV infection among PWID in MENA, by assessing the status of the HIV 
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epidemic, estimating HIV epidemic potential, and estimating HIV incidence and the impact of 
interventions on HIV incidence at country-level among this population group. 
 
Specific objectives are as follows: 
 
Objective 1 
To provide a critical description of the epidemiology of HIV infection among PWID in MENA 
through a systematic review, synthesis, and analysis of biological and behavioural data. 
 
Objective 2 
To explore, through mathematical modelling, the use of hepatitis C virus (HCV) prevalence as a 
proxy biomarker of future HIV prevalence, as a novel and practical tool to estimate HIV 
epidemic potential among PWID in resource-limited settings such as MENA. 
 
Objective 3 
To analyse, through ecological analysis of systematic review data, the epidemiological 
association between HCV and HIV prevalence among PWID in MENA, and to estimate HIV 
epidemic potential in this population across MENA countries using HCV prevalence data. 
 
Objective 4 
To estimate, through mathematical modelling, at country-level in MENA: HIV incidence among 
PWID that is due to sharing non-sterile injecting equipment, HIV incidence among PWID sexual 
partners that is due to heterosexual sex with infected PWID, the role of injecting drug use as a 
driver of the HIV epidemic in the population, and the impact of select interventions on HIV 
incidence. 
  
1.3. BACKGROUND 
 
This section provides background information on the global epidemiology of injecting drug use 
and of HIV and HCV among PWID. A discussion of the epidemiological links between HIV and 
HCV infections among PWID, and an overview of HIV and HCV prevention interventions among 
PWID are provided. This section also highlights the significance of conducting this research work 
in MENA, by describing in this region: the context of risk and vulnerability, overall 
understanding of HIV epidemiology, and, briefly, the status of HIV response. 
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1.3.1. Global epidemiology of injecting drug use and associated HIV and HCV 
infection burden 
PWID are typically one of the most hidden and hard-to-reach KPs. They face criminalization, 
stigma and discrimination, and are marginalized by family members and society [5]. This makes 
population size estimates for PWID challenging to ascertain; and hence global estimates for 
injecting drugs use have wide ranges. It is estimated that there are 11-21 million PWID 
worldwide, with a middle estimate of 16 million, with China, the USA, and Russia carrying the 
largest numbers [6]. The population prevalence of injecting drug use across all countries is 
estimated at 0.36%, and ranges from 0.06% in South Asia to 1.50% in eastern Europe [6]. These 
estimates by the Reference Group to the UN on HIV and Injecting Drug Use, are based on 
extrapolations using injecting drug use estimates identified in 61 out of 148 countries where 
this practice has been documented [6, 7].   
 
Injecting drug use is a major global health issue and contributor to the global burden of disease 
due to associated morbidity and mortality, largely caused by the transmission of blood-borne 
viral infections - namely HIV and HCV - through unsafe drug injection [8]. The Reference Group 
to the UN on HIV and Injecting Drug Use estimates that about 3.0 million PWID worldwide are 
infected with HIV (range 0.8-6.6 million), leading to a global HIV prevalence of 19% among 
PWID [6]. HIV prevalence among PWID varies considerably between and within countries and 
ranges between less than 0.01% to 72% (Estonia) [6]. It is overall highest in countries of 
Southeast Asia, eastern Europe, and Latin America where it has been reported to exceed 40% 
among PWID subpopulations [6].   
 
HCV infection burden among PWID is even more substantial, due to more efficient transmission 
than HIV via the parenteral route [9]. It is estimated that about 10.0 million PWID are anti-HCV 
positive (range: 6.0-15.2 million) [10]. With the estimated 16 million PWID globally, this leads to 
an HCV prevalence of 63% among PWID [10]. Out of 77 countries with HCV prevalence data 
among PWID, anti-HCV prevalence is in the range of 60-80% in 25 countries, and over 80% in 12 
countries [10]. It is reported lowest in Paraguay at 10% and highest in Mexico at 97% [10]. 
 
1.3.2. HIV and HCV epidemiological links among PWID 
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Because HIV and HCV are transmitted along the same parenteral route among PWID, they often 
co-infect the same individuals. HCV is however 4-10 times more transmissible per percutaneous 
injection than HIV [11-14], and therefore is usually acquired before HIV at the individual level. 
This also explains why HCV prevalence among PWID is larger than HIV prevalence, and why HCV 
is hyperendemic among PWID globally but HIV is not [6, 10]. A recent meta-analysis identified 
that 82% of HIV-infected PWID globally are co-infected with HCV [15]. HIV-positive PWID were 
found to have a six-time increased odds of HCV infection compared with HIV-negative PWID 
[15], a finding consistent with the fact that both infections are caused by the same injecting risk 
behaviour. Although HIV and, in specific situations [16], HCV can be transmitted sexually, 
sharing of needles/syringes is their main transmission mode among PWID [17].   
 
1.3.3. Overview of prevention interventions among PWID 
 
A number of prevention interventions have proven to be successful in curbing HIV transmission 
among PWID [18]. Harm reduction strategies include primarily the provision of sterile injecting 
equipment through needle and syringe programmes (NSP), and opioid substitution therapy 
(OST) - the supervised administration of psychoactive medications that aim at reducing opioid 
dependence and withdrawal symptoms [19]. Recent systematic reviews and meta-analyses 
have documented a reduction in HIV transmission by up to 58% associated with exposure to 
NSP [20] and by 54% to OST [21]. OST was also associated with improved ART-related outcomes 
(recruitment onto ART, ART coverage and adherence, and viral suppression) among PWID living 
with HIV [19].  
 
Evidence on the prevention benefit of ART in reducing HIV parenteral transmission among PWID 
appears to be confined to one cohort study in Vancouver where a temporal association was 
observed between PWID community viral load and reduced HIV incidence [22]. However, ART 
has been proven to reduce heterosexual HIV transmission by up to 96% due to decreased viral 
load [23, 24], and recent evidence suggested also prevention benefit among MSM [25]. It is 
therefore plausible and likely that ART could similarly reduce HIV parenteral transmission 
through the same biological mechanism.  
 
While unsafe injection is the main mode of HIV transmission among PWID, sexual transmission 
can occur and might not be insignificant among specific sub-populations of PWID who are also 
MSM or FSWs [26, 27]. Therefore, ART, coupled with sexual-risk reduction strategies including 
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condom provision and education, play a role in reducing sexual HIV transmission among PWID, 
and also, importantly, transmission to their non-injecting sexual partners [18, 28].    
 
Each of these prevention interventions, however, may achieve modest reductions in HIV 
transmission if implemented alone. The evidence indicates that efficient strategies for 
prevention of HIV infections in PWID need comprehensive packages and combined approaches, 
in addition to high coverage, especially in settings with high prevalence and substantial levels of 
risk behaviour [18, 19, 28, 29]. Such comprehensive approaches would include NSP, OST, 
voluntary counselling and testing, ART, prevention of sexually transmitted infections, education 
programs, in addition to hepatitis diagnosis and treatment [28]. 
 
Although the use of ART for pre-exposure prophylaxis was significantly associated with a 49% 
reduction in HIV incidence among PWID in a randomised, double-blind, placebo-controlled trial 
[30], more research is needed to establish, not only effectiveness, but also strategies for large-
scale implementation of this intervention among PWID [30]. Currently, pre-exposure 
prophylaxis is not included as part of WHO’s recommendations of HIV prevention packages 
among PWID [31]. 
 
While reduction of HCV transmission is also expected with harm reduction services in view of 
the associated reduction in injecting risk behaviour, there is overall insufficient evidence of 
these services impact on HCV incidence [32]. However, recent epidemiological and 
mathematical modeling analyses have suggested that high coverage NSP and OST can reduce 
HCV incidence and prevalence, especially if in combination [33, 34]. These reductions, 
nevertheless, are overall modest in scale and would require a long time to materialize, mainly 
due to high background HCV prevalence among most PWID populations globally [33]. 
Combining harm reduction services with current HCV treatment were shown to enhance their 
impact [35], and potentially more so with the new direct-acting antivirals to treat HCV [36].  
 
Despite the prevention benefits of harm reduction services among PWID, coverage remains 
insufficient globally. In 2014, NSP and OST were implemented respectively in about half of all 
countries where injecting drug use has been documented [37]. Generally, coverage is lower in 
low- and middle-income countries, though it varies widely among and within regions and 
countries [37]. Between 2012 and 2014, the greatest increase in NSP provision was seen in 
Malaysia, Iran, and Australia, while the most striking scale-up of OST was implemented in 
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Vietnam [37]. A decrease in provision of services was seen in a few countries including Pakistan 
and Oman, two MENA countries [37].  
 
1.3.4. Context of risk and vulnerability in MENA 
 
Similar to other regions, MENA has several vulnerability factors for HIV. Overall, the social 
determinants of health in terms of political conflict, limited resources, and gender inequity 
continue to challenge the region [38]. Youth constitute a major proportion of MENA 
populations, with one-fifth of the population aged 15-24 years [39, 40], normally the age of 
sexual debut [40]. It is estimated that in 2015, the average median age across the 23 MENA 
countries was 24.0 years [41]. The recent Arab spring revealed the frustrations and challenges 
youth are experiencing, including high unemployment rates, widening gap between rising 
aspirations with mass education and lack of political reforms, poverty, and oppression.  
 
MENA has the highest number of refugees and internally displaced persons in the world [42]. In 
2015, over half of refugees worldwide came from three MENA countries (Syria, Afghanistan, 
and Somalia), and 39% of the world’s displaced people were hosted by MENA countries [42]. 
The Arab Middle East has received more than 10% of the world’s migrants [43]. The 
overwhelming majority of these are males, and about half are single or without their spouses 
[44, 45], and therefore may be vulnerable to practices that increase the risk of exposure to HIV 
[46]. 
 
Denial that HIV exists in society or is an important challenge remains widespread. KPs including 
PWID, MSM, and female sex workers (FSWs) are highly stigmatized and lack access to 
comprehensive and confidential services. Despite the emergence of community organizations 
serving vulnerable groups, their efforts are in most instances not well coordinated and remain 
insufficient to meet current needs. Health promotion approaches remain didactic, prescriptive, 
largely non-participatory, and divorced from behavioural theory. 
 
PWID are one of the central KPs in MENA, a region with several vulnerability factors for 
injecting drug use. For example, 83% of the global supply of heroin is produced in Afghanistan 
[47], and over 75% of this is trafficked through Iran and Pakistan, which contributed to opioids 
dependence epidemics in these neighbouring countries [48]. In 2014, Iran bore the highest 
fraction of the global opium and heroin seizures (75% and 17%, respectively) [49]. Increased 
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availability and purity of heroin at lower prices in MENA appears to have led to a subsequent 
rise in injecting drug use [50]. In 2010, one gram of heroin in Afghanistan could be purchased 
for about US$4 compared with up to US$100 in West and Central Europe, US$200 in the United 
States and Northern Europe, and US$370 in Australia [47]. The pattern of heroin dependence 
epidemics fuelling heroin injection epidemics; in turn fuelling HIV epidemics among IDUs, has 
been previously documented in settings with a similar risk environment of drug production, 
trafficking, and use such as Uzbekistan, Tajikistan, and European Russia [50]. 
 
The region has also several vulnerability factors for sexual risk behaviour. Within prevailing 
socio-economic conditions, it has been difficult for youth to start sanctioned sexual activity, and 
the age at first marriage has increased in most countries by as much as 8 years in 20 years [51]. 
There appears to be an ongoing socio-cultural transition in multiple countries leading to 
increased tolerance of practices such as premarital and extramarital sex [52]. This is 
accompanied by accelerated modernization - including mass education and urbanization, 
exposure to different cultures, and enhanced communication and technology means [52-54].  
 
1.3.5. Understanding of HIV epidemiology in MENA 
 
MENA is one of the regions where knowledge of the HIV epidemic continues to be limited, and 
there is a widespread belief that the region is “a real hole in terms of HIV/AIDS epidemiological 
data” [55]. When this thesis was planned, UNAIDS stated in their 2010 Global Report that “data 
on the epidemics in MENA remain in short supply” [1], and that the available data suggest that 
despite overall low HIV prevalence, MENA is one of the regions with the fastest growing HIV 
epidemic [1, 2]. They estimated that the number of new infections and AIDS-related deaths in 
their definition of MENA (excluding Afghanistan and Pakistan) increased by almost two-folds 
between 2001 and 2010 when they reached  84,000 and 39,000 people respectively [2]. More 
recently, MENA was found to be one of the few regions where the number of new HIV 
infections increased between 2010 and 2015; and the vast majority of these infections seemed 
to be happening among KPs and their sexual partners [3]. 
 
The apparent lack of data has stimulated an intense debate on the status of the epidemic in 
MENA [56]. One viewpoint, prominent in the earlier years of the epidemic, was that the region 
is protected from HIV because of its conservative socio-cultural traditions, including strong 
prohibitions against premarital and extramarital sex, homosexuality, and alcohol and drug use 
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[57, 58]. This perhaps has incited a radically opposing view that considered “cultural immunity” 
a form of denial of a major public health crisis “behind the veil”, predicting a severe health 
burden and mortality among the 15 to 49 year age group if immediate action was not taken [59, 
60]. In truth, much of these assumptions seemed to be fuelled by preconceived notions and 
none were substantiated by scientific evidence [56].  
 
This thesis work comes in the context of a large effort to provide a scientific and data-driven 
characterization of HIV epidemiology in MENA. As part of this endeavour, an earlier in-depth 
study was conducted among MSM in the region [4]. This systematic review and data synthesis 
documented for the first time emerging HIV epidemics among MSM in about half of MENA 
countries, with a risk environment suggesting potential for further spread [4]. These findings 
further motivated the need for detailed and in-depth analyses for a better understanding of the 
HIV epidemic and HIV transmission patterns among the other KPs, including PWID, and to 
assess the drivers of HIV incidence in this region.  
 
1.3.6. Context of HIV response in MENA 
 
The timid leadership and political commitment to address the sensitive HIV issue remain an 
important challenge in the region. After years of denial that HIV exists in MENA, there is an 
increasing recognition in the public sphere that HIV is a domestic public health concern [61]. 
Nevertheless, most HIV programming efforts are small-scale, not well coordinated, and 
insufficient to meet current needs. With a median antiretroviral therapy (ART) coverage of 17%, 
MENA has the lowest ART coverage of all regions globally [62]. Also, HIV response among KPs is 
still largely the province of non-governmental organizations (NGOs) [63]. Political leaders are 
often reluctant to even acknowledge the existence of KPs. PWID, MSM, and FSWs continue to 
be stigmatised and lack access to comprehensive and confidential services [63, 64]. While it is 
widely perceived that political and socio-cultural sensitivities are behind this lagging response, 
in truth political leaders are not confronted with concrete data to warrant a sense of urgency to 
address the epidemic. The low HIV prevalence observed among blood donors and other select 
general population samples is feeding a culture of complacency towards the epidemic [63, 64]. 
Most prevention and health promotion efforts remain didactic and geared to the general 
population, rather than the populations most affected.  
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The findings of this research work will provide a scientific assessment of the status, scale, and 
epidemic potential of the HIV epidemic among PWID in MENA, and accordingly will inform HIV 
policy and programming in the region. 
 
1.4. THESIS STRUCTURE AND RESEARCH PAPERS OUTLINE 
 
This thesis follows the research paper style and has resulted in five research papers. Four of 
these papers have been published, while one is nearly ready to be submitted for publication. 
Each research paper constitutes an independent chapter, or is incorporated into a broader 
chapter. Published papers are included in their published formats, which inevitably results in 
some inconsistencies in formatting, referencing style, and terminology. Research papers are 
supplemented as appropriate by additional material to provide further methodological 
information, results, and linking material with other chapters. In most cases, additional 
methodology details and results pertaining to research papers were published as part of 
extensive supplementary online material, and they are included as such, in their published 
format. The supplementary online material of each research paper is included in a separate 
Appendix to this thesis. 
 
Each research paper includes its own list of references within its corresponding chapter, while 
references pertaining to all other material in the body of the thesis (excluding appendices) are 
included together at the end of the thesis. Files in the appendices include their own references 
each.  
 
The thesis structure is as follows: 
 
Chapter 2 corresponds to Research paper 1, which was published in PLoS Medicine. This paper 
provides a first time in-depth characterization of the state of the HIV epidemic among PWID 
across MENA countries, through a comprehensive systematic review and data synthesis 
(objective 1). This paper is a basis for the subsequent research papers. The emerging HIV 
epidemics and the high injecting risk environment it identified motivated the need to estimate 
HIV epidemic potential (research papers 2 & 3) and how interventions could halt the growing 
epidemics (research paper 4). It also provided the epidemiological data to conduct the 
ecological analysis for the HCV-HIV association (research paper 3), and provided the MENA-
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specific data needed to parameterize the HIV incidence study using mathematical modelling 
(research paper 4).   
 
Chapter 3 corresponds to Research paper 2, which was published in BMC Public Health. This is a 
mathematical modelling study that theoretically explores the association between HCV and HIV 
among PWID, and provides the foundation for the concept of using HCV as proxy biomarker of 
future HIV epidemic spread (objective 2). The main importance of this study is that it provides a 
practical tool to predict the future size of HIV epidemics using existing data (HCV prevalence). 
This has important policy-implications as it can inform prioritization and resource allocation for 
prevention interventions, which is especially valuable in resource-limited settings such as most 
of MENA. 
 
Chapter 4 corresponds to Research paper 3, which was published in AIDS. This chapter includes 
an applied epidemiological analysis of the concept of using HCV as proxy for future HIV 
epidemic spread demonstrated in Chapter 3. The study is an ecological analysis of the HCV-HIV 
association in PWID using the epidemiological data extracted in research paper 1. This 
association is then applied in MENA to predict HIV epidemic potential among PWID at country-
level using current HCV prevalence (objective 3).  
 
Chapter 5 corresponds to Research paper 4, which is nearly ready to be submitted for 
publication at the Journal of the International AIDS Society (JIAS). This is a mathematical 
modelling study that estimates, at country-level in MENA, HIV incidence that is due to injecting 
drug use (objective 4). The study not only provides estimates of HIV incidence among PWID, but 
also delineates the role of injecting drug use as a driver of HIV infection in the wider population, 
namely through history of past injection and onward transmission to sexual partners. It also 
estimates impact of select interventions on HIV incidence. Quantifying HIV incidence among 
PWID in MENA is timely and warranted, as it provides baseline data to track progress towards 
the global and regional targets of reducing the number of new HIV infections, as part of UNAIDS 
90-90-90 scheme [65].    
 
Finally, Chapter 6 summarizes the findings of the previous chapters, describes their implications 
for HIV/drug use policy and programming, and makes recommendations for future research. 
This chapter includes Research paper 5, which provides a high-level summary of HIV and HCV 
epidemiology among PWID in MENA, with a focus on the response and ways to move forward in 
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the context of the thesis findings. This paper is an invited, peer-reviewed, viewpoint that was 
published in the Journal of the International AIDS Society (JIAS) on the occasion of the World 
Hepatitis Day - July 28, 2015. 
 
1.5. ROLE OF CANDIDATE  
 
The research work undertaken as part of this thesis falls under the MENA HIV/AIDS 
Epidemiology Synthesis Project [63] which was funded in its initial phase by the World Bank, 
WHO, and UNAIDS, and, in its subsequent phases, by the Qatar National Research Fund (NPRP 
04-924-3-251 and NPRP 9-040-3-008). The MENA HIV/AIDS Epidemiology Synthesis Project was 
conceptualized, proposed, and awarded to my co-supervisor on the thesis, Dr. Laith Abu-
Raddad. I was the lead scientist working on the sub-project that addresses HIV epidemiology 
among PWID in MENA, and which led to this thesis.  
 
I am first and corresponding author on all research papers in the thesis. For all papers, I co-
conceptualized the studies, conducted the vast majority of the analyses, wrote the first draft, 
and revised and finalised the paper based on feedback from co-authors.   
 
I wrote the protocol of the systematic review (Research paper 1), devised the search criteria 
(guided by colleagues), conducted database searches, screened all titles and full-texts, 
extracted data on a computerized database, devised the quality assessment methodology, and 
analysed the data.   
 
Research papers 2 and 4 include co-authors who provided technical assistance in Matlab codes 
pertaining to the mathematical modelling. Research paper 2 includes a co-first author who 
conducted all the Matlab coding in this study that has a complex dynamical mathematical 
model. I led the conceptualization of the plan of analysis and interpretation of findings, and 
along with the co-first author, conducted the analyses. In Research paper 4, I coded the 
mathematical model and conducted all analyses, while receiving technical programming 
assistance from a co-author who helped me solve some of the coding issues.  
  
I conducted all the statistical analyses in Research paper 3. The mathematical modelling used in 
the conceptual framework of this study is based on the same model used in Research paper 2 
and hence was developed and coded by my co-authors.  
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Part of the research work undertaken in this thesis was conducted in partnership with the 
WHO, UNAIDS, and the World Bank. These organizations were co-authors on two of the 
research papers (Research papers 1 & 4) where they provided or facilitated access to key data, 
access to which is otherwise difficult. They facilitated communication with national 
stakeholders and provided strategic data and information pertaining to HIV epidemiology and 
response in the region.  
 
Further details on my contribution and the role of all co-authors are described in the research 
papers.  
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2. HIV EPIDEMIOLOGY AMONG PWID IN MENA 
 
2.1. INTRODUCTION 
 
This chapter aims to provide a critical and systematic assessment of the status of the HIV 
epidemic among PWID at country-level in MENA. The rationale for this study came from signs of 
a growing HIV infection burden, in particular among MSM where emerging HIV epidemics were 
recently documented [4], in a region with several vulnerability factors for HIV and injecting drug 
use, and where scientific evidence was critically needed to inform an overall limited and non-
supportive policy response.   
 
This aim was addressed by conducting a systematic review and data synthesis of all available 
PWID-related data in the region. The study analysed all aspects of HIV epidemiology among 
PWID to draw a comprehensive understanding of the status of the HIV epidemic in each country 
and in the region as a whole. These aspects included the prevalence of injecting drug use; HIV 
prevalence level, trend, geographical distribution, and quality of data; HIV incidence; injecting 
and sexual risk behaviour; mixing with other KPs; and prevalence of proxy biomarkers of risk.   
 
2.2. EPIDEMIC STATE CLASSIFICATION 
 
This section provides details on the approach used for the HIV epidemic state assessment and 
classification, which was described briefly in the published manuscript. Based on the extent of 
HIV transmission and prevalence in the different population groups in a given country/setting, 
HIV epidemics can be classified into three different states: low-level, concentrated, and 
generalised - a classification devised by UNAIDS/WHO to guide surveillance and policy-making 
at country level [66].  
 
In low-level HIV epidemics, HIV has not spread to significant levels in any sub-population 
including KPs. In concentrated HIV epidemics, HIV transmission has taken roots in one or more 
KPs but HIV is rarely transmitted outside of these KPs and their sexual partners. In generalized 
HIV epidemics, HIV is established in the general population where there is sustainable HIV 
transmission [66].  
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I adapted the HIV epidemic state definitions devised by UNAIDS/WHO and applied them to 
describe the epidemic level in PWID. In addition to the “low level” and “concentrated” states, I 
added a third category, “at least outbreak-type”, to describe a pattern of HIV transmission 
where the level of evidence is not sufficient to categorize the epidemic into either of the low-
level or concentrated epidemic states, but there is evidence for tangible transmission. The 
classification and definitions of the different epidemic states among PWID are in Figure 2.1 and 
Table 1, and can be visualized on the epidemic curve of a prototype KP in Figure 2.2.  
 
 
 
 
Figure 2.1. Flow chart of the classification of HIV epidemic states among people who inject 
drugs in the Middle East and North Africa. 
  
HIV epidemic state among PWID in a 
specified country or setting 
Low-level Epidemic  
Emerging Established  Saturated 
Concentrated Epidemic At least outbreak-type  
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Table 2.1. HIV epidemic states definitions among people who inject drugs. 
Low-level HIV epidemic among PWID 
Definition: Based on the extent of available evidence, HIV has not reached considerable 
levels among PWID. In a low-level epidemic, HIV may not have been introduced to the PWID 
population, may have been recently introduced, or may have been spreading for some time 
but slowly and inefficiently. The latter may reflect infrequent and few repeated transmission 
contacts among members of the PWID population to sustain higher HIV prevalence, or could 
be a consequence of stochastic effects where the small number of individuals who 
introduced HIV to the population happened by chance not to have transmission links that 
can sustain large transmission chains. 
 
Concentrated HIV epidemic among PWID 
Definition: Based on the extent of available evidence, HIV has reached considerable levels 
and taken root among PWID through transmission chains between members of this 
population. With no sufficient behaviour changes or introduction of interventions, HIV 
transmission among members of PWID will continue to take place.  
 
Concentrated epidemics can be further categorised into the following categories based on 
trends of HIV prevalence: 
 
Emerging epidemic: HIV started its initial growth among this HRP and continues in a trend of 
increasing HIV prevalence. 
 
Saturated epidemic: The emerging epidemic has reached its peak and HIV prevalence is 
stabilizing towards its endemic level. 
 
Established epidemic: The saturated epidemic has reached endemic equilibrium. 
 
“At least outbreak-type” transmission among PWID 
Definition: Applies to settings where we do not have enough evidence to support a 
concentrated epidemic, but there is some evidence, usually of lower quality, which suggests 
that considerable HIV transmission has occurred, or is occurring, among at least some 
groups of the PWID population. 
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Figure 2.2. HIV epidemic states in a prototype key population at increased risk. 
Note: Simulation produced using a stochastic compartmental model [67] 
 
In classifying the HIV epidemics among PWID at country-level in MENA, I followed most recent 
UNAIDS/WHO guidelines where the proxy threshold defining the different epidemic states (such 
as the 5% defining a concentrated epidemic) have been discarded [66, 68]. The change was 
because use of these thresholds caused confusion in interpreting surveillance findings, 
especially when considered as rigid and conclusive thresholds [66]. Instead, under an updated 
“know your epidemic” approach, the assessment of the status of the epidemic was based on 
rigorously grounded epidemiological syntheses and an understanding of transmission dynamics, 
rather than “arbitrary” prevalence thresholds [68, 69]. This approach takes into consideration 
that each country has a unique epidemic (or epidemics) and that the epidemic might differ 
within sub-populations and between geographical areas within a given country [68, 69]. Figure 
2.3 describes the triangulation approach used where multiple lines of evidence were 
synthesized side by side to assess HIV epidemic state among PWID at country-level in MENA. 
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Figure 2.3. Data synthesis of the multiple lines of evidence for characterizing the status of the 
HIV epidemic among people who inject drugs in the Middle East and North Africa. 
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2.3. RESEARCH PAPER 1 – SYSTEMATIC REVIEW AND DATA SYNTHESIS 
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2.4. SUPPLEMENTARY ONLINE MATERIAL OUTLINE 
 
The following is the outline of the supplementary online material as cited in Research paper 1. 
The corresponding files are found in Appendix A. 
 
Text S1. PRISMA checklist 
Text S2. Search criteria 
Text S3. Narrative justification for quality of the evidence and status of the epidemic at 
the country level 
Table S1. Precision and risk of bias of individual HIV prevalence measures among people 
who inject drugs in the Middle East and North Africa as extracted from eligible 
reports 
Table S2. Summary of precision and risk of bias of HIV prevalence measures as extracted 
from eligible reports 
Table S3. Subnational estimates of the number and prevalence of people who inject drugs 
in the Middle East and North Africa 
Table S4. HIV point-prevalence measures among people who inject drugs as extracted 
from various databases including the US Census Bureau database, the 
WHO/EMRO testing database, the UNAIDS epidemiological fact sheets 
databases, and other sources of data with unidentified reports 
Table S5. Measures of injecting risk behaviour among people who inject drugs in the 
Middle East and North Africa 
Table S6. Measures of sexual risk behaviour and sexually transmitted infections 
prevalence among people who inject drugs in the Middle East and North Africa 
Table S7. HIV/AIDS knowledge, perception of risk, and HIV testing among people who 
inject drugs in the Middle East and North Africa 
 
 
  
 66 
 
2.5. SUMMARY OF FINDINGS  
 
This study identified a large volume of HIV-related biological and behavioural data among 
PWID, including quality IBBSS in multiple countries. The population proportion of injecting drug 
use in MENA was found to be comparable to global figures. There is evidence for HIV epidemics 
among PWID in one third of countries, most of which are concentrated emerging HIV epidemics 
that emerged in the last decade. Iran is the only country where there is conclusive evidence for 
an established HIV epidemic at a national level. The status of the HIV epidemics is unknown in 
about half of countries, and the lack of sufficient evidence does not preclude the possibility of 
hidden epidemics among PWID in these settings. The high injecting and sexual risk behaviour 
environment suggests potential for further HIV spread among PWID. There is also overlap of 
risk behaviour between PWID and the other KPs which facilitates bridging of the HIV epidemic 
from one KP to the other, as has happened in Pakistan and possibly in Egypt. Since most HIV 
epidemics among PWID in MENA are nascent, there is a window of opportunity for prevention. 
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3. HCV AS A PREDCITOR OF HIV EPIDEMIC POTENTIAL AMONG PWID: 
THEORETICAL UNDERPINNINGS                           
 
3.1. INTRODUCTION 
 
Chapter 2 documented a pattern of nascent HIV epidemics and a high risk environment among 
PWID in several MENA countries. Considerable overlap of risk behaviour with other KPs, such as 
MSM, who may be experiencing HIV epidemics was also documented. All these findings suggest 
that there could be further HIV spread in these settings. Also, in many countries with 
insufficient data to characterize HIV epidemic state, there could be undetected HIV 
transmission and similar epidemic patterns. Sharp increases in HIV prevalence among PWID 
over short periods of time have been observed in the region, such as in Pakistan [70], testifying 
to the prevailing high risk environment and high HIV epidemic potential. 
 
These findings highlighted the necessity to identify settings in the region that are at high risk of 
future HIV spread and potentially large HIV epidemics among their PWID populations. Most 
MENA countries, however, have limited resources for conducting repeated surveys to track the 
course of the HIV epidemic. Also, in a context of emerging, and at times rapidly growing, 
epidemics, time is an important factor for consideration. For example, in Egypt, the first round 
of IBBSS was conducted in 2006 and found very little HIV transmission among PWID (1% 
prevalence) [71, 72]. It was only until 2010 that the second round was implemented, by which 
time HIV prevalence among PWID had reached over 7% [73]. Relying on existing sources of data 
to predict the future spread of HIV is a cost-effective and practical way to prioritize PWID 
populations for HIV prevention and treatment, and to inform policy and resource allocation. 
One of these existing sources of data is HCV prevalence data. HCV infection is transmitted 
among PWID along the same parenteral route, and could be used as a proxy biomarker of 
injecting risk behaviour and, hence, of future HIV spread. 
 
In this chapter, mathematical modelling is used to theoretically explore the association 
between HCV and HIV infections among PWID and to demonstrate whether HCV could be used 
as a predictor of future HIV epidemic spread. This chapter lays the theoretical foundation for 
the application of this concept among PWID in MENA (Chapter 4). 
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3.2. RESEARCH PAPER 2 - MATHEMATICAL MODELLING STUDY 
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3.3. SUPPLEMENTARY ONLINE MATERIAL OUTLINE 
 
The following is the outline of the supplementary online material as cited in Research paper 2. 
The corresponding files are found in Appendix B. 
 
Additional file 1. Mathematical models description 
Additional file 2. Models assumptions in terms of parameter values 
Additional file 3. Trend of HIV prevalence among PWID in Iran as described by available 
HIV point-prevalence measures 1990-2013 
Additional file 4. Effect of stochasticity (purple) and of behavioural (blue) and biological 
(red) uncertainty on the modeling predictions of the endemic HIV 
prevalence, /HCV HIVRR  and /HCV HIVOR  at 59.4% HCV prevalence in Iran 
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3.4. SUMMARY OF FINDINGS  
 
This study characterized the poorly-understood association between HCV and HIV infections 
among PWID. HCV was found to be eight times more transmissible per shared injection than 
HIV. There is a threshold HCV prevalence of 29% below which HIV is not sustainable in a PWID 
population (HIV prevalence <1%). There is also a threshold HCV prevalence of 47% needed to 
sustain a concentrated HIV epidemic among PWID (HIV prevalence >5%). Both HCV thresholds 
for sustainable and concentrated HIV epidemics are largely insensitive to the details of injecting 
risk behaviour, except near extreme values of some behavioural attributes. 
 
The association between HCV and HIV prevalence at endemic equilibrium is characterized with 
six dynamical regimes which define the nature and magnitude of the association between HCV 
and HIV prevalence. Existing HCV prevalence levels in a PWID population can predict future 
endemic HIV prevalence, and HIV predictions across a wide range of HCV prevalence are overall 
robust with respect to behavioural uncertainty. HCV acts like a temperature scale of the level of 
risk behaviour in an injecting network and can be used as an index to measure the risk and 
severity of potential HIV epidemics among PWID. 
  
This study offers a simple applied tool for policy makers and program officers to make 
predictions for HIV epidemic potential in PWID populations using existing HCV prevalence 
levels. Although the priority for public health programs should be settings already at high HIV 
prevalence, this method helps in prioritizing PWID populations that are likely to experience such 
HIV infection spread before it actually happens.  
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4. HCV AS A PREDCITOR OF HIV EPIDEMIC POTENTIAL AMONG PWID: 
APPLIED ECOLOGICAL ANALYSIS IN MENA 
 
4.1. INTRODUCTION 
 
After the concept of using HCV prevalence as a predictor of future endemic HIV prevalence was 
theoretically demonstrated in Chapter 3, Chapter 4 follows with an epidemiological application 
of this concept in MENA. In this study, the paired HCV-HIV epidemiological data (that is HCV and 
HIV prevalence on the same PWID population) extracted from Chapter 2 systematic review are 
used to analyse and quantify the association between HCV and HIV prevalence at endemic 
equilibrium. This association is then used to make predictions of HIV epidemic potential among 
PWID at country-level, based on existing HCV prevalence levels.  
 
Chapter 2 documented relatively high levels of sharing needles/syringes among PWID in MENA 
which suggest that there could be room for further HIV spread, especially that the observed HIV 
epidemics are for the most part probably in their early phase. However, measures of injecting 
risk behaviour could be subject to reporting bias, whether under-reporting or over-reporting. 
Also injecting risk behaviour is a complex phenomenon that encompasses factors that are 
beyond simple measures of needles sharing, such as patterns of partnership formation and 
heterogeneity in levels of risk and mixing. The levels of these risks are in large part dictated by 
network structure [74-77], which is not easy to capture, measure, or quantify. For these 
reasons, the behavioural data need to be complemented by other more objective biological 
measures, such as HCV infection, which reflect levels of injecting risk behaviour, and also can be 
used as summary proxy measures to indicate HIV epidemic potential.  
 
In this chapter, we complement our epidemiological understanding of the injecting risk 
behaviour environment in MENA, by using measured levels of HCV prevalence to make 
quantitative (estimate HIV prevalence at endemic equilibrium) and qualitative (classify HIV 
epidemic growth relative to current levels) estimations of HIV epidemic potential among PWID 
at country-level in MENA. 
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4.2. RESEARCH PAPER 3 – ECOLOGICAL ANALYSIS 
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4.3. SUPPLEMENTARY ONLINE MATERIAL OUTLINE 
 
The following is the outline of the supplementary online material as cited in Research paper 3. 
The corresponding files are found in Appendix C. 
 
Table S1. HIV epidemic states among people who inject drugs in select Middle 
East and North Africa countries with sufficient data to explore the 
HCV-HIV association 
Table S2. Summary of the 54 paired HCV-HIV prevalence data among people 
who inject drugs in the Middle East and North Africa 
Figure S1. Forest plot for the meta-analysis of the risk ratio of HCV to HIV 
prevalence among people who inject drugs in Middle East and North 
Africa settings of low-level HIV epidemics 
Figure S2. Forest plot for the meta-analysis of the risk ratio of HCV to HIV 
prevalence among people who inject drugs in Middle East and North 
Africa settings of emerging HIV epidemics 
Figure S1. Forest plot for the meta-analysis of the risk ratio of HCV to HIV 
prevalence among people who inject drugs in Middle East and North 
Africa settings of established HIV epidemics 
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4.4. SUMMARY OF FINDINGS 
 
This ecological analysis in MENA supports the theoretical findings of Chapter 3, whereby HCV 
prevalence was a significant predictor of HIV prevalence in settings where the HIV epidemic is 
established and therefore where both HCV and HIV infections are at endemic equilibrium. Our 
analyses in MENA suggest that HIV prevalence will reach, at endemic equilibrium, about one 
third of HCV prevalence in a given PWID population where HIV is introduced. Using this 
association, it is predicted that there will be further HIV epidemic growth among PWID in 
several MENA countries, based on existing HCV prevalence levels. Out of nine MENA countries 
with HCV prevalence data among PWID, five have high HIV epidemic potential, three have 
medium HIV epidemic potential, and one has low HIV epidemic potential. Settings with limited 
current HIV transmission among PWID, but where further HIV epidemic expansion is predicted, 
should be prioritized for HIV/drug use prevention interventions, alongside settings with already 
large HIV PWID epidemics.  
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5. HIV INCIDENCE AMONG PWID IN MENA 
 
5.1. INTRODUCTION  
 
Chapter 2 documented emerging HIV epidemics among PWID in several MENA countries, some 
of which are already at high prevalence exceeding 10-15%. The potential for larger HIV 
epidemics in these countries was predicted using HCV prevalence levels which suggest high 
levels of sharing and connectivity of injecting networks (Chapter 3). Considerable HIV epidemic 
potential was also predicted in several countries where the HIV PWID epidemic is currently at 
low-level or of unknown status (Chapter 3).  
 
All of these findings suggest that there is or could be substantial incidence occurring among 
PWID in MENA, and that, if appropriate interventions are not implemented, the region may 
witness large HIV epidemics among PWID. This is even more of a concern in a region where the 
HIV response to the growing HIV epidemics among PWID lags far behind other regions and 
behind current needs [78]. ART coverage levels in MENA are the lowest in the world and the 
HIV treatment cascade among PWID suggest even lower ART coverage and retention in care 
than in all those living with HIV [62]. In a region where the HIV epidemic appears to be strongly 
driven by injecting drug use, reducing incidence among this pivotal population group is essential 
to reach the Fast-Track target of reducing the number of new infections by 75% in MENA by 
2020 [65]. 
 
In this study, mathematical modeling is used to estimate HIV incidence among PWID in MENA 
countries and the impact of interventions on incidence. The study further explores the role of 
injecting drug use as a driver of HIV incidence in the wider population, mainly through onward 
transmission to sexual partners. 
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5.2. UPDATED RISK GROUP SIZE ESTIMATES AND HIV IBBSS PREVALENCE DATA 
 
The mathematical model used in this chapter was parameterized mainly using country-specific 
bio-behavioural data extracted as part of the systematic review of PWID in MENA conducted in 
Chapter 2. 
 
The size of the PWID population and HIV prevalence among PWID at country-level are two 
central parameters in the estimations of HIV incidence in this study. To check whether any 
important new data were generated after my systematic review was conducted, the evidence 
on these two measures were updated with recent data, as provided by partner international 
organizations and national country-level collaborators and stakeholders conducting/overseeing 
main mapping studies and IBBSS in the region.  
 
A number of PWID risk group size estimates were performed in several countries of the region 
since research paper 1 was published. These estimates were compiled and provided by WHO-
EMRO [79]. In total, there were ten new estimates of the number of PWID in the following 
countries: Afghanistan, Bahrain, Egypt, Kuwait, Lebanon, Morocco, Pakistan, Syria, and Tunisia.  
Table 5.1 below is an updated version of Table 2 in research paper 1. It summarizes available 
national estimates of the number of PWID in MENA countries. The table also includes updated 
estimates of the total adult population in each country (for the year 2015 versus 2010 in the 
publication of research paper 1).  
 
In this study, HIV incidence was conducted in countries with epidemiological evidence indicating 
HIV prevalence greater than 1%. At the time that estimations were conducted, no new (since 
Research paper 1 was published) IBBSS were conducted among PWID and that found HIV 
infections among PWID. HIV prevalence data as published in Research paper 1 was therefore 
used in parameterizing the model.  
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Table 5.1. Updated national estimates of the number and prevalence of people who inject 
drugs in the Middle East and North Africa. 
  PWID estimate (number)   
Country Population  
15-64 years [41] 
Low Middle High 
Year of 
estimate 
Source 
Afghanistan 17,398,120 22,720 34,080 45,440 * [80] 
  6,870 6,900 6,930 2005 [6] 
  18,000 20,000 23,000 2009 [81] 
     2009 [82] 
  1,465 17,640 23,000 2012 [79] 
Algeria 25,990,793 26,333 40,961 55,590 * [80] 
Bahrain 1,048,273 337 674 1,011 * [80] 
   3,200 30,000 2006 [79] 
Djibouti 560,045 -- -- -- -- -- 
Egypt 56,386,786 56,970 88,618 120,265 * [80] 
  86,000 93,000 119,000 2014 [79] 
Iran 56,428,180 70,000 185,000 300,000 * [80] 
   180,000  2004 [6] 
   250,000  2007 [83] 
Iraq 20,382,898 23,115 34,673 46,230 * [80] 
Jordan 4,609,030 3,200 4,850 6,500 * [80] 
Kuwait 2,946,556 2,700 4,100 5,500 * [80] 
   4,000 12,000 2014 [79] 
Lebanon 3,970,975 2,200 3,300 4,400 * [80] 
  812 3,114 5,416 2015 [79] 
Libya 4,120,317 4,633 7,206 9,779 * [80] 
   1,685  2001 [6] 
Morocco 22,898,757  18,500  * [80] 
   18,000  2011 [79] 
   3,000  2013 [84] 
Oman 3,453,143 2,800 4,250 5,700 * [80] 
OPT 2,652,509 1,200 1,850 2,500 * [80] 
Pakistan 114,295,357 54,000 462,000 870,000 * [80] 
  125,000 130,460 150,000 2006 [6] 
   102,042  2006 [85] 
   99,000  2010 [83] 
   104,804  2011 [79] 
Qatar 1,861,947 780 1,190 1,600 * [80] 
Saudi Arabia 21,622,717 15,172 23,600 32,028 * [80] 
   10,000  2008 [83] 
Somalia 5,444,348  1,000  * [80] 
Sudan 22,599,407 24,319 37,828 51,337 * [80] 
Syria 10,881,822 4,000 6,000 8,000 * [80] 
   10,000  2011 [79] 
Tunisia 7,770,711 8,462 13,163 17,864 * [80] 
   9,000  2009 [83] 
  9,000 11,000  2013 [79] 
UAE 7,776,519 3,200 4,800 6,400 * [80] 
Yemen 15,280,727 12,710 19,770 26,830 * [80] 
OPT: Occupied Palestinian Territories, UAE: United Arab Emirates 
* The specific year of the estimate was not mentioned in the original report, but the report covered data from 1998-
2005 
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5.3. RESEARCH PAPER 4 - MATHEMATICAL MODELLING STUDY 
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ABSTRACT   
 
Introduction Emerging HIV epidemics have been documented among people who inject drugs 
(PWID) in the Middle East and North Africa (MENA). This study estimates HIV incidence among 
PWID that is due to sharing needles/syringes in MENA. It also delineates injecting drug use role 
as a driver of the epidemic in the population, and estimates impact of interventions. 
 
Methods A mathematical model of parenteral HIV transmission among PWID was applied in the 
seven MENA countries with sufficient epidemiological evidence and HIV prevalence ≥ 1%. 
Estimations of incident and/or prevalent infections among PWID, ex-PWID, and sexual partners 
of infected current and ex-PWID were conducted. 
 
Results Estimated HIV incidence rate among PWID ranged between 0.7% per person-year (ppy) 
in Tunisia and 7.8% ppy in Pakistan, with Libya being an outlier (24.8% ppy). The number of 
annual incident infections was lowest in Tunisia (n=79) and Morocco (n=99), and highest in Iran 
and Pakistan (about n=6,700 each). In addition, 20-2,208 and 5-837 incident annual infections 
were estimated across countries among sexual partners of PWID and ex-PWID, respectively. 
Since epidemic emergence, the number of total incident infections across countries was 706-
90,015 among PWID, 99-18,244 among PWID sexual partners, and 16-4,360 among ex-PWID 
sexual partners. The estimated number of prevalent infections across countries was 341-23,279 
among PWID, 119-16,540 among ex-PWID, 67-10,752 among PWID sexual partners, and 12-
2,863 among ex-PWID sexual partners. Increasing ART coverage to the global target of 81% - 
factoring in ART adherence and current coverage - would avert about half of total incident 
infections among PWID and their sexual partners. Combining ART with harm reduction could 
avert as much as 90% and 70% of incident infections among PWID and their sexual partners, 
respectively. 
 
Conclusions We estimated considerable HIV PWID incidence among PWID in MENA. Of all 
incident infections due to injecting drug use, about 75% are occurring among PWID and the rest 
among sexual partners. Out of all prevalent infections attributed to injecting drug use as 
epidemic driver, about half are among PWID, 30% among ex-PWID, and 20% among PWID/ex-
PWID sexual partners. These findings call for scale up of services for PWID and their retention 
throughout the treatment cascade.     
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INTRODUCTION   
 
As part of the global commitment to end the AIDS epidemic by 2030, the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) stipulated the ambitious ‘90-90-90’ target calling to diagnose 
90% of all people living with HIV/AIDS (PLHIV), provide antiretroviral therapy (ART) for 90% of 
those diagnosed, and achieve viral suppression for 90% of those treated, all by 2020 for all 
countries [1]. With gaps persisting along this HIV cascade, the United Nations General Assembly 
agreed in 2016 that staying on the Fast-Track to ending AIDS by 2030 would only be possible if 
key populations at higher risk of infection (KPs) have access to comprehensive prevention 
services [2]. These populations and their sexual partners were estimated to account for 36% of 
new HIV infections globally in 2015; yet are among those with the least access to HIV 
prevention, care, and treatment services [2].  
 
The Middle East and North Africa (MENA), which includes 24 countries extending from Morocco 
in the West to Afghanistan and Pakistan in the East, is one of the few regions where the number 
of new HIV infections increased between 2010 and 2015 [2]. The vast majority of these 
infections seem to be occurring among KPs, including people who inject drugs (PWID) and their 
sexual partners [2]. Emerging HIV epidemics have been recently documented among PWID in 
one-third of MENA countries, with a risk environment suggesting potential for further HIV 
spread [3, 4]. As a central population to the epidemic in several MENA countries [3], PWID are a 
priority population if the Fast-Track target of reducing the number of new HIV infections by 75% 
by 2020 is to be achieved [5].    
 
PWID remain, globally and more so in MENA, one of the hardest-to-reach KPs. They face stigma, 
discrimination, and criminalization which hinder the delivery of HIV prevention, diagnosis, and 
treatment services. This also impedes the collection of epidemiological data to track PWID 
through the HIV cascade and inform policy and programs [5-8]. Despite noticeable progress in 
the collection of HIV prevalence data among PWID in MENA, HIV incidence data remain scarce 
[3]. Quantifying HIV incidence among PWID in MENA is urgently needed to provide baseline 
data to track progress towards UNAIDS target of reducing the number of new HIV infections.    
 
In this study, we use mathematical modeling to estimate, at country-level in MENA, HIV 
incidence among PWID due to sharing non-sterile injecting equipment. We also estimate HIV 
incidence among sexual partners of PWID due to heterosexual sex with infected PWID, and 
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delineate the role of injecting drug use as a driver of the HIV epidemic in the population. Our 
approach is to explore and quantify HIV dynamics surrounding PWID from a comprehensive 
perspective that factors in the different HIV transmission pathways that are initiated by 
injecting drug use.  
 
The specific objectives of our study are to estimate in each country: 1) the number of incident 
HIV infections among PWID and their sexual partners, 2) the total number of HIV infections that 
occurred among PWID and their sexual partners since the emergence of the PWID HIV 
epidemic, 3) the number of HIV infections among ex-PWID and their sexual partners, where ex-
PWID are individuals who acquired HIV infection while injecting but are no longer injecting, and 
hence could be missed by programs targeting current drug users, and 4) the impact of select 
interventions on HIV incidence among PWID and their sexual partners.  
 
METHODS 
 
Description of the model 
We adapted the model developed by Kwon et al [9], a mathematical model of parenteral HIV 
transmission among PWID, to estimate HIV incidence among PWID. The model assumes that 
sharing of needles/syringes occurs in groups of specific size, where PWID share in random 
order, and where each PWID injects once per sharing event. The model uses input data on HIV 
prevalence, number of times a needle/syringe is reused before disposal, and levels of effective 
syringe cleaning to estimate number of HIV transmissions per sharing event. The model then 
estimates HIV incidence in the total PWID population using data on size of the PWID population, 
frequency of injecting, and levels of sharing. We adapted the model by adjusting for the effect 
of ART and allowing heterogeneity in injecting risk behavior. We also allowed the number of 
times a needle/syringe is reused to be a function of the sharing group size, instead of assuming 
a fixed number. Further details on model structure and equations are in Additional file 1.   
 
To account for heterogeneity in risk behavior, we assumed that the size of the sharing group in 
each country follows a gamma distribution. With this distribution, the majority share injections 
in smaller groups whereas a small fraction shares in larger groups (such as at shooting galleries). 
This pattern is suggested by behavioral and qualitative studies whereby injecting in larger 
groups has been reported in a few settings in Iran, Pakistan, and Libya; but the most common 
pattern, even in these countries, appears to be among closed small networks [3, 8]. In absence 
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of clear data to parameterize the variability in injecting risk behavior, the structure of the model 
was informed by data on the variability in sexual risk behavior and networking, and assumed 
that the variance of the gamma distribution is equal to its mean [10].   
 
Data sources 
The model parameters, their values, and justifications are listed in Table 1, and are based on 
recent empirical HIV natural history and epidemiology data. Whenever available, country-
specific parameter values were used, as informed mainly by a recent systematic review of PWID 
in MENA [3]. MENA-wide aggregate data [3] and global data were used to complement country-
specific data as needed (Table 1). Model fitting was used to derive one parameter, the average 
size of the sharing group (mean of the gamma distribution). We used a deterministic 
compartmental model [11] to fit the trend in HIV prevalence in two countries with sufficient 
available trend data (Iran and Pakistan), and then used the estimated incidence rate and the 
present adapted Kwon et al model to predict, using fitting, the value of the sharing group size 
(Table 1). The fitting was implemented by minimizing the residual sum of squares between all 
data points and model predictions [12]. 
 
Table 1. Model assumptions in terms of parameter values. 
Parameter Value Source 
Biological parameters   
Transmission probability per unsterile injection 0.007 Systematic review and meta-analysis [13] and 
long-term cohort study [14] 
Transmission probability per unprotected coital 
act (non-commercial) 
0.003 Systematic review and meta-analysis [15] 
Efficacy of ART in reducing HIV transmission 0.96 Clinical trial of treatment for prevention and 
other observational data [16, 17] 
Effectiveness of ART in reducing HIV 
transmission 
0.69 Calculated as the product of ART efficacy and 
adherence  
Epidemiology parameters   
Total number of PWID See Table 2 MENA PWID data [3, 18-22] 
ART coverage See Table 2 UNAIDS country estimates for ART coverage 
among all people living with HIV/AIDS [23] 
HIV prevalence among PWID See Table 2 MENA PWID data [3] 
HIV prevalence among sexual partners  One-third of HIV 
prevalence in PWID 
Bio-behavioral survey in Iran [24], consistent 
with similar modeling work in the region [25] 
Natural history parameters   
Natural mortality rate 0.02 Cohort studies [26, 27] 
HIV disease mortality rate 0.091 UNAIDS data compilation [28] and cohort 
studies [29-31]  
Behavioral parameters   
Adherence of PWID to ART 0.72 Systematic review and meta-analysis [32] 
Stopping injection rate 0.10 MENA PWID data [3] 
Number of years of injecting after 
seroconversion 
4.7 years 
 
Estimated from the natural mortality, HIV 
disease mortality, and stopping injection rates  
Average size of sharing group Ira: 3, Pak: 2, 
Others: 3 
Iran and Pakistan: model fitting to 
epidemiological data 
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Parameter Value Source 
Others: informed by Iran and Pakistan fitted 
values and epidemiological data from Iran [33, 
34] 
Proportion of PWID who inject daily 0.50 Global survey data [9, 35] 
Number of injections per PWID per day among 
those who inject daily 
Ira: 3.3, Pak: 2.2, 
Others: 2.2 
Iran and Pakistan: country-specific 
epidemiological data [3] 
Others: median of all MENA measures [3] 
Average time between two subsequent 
injections for PWID who inject less frequently 
than daily 
14 days Global survey data [9] 
Average frequency of injecting per PWID per 
year  
Ira: 602, Pak: 402, 
Others: 402 
Calculated as a weighted average of daily and 
non-daily injectors [9] 
Proportion of PWID who share injections Afg: 0.29, Egy: 0.40, 
Ira: 0.31, Lib: 0.45, 
Mor: 0.35, Pak: 
0.60, Tun: 0.30 
MENA PWID data [3] 
Proportion of the injections that are shared for 
PWID who share injections 
Egy: 0.62, Ira: 0.28, 
Mor: 0.52, Pak: 
0.40, others: 0.40 
Egypt, Iran, and Pakistan: country-specific 
epidemiological data [3] 
Others: calculated using MENA measures [3]  
Average number of times a shared 
needle/syringe is used before disposal 
Equal to the size of 
the sharing group, 
with a maximum 
value of 10 
 
Proportion of PWID with regular sexual partners 
in the last year 
0.660 MENA PWID data [3] 
Proportion of PWID with non-regular sexual 
partners in the last year 
0.337 MENA PWID data [3] 
Number of yearly coital acts with regular sexual 
partners 
50 Bio-behavioral survey in Iran [24] 
Number of yearly coital acts with regular sexual 
partners 
20 Bio-behavioral survey in Iran [24] 
Condom use with regular sexual partners 0.295 MENA PWID data [3] 
Condom use with non-regular sexual partners 0.359 MENA PWID data [3] 
Needle/Syringe cleaning parameters   
Effectiveness of needle/syringe cleaning 0.75 Modeling work [9] based on [36] and [37] 
Proportion of shared injections that are cleaned 0.15 MENA PWID data [3], & modeling work [38] 
based on [39] 
Afg: Afghanistan, ART: antiretroviral therapy, Egy: Egypt, Ira: Iran, Lib: Libya, MENA: Middle East and North Africa, Mor: Morocco, Pak: 
Pakistan, PWID: people who inject drugs, Tun: Tunisia  
 
Plan of analysis 
The following estimations were applied to seven MENA countries with sufficient 
epidemiological evidence and HIV prevalence ≥1% [3]: Afghanistan, Egypt, Iran, Libya, Morocco, 
Pakistan, and Tunisia. Remaining MENA countries have either zero or unknown HIV prevalence 
among PWID [3]. The estimations capture the different HIV transmission pathways that arise 
from injecting drug use in the population and that are described in Figure 1A. They include 
estimations of incident and/or prevalent HIV infections among PWID, ex-PWID, and sexual 
partners of infected current and ex-PWID. We estimated incidence due to heterosexual sex 
between infected PWID and their partners, and did not account for anal sex. In this study, HIV 
incidence was defined as the number of new HIV infections per year. Incidence rate was 
defined as the number of new HIV infections per susceptible person per year. 
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Figure 1. HIV transmission pathways in the population arising from injecting drug use. Panel (A) displays the various HIV transmission pathways that are 
due to injecting drug use, starting among PWID and percolation of infection to the wider non-injecting community - mainly sexual partners of current and 
ex-PWID. Panels (B) and (C) provide one example from Pakistan for the number of incident (B) and prevalent (C) infections that are caused by these 
transmission pathways and that affect the different members of the injecting and non-injecting communities. 
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Current year estimations 
The model was applied to estimate, based on observed HIV prevalence and injecting risk data, 
HIV incidence for the current year (rate and number of incident infections). The estimated 
number of incident infections among PWID was compared to the number of incident HIV 
infections in the total population as estimated by UNAIDS SPECTRUM model [40]. The number 
of incident infections among sexual partners of PWID living with HIV for the current year was 
estimated using input data on the proportion of PWID who had a sexual partner in the last year, 
HIV prevalence among PWID and among their sexual partners, and the annual number of 
unprotected coital acts per partnership. Separate parameterization and estimations were made 
for regular and non-regular sexual partners, with their sum being reported in the results. The 
number of incident infections among sexual partners of infected ex-PWID were similarly 
estimated. 
 
Analysis of past exposures 
We estimated the total number of HIV infections that occurred since the start of the epidemic 
among PWID in each country. This was done by retracing the course of the HIV epidemic among 
PWID starting from the year of epidemic emergence, informed by epidemiological data [3] 
(Table 2). We started with an HIV prevalence of 1% and, in each country ran the model the 
number of times equal to the years since HIV epidemic emergence. HIV prevalence in each year 
was recalculated by adding the number of incident HIV infections in this year to the number of 
prevalent HIV infections from previous years, while adjusting for PWID who left injection or 
died from natural or HIV disease mortality.  
 
Iterating this process over time provides an estimate for HIV prevalence in the last year. As the 
observed HIV prevalence in the last year tended to be higher than the estimated prevalence in 
that year, we increased the level of risk behavior in the first iteration, to account for higher risk 
behavior in earlier years of the epidemic, and used linear interpolation in order to reach 
observed levels of risk behavior and HIV prevalence at the last year. In Libya, the measured HIV 
prevalence (87% [41]) was not consistent with reported levels of current risk behavior. With 
these levels, the maximum HIV prevalence the model could reach was 52%; and hence, 
estimations of past exposures were not possible in Libya.   
 
The past exposures model was also used to estimate the total number of incident cases that 
ever happened among sexual partners of infected current and ex-PWID since HIV epidemic 
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emergence. The prevalent number of infected individuals in the different affected population 
groups were also estimated (current and ex-PWID, and their partners).  
 
Endemic HIV prevalence 
We estimated HIV prevalence at endemic equilibrium among PWID at country level. This 
calculation is based on a generic deterministic compartmental model for HIV infection 
(Additional file 1). It uses input data on the estimated HIV incidence rate, rate of leaving 
injection, and natural and HIV disease mortality rates. 
 
Uncertainty analysis  
Multivariate uncertainty analysis was conducted to specify the range of uncertainty in the 
estimated HIV incidence among PWID and their sexual partners. All biological and behavioral 
parameters were varied within 25% of their point estimates, as a reasonable range for 
uncertainty, except for HIV prevalence among PWID which was varied within its measured 95% 
confidence intervals (Table 2). We implemented 10,000 runs of the model using Monte Carlo 
sampling from uniform probability distributions for the uncertainty in the parameters. 95% 
uncertainty intervals (UI) for the estimates were determined.  
 
Impact of interventions 
We examined the impact of several HIV interventions targeted at PWID. Specifically, we 
assessed the effect of: 1) Reducing current sharing of needles/syringes by 25%, 50%, and 75% 
on HIV incidence among PWID, 2) Expanding ART coverage among PWID based on most recent 
test-and-treat World Health Organization (WHO) guidelines [42, 43] to reach coverage levels of 
25%, 50%, and the global target of 81% [2], on HIV incidence among PWID and their sexual 
partners, and 3) Increasing current condom use by 25%, 50%, and 75% on HIV incidence among 
sexual partners. Of note that the impact of ART is dependent on adherence and existing 
coverage levels in each country.   
 
We also examined the impact of two packages that include a combination of the above 
interventions. These intervention packages bracket the realm of plausibility for interventions 
within the MENA context. The less optimistic scenario includes reducing sharing by 25%, 
increasing ART coverage to 50%, and increasing condom use by 25%. The more optimistic 
scenario includes reducing sharing by 75%, increasing ART coverage to 81%, and increasing 
condom use by 75%.  
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RESULTS  
 
Results of all main estimations of HIV infection among PWID and their sexual partners are in 
Table 2. The estimated incidence rate among PWID was lowest in Tunisia and Afghanistan at 
0.7% (95% UI: 0.4-1.4%) and 1.2% (95% CI: 0.8-2.4%) per person-year (ppy), respectively, and 
highest in Pakistan at 7.8% ppy (95% UI: 4.3-13.4). Libya, at an HIV prevalence of 87% among 
PWID [41], was an outlier with an estimated incidence rate of 24.8% ppy (95% UI: 13.3-41.3). 
The incidence rate in remaining countries was around 4% ppy. The estimated number of 
incident infections for the current year was lowest in Tunisia (n=79) and Morocco (n=99), and 
highest in Iran and Pakistan (around 6,700 each). These PWID incident infections represent over 
90% of all incident cases in the total population in Iran, 39% in Pakistan, 16-21% in Tunisia and 
Afghanistan, and 8% in Morocco. In addition, 20-2,208 and 5-837 new infections were 
estimated at country-level among sexual partners of current and ex-PWID for this year, 
respectively (Table 2).   
 
In total, we estimated that about 82,000-90,000 infections happened among PWID since the 
start of the PWID HIV epidemic in Iran and Pakistan each; over 12,250 happened in Egypt; 1,753 
happened in Afghanistan; and over 760 happened in Morocco and Tunisia each (Table 2). 
Similarly, up to 18,244 and 4,360 HIV infections were among sexual partners of current and ex-
PWID, respectively, in each of Iran and Pakistan since the start of the PWID HIV epidemic. After 
accounting for stopping injection and mortality, we estimated that there are currently, at 
country-level, 347-32,279 prevalent HIV infections among current PWID, 119-16,540 among ex-
PWID, and 67-10,752 and 12-2,863 among sexual partners of current and ex-PWID, respectively. 
The lowest numbers of prevalent infections were in Morocco and Tunisia, while the highest 
were in Iran and Pakistan (Table 2). The estimated incidence rates suggest that HIV prevalence 
may increase in Egypt and Morocco to reach, at endemic equilibrium, 15%. Little or no further 
increase in HIV prevalence is predicted in the remaining countries, based on current estimated 
incidence rates (Table 2). 
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Table 2. HIV infection estimations among people who inject drugs and their heterosexual sex partners in the Middle East and North Africa. 
Country  Afghanistan Egypt Iran Libya Morocco Pakistan Tunisia 
HIV PWID epidemic characteristics         
Total number of PWID [3, 18-22] n 18,820 90,809 185,000 4,446 3,000 117,632 11,000 
Date of HIV epidemic emergence among PWID [3] Year 2009 2008 2001 2000 2008 2004 2009 
HIV epidemic state among PWID [3] Level-
trend 
Concentrated 
- Emerging 
Concentrated 
- Emerging 
Concentrated 
- Established 
Concentrated- 
Unknown 
Concentrated 
- Emerging 
Concentrated - 
Emerging 
Low-level 
Most recent representative HIV prevalence [3] %  
(95% CI) 
4.4  
(3.3-5.7) 
7.2 
(5.2-9.6) 
15.1 
(13.7-16.6) 
87.1 
(81.5-91.9) 
11.5 
(9-14.5) 
27.2 
(26.0-28.5) 
3.1 
(3.1-1.9) 
HIV incidence in the total population [40] n 
(range) 
1,000  
(500-2,700) 
1,500  
(1,000-2,800) 
7,100  
(4,400-16,000) 
No data 
1,200  
(1,000-1,600) 
17,000  
(12,000-30,000) 
500  
(200-500) 
Number of PLHIV [40] n 6,900 11,000 73,000 No data 24,000 100,000 2,600 
ART coverage among PLHIV [23] % 5.3 18.7 8.7 16.7* 36.7 6.1 28.3 
Current year estimations of:          
HIV incidence rate in PWID % ppy 
(95% UI) 
1.2 
(0.8-2.4) 
3.8 
(2.1-6.6) 
4.4 
(2.3-7.1) 
24.8 
(13.3-41.3) 
3.7 
(2.0-6.3) 
7.8 
(4.3-13.4) 
0.7 
(0.4-1.4) 
HIV incidence in PWID n  
(95% UI) 
214 
(124-446) 
3,217 
(1,639-5,847) 
6,773 
(3,328-11,842) 
142 
(73-262) 
99 
(49-175) 
6,679 
(3,369-11,997) 
79 
(41-152) 
Contribution of PWID to total incidence % 
(95% UI) 
21.4  
(12.4-44.6) 
NA 
95.4 
(46.9-100) 
No data 
8.2 
(4.1-14.6) 
39.3 
(19.8-70.6) 
15.9 
(8.2-30.4) 
HIV incidence in sexual partners of infected 
current PWID 
n  
(95% UI) 
62 
(33-109) 
442 
(226-787) 
1,977 
(1,112-3,218) 
193 
(109-311) 
20 
(11-35) 
2,208 
(1,239-3,566) 
22 
(10-42) 
HIV incidence in sexual partners of infected ex-
PWID 
n  
(95% UI) 
15 
(9-26) 
87 
(49-148) 
720 
(441-1,095) 
--† 
5 
(3-8) 
837 
(521-1,261) 
6 
(3-11) 
Estimated total number of incident HIV infections, 
since epidemic emergence, among: 
        
PWID  n 1,753 12,257 82,069 --† 706 90,015 764 
Sexual partners of infected current PWID  n 331 1,892 17,369 --† 99 18,244 125 
Sexual partners of infected ex-PWID  n 54 301 4,360 --† 16 4,338 21 
Estimated total number of prevalent HIV infections among:        
Current PWID  n 829 6,553 28,139 --† 347 32,279 341 
Ex-PWID  n 303 1,875 14,484 --† 119 16,540 136 
Sexual partners of infected current PWID n 224 1,293 9,640 --† 67 10,752 84 
Sexual partners of infected ex-PWID n 40 219 2,692 --† 12 2,863 16 
Estimated HIV prevalence at endemic equilibrium in 
PWID 
% 5.3 15.2 16.9 53.9 14.9 26.8 3.4 
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* No data were available - the median ART coverage across all MENA countries was used 
† The measured HIV prevalence in Libya was not consistent with reported levels of risk behavior; hence estimations of past exposures were not possible 
CI: Confidence interval, PLHIV: people living with HIV/AIDS, PWID: people who inject drugs, pyr: per person-year, UI: Uncertainty interval 
 
Table 3. Number and proportion of HIV infections averted due to select interventions in comparison with baseline (current year) estimations of 
incidence among people who inject drugs and their heterosexual sex partners in the Middle East and North Africa. 
 Afghanistan Egypt Iran Libya Morocco Pakistan Tunisia 
 n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
People who inject drugs         
Reducing sharing needles/syringes by 25% 53 (25) 804 (25) 1,693 (25) 36 (25) 25 (25) 1,670 (25) 20 (25) 
Reducing sharing needles/syringes by 50% 107 (50) 1,608 (50) 3,386 (50) 71 (50) 49 (50) 3,340 (50) 40 (50) 
Reducing sharing needles/syringes by 75% 160 (75) 2,412 (75) 5,080 (75) 107 (75) 74 (75) 5,009 (75) 60 (75) 
        
Increasing ART coverage among PWID to 25% 30 (14) 161 (50) 810 (12.0) 9 (6.5) NA* 909 (13.6) NA* 
Increasing ART coverage to 50% 68 (32) 798 (24) 2,053 (30) 37 (26) 12 (12) 2,112 (32) 15 (19) 
Increasing ART coverage to 81% 116 (54) 1,588 (49) 3,595 (53) 71 (50) 40 (41) 3,604 (54) 36 (45) 
        
Intervention packages:        
Less optimistic scenario† 105 (49) 1,402 (44) 3,233 (48) 63 (45) 34 (34) 3,254 (49) 31 (39) 
More optimistic scenario ‡ 189 (89) 2,809 (87) 5,978 (88) 125 (88) 84 (85) 5,910 (88) 69 (86) 
Sexual partners         
Increasing ART coverage to 25% 8 (14) 21 (5) 228 (12) 12 (6) NA* 289 (13) NA* 
Increasing ART coverage to 50% 19 (31) 106 (24) 581 (29) 49 (25) 2 (12) 677 (31) 4 (18) 
Increasing ART coverage to 81% 33 (53) 214 (48) 1,028 (52) 95 (49) 8 (40) 1,167 (53) 10 (44) 
        
Increasing condom use by 25% 7 (11) 47 (11) 210 (11) 21 (11) 2 (11) 234 (11) 2 (11) 
Increasing condom use by 50% 13 (21) 94 (21) 421 (21) 41 (21) 4 (21) 470 (21) 5 (21) 
Increasing condom use by 75% 20 (32) 142 (32) 635 (32) 62 (32) 6 (32) 709 (32) 7 (32) 
        
Intervention packages:        
Less optimistic scenario† 24 (38) 142 (32) 731 (37) 64 (33) 4 (21) 841 (38) 6 (27) 
More optimistic scenario ‡ 43 (68) 288 (65) 1,337 (68) 127 (66) 12 (60) 1,506 (68) 14 (62) 
ART: Antiretroviral therapy 
* Baseline ART coverage is greater than 25% 
† Reducing sharing needles/syringes by 25%, increasing ART coverage to 50%, and increasing condom use by 25% 
‡ Reducing sharing needles/syringes by 75%, increasing ART coverage to 81%, and increasing condom use by 75% 
Note: The effectiveness of ART in reducing HIV transmission is non-optimal due to adherence issues among PWID (Table 1) 
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Figure 2. Effect of expanding antiretroviral therapy coverage (ART) on HIV incidence among people who inject drugs (PWID) and their heterosexual sex 
partners in the Middle East and North Africa (MENA). The graphs display, at various ART coverage levels, the number of new HIV infections and the 
number of infections averted in comparison with baseline (current year) estimations of HIV incidence among PWID and their heterosexual sex partners.
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The impact of select interventions on HIV incidence among PWID and/or their sexual partners is 
summarized in Table 3 and Figures 2 & 3. Reducing sharing by 25%, 50%, and 75% respectively 
was associated with a similar proportional reduction in the number of incident infections 
among PWID. Reducing sharing by 25% would avert 20-53 infections per year in Afghanistan, 
Libya, Morocco and Tunisia; over 800 infections in Egypt; and about 1,700 infections in Iran and 
Pakistan each. A reduction of sharing by 75% would avert over 5,000 infections per year in each 
of Iran and Pakistan (Table 3). 
 
Increasing ART coverage to 25%, 50%, and 81% of all infected PWID would reduce incidence 
among PWID and their sexual partners at country-level by 5-14%, 12-32%, and 40-54%, 
respectively (Table 3, Figure 2). In all seven countries combined, 50% ART coverage would result 
in 5,100 and 1,400 infections averted per year among PWID and their sexual partners, 
respectively (Figure 2). Increasing condom use by 25%, 50%, and 75% would result in 11%, 21%, 
and 32% reduction in the number of annual infections among sexual partners of PWID (Table 3).  
 
Finally, implementing the less optimistic intervention package would avert 47% (n=31-3,254 at 
country-level) and 37% (n=4-481) of incident infections per year among PWID and their sexual 
partners, respectively, while the more optimistic scenario would avert 88% (n=69-5,978) and 
68% (n=12-1,337) of these infections, respectively (Table 3, Figure 3). 
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Figure 3. Effect of two comprehensive intervention packages on HIV incidence among people 
who inject drugs (PWID) (A) and their heterosexual sex partners (B) in all seven Middle East 
and North Africa (MENA) countries. The package with the less optimistic scenario includes 
reducing sharing by 25%, increasing ART coverage to 50%, and increasing condom use by 25%. 
The package with the more optimistic scenario includes reducing sharing by 75%, increasing 
ART coverage to 81%, and increasing condom use by 75%. The graphs display the number of 
new HIV infections and the number of infections averted in comparison with baseline (current 
year) estimations of HIV incidence among PWID and their heterosexual sex partners. 
 
DISCUSSION  
 
A relatively high HIV incidence rate among PWID was found in most MENA countries with at 
least 1% prevalence (range: 4-25% ppy), supporting recent analyses indicating concentrated and 
at times rapidly growing HIV epidemics among PWID [3]. A lower incidence rate of about 1% 
ppy was estimated in Afghanistan, where epidemiological data points to a nascent localized HIV 
epidemic among PWID [3], and in Tunisia where the PWID HIV epidemic appears to be at low-
level [3].  
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Our estimates of HIV incidence among PWID are overall consistent with our epidemiological 
understanding of the HIV epidemic among PWID in each country [3], and are congruent with 
the estimated size of the epidemic and HIV incidence in the whole population per most recent 
UNAIDS SPECTRUM estimates [40]. For example, we found that PWID contribute the vast 
majority of HIV infections in Iran, a country with an established HIV epidemic among PWID [3, 4, 
11] and where injecting drug use is the main driver of the epidemic at the national level [3, 44]. 
A small contribution of PWID to total HIV incidence was found in Tunisia and Morocco, which is 
also in agreement with our epidemiological understanding that the HIV epidemic in these two 
countries is mainly focused among men who have sex with men (MSM) and female sex workers 
and their clients, respectively [25, 45-48].  
 
We also found that a substantial number of HIV infections in the general population are linked 
to infections among PWID, due to individuals who acquired the infection in the past through 
drug injection, but are no longer injecting, and due to onward transmission to sexual partners. 
We estimated that about 30% of incident HIV infections are among sexual partners of current 
and ex-PWID, and about half of prevalent HIV infections are among ex-PWID and sexual 
partners of current and ex-PWID (Figure 1B and C). Figure 1 highlights how injecting drug use 
drives HIV transmission not only among current PWID but also among individuals with no or no 
recent injecting drug use. Our findings agree with recent Mode of Transmission analyses in the 
region that estimated a substantial number of HIV infections among sexual partners/spouses of 
persons engaging in HIV high risk behavior such as PWID, clients of female sex workers, and 
MSM [25, 44, 47]. In Iran for example, sexual partners of PWID were found to contribute the 
second largest number of incident HIV infections in the population after PWID, contributing 
alone 12% of total incidence [44].  
 
Since injecting drug use in MENA seems to be heavily concentrated among men [3], our findings 
highlight the vulnerability of PWID sexual partners who are mostly females, and often wives. 
Indeed, a large number of HIV infections have been documented in MENA among low-risk 
women who acquired the infection from their PWID husband/sexual partners [24, 49-51]. The 
context of sexual behavior in MENA, however, suggests limited onward transmission in the 
population beyond the direct spouses/sexual partners [8, 52].  
 
Despite the growing epidemics among PWID, the region still lags behind other regions in HIV 
response. With a median ART coverage of 17% among PLHIV in 2015, MENA has the lowest ART 
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coverage globally [53], and could not reach the 2015 mid-term regional objective of 50% 
coverage under WHO’s initiative to end MENA’s HIV treatment crisis [54]. The treatment 
cascade among PWID seems to suggest an even harsher reality. According to unpublished data 
provided by the WHO, 27% of infected PWID know their status, 20% are ever enrolled in care, 
4% are on ART, and it is unknown how many are virally suppressed. The striking gap between 
regional figures and the set 90-90-90 target is of great concern, especially in a region where the 
epidemic is strongly driven by injecting drug use. The punitive legal environment, stigma around 
HIV testing, and fear of discrimination are all challenges that hamper uptake of treatment by 
PWID [2]. In some settings, active injecting drug use is a criterion for ART exclusion, even after 
registration at a service delivery program [54]. These challenges need to be addressed to scale 
up testing, access to ART, and retention in care. Our study estimated that increasing ART 
coverage to the global target of 81% (90% of 90%), would alone avert close to half of incident 
infections among PWID and their sexual partners. Combining scale up of ART with harm 
reduction services, including needle and syringe programmes (NSP) and condom distribution, as 
part of an optimistic intervention package would avert close to 90% of infections among PWID 
and close to 70% of infections among their sexual partners (Figure 3).  
 
Despite improvement in initiation of harm reduction services in recent years, they remain 
overall limited in most of MENA. By 2014, NSP were available in nine countries, and opioid 
substitution therapy (OST) in five [55]. Increased political will, the integration of harm reduction 
in national strategies, and further engagement of civil society organizations are needed to 
enhance and implement harm reduction approaches. Lessons could be learned from the 
successful experience of Iran, a leader in harm reduction in the region [55], and from other 
settings with similar socio-cultural background such as Malaysia and Indonesia [56, 57], to find 
innovative ways to integrate harm reduction services within the socio-cultural and health 
services framework of the region. 
 
There were several limitations in our study. Though we used an elaborate mathematical model 
structure to capture the complexity of HIV dynamics, our results may depend on the type of 
model structure used. For example, our model did not include sexual transmission of HIV 
among PWID, and we did not account for onward transmission beyond the direct 
spouses/sexual partners. We also did not assess transmission through anal sex between 
infected PWID and their same-sex partners, even though behavioral data suggest not 
insignificant levels of male same-sex sex among PWID in MENA [3].   
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As with all modeling work, the robustness of our findings depend on the quality of input data. 
This study used the best-available data in the region, collected through the comprehensive 
MENA PWID systematic review [3]. Most data came from quality integrated bio-behavioral 
surveillance surveys (IBBSS) using state-of-the-art sampling methodologies for hard-to-reach 
populations and using large samples [3]. Still, many studies were limited by reliance on self-
reported behavioral data. The availability and quality of data varied between countries, and 
there were no MENA-specific data on some parameters. There were also no country-specific 
data on ART coverage among PWID. For this reason, we used country-specific estimates of HIV 
coverage among all PLHIV [23]. Unpublished MENA-wide aggregate data suggest that ART 
coverage among PWID could be lower than that among PLHIV, suggesting that we may have 
underestimated HIV incidence. To accommodate for the uncertainty in input parameters, we 
conducted uncertainty analyses with wide uncertainty ranges for parameters, including non-
MENA specific parameters that may not be precisely measured such as HIV transmission 
probability and syringe cleaning efficiency.  
 
This study aimed to estimate incidence at national level, and hence assumed that HIV bio-
behavioral data in each country is representative of the epidemic at national level, which may 
not be the case. For example, in Libya, the data came from one city, Tripoli [41], and the scale of 
the epidemic in other parts of Libya is unknown. Similarly, HIV prevalence in each of Cairo and 
Alexandria was 7%, but no other localities in Egypt were covered by the IBBSS [58]. In Morocco, 
we used average HIV prevalence of two cities where studies were conducted, and estimated an 
incidence rate of 3.7% ppy. Running our model separately in the two localities generated an 
incidence of 0.1% ppy in Tanger and 7.4% ppy in Nador, highlighting the diversity of the 
epidemic within Morocco (data not shown). There is however solid epidemiological evidence 
that the HIV PWID epidemic in both Iran and Pakistan has reached high levels at the national 
level.  
 
We also assumed that current HIV prevalence is the same as the most recent representative HIV 
prevalence. Although this may not necessarily be true, all studies were conducted in the last 
few years [3]. If there have been any changes in prevalence, it is most likely to be an increase 
given the overall emerging nature of the HIV PWID epidemic [3], suggesting that we may have 
underestimated HIV incidence in some countries. In Iran and Pakistan, however, it is unlikely 
that there have been substantial changes in HIV prevalence. In Iran, multiple data sources 
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indicate an established HIV epidemic among PWID with stable prevalence of about 15% over 
the last few years [3, 59, 60]; while in Pakistan it is predicted that the HIV PWID epidemic may 
be approaching saturation [4].    
 
Despite these limitations, this study fills an important gap in estimating HIV infection levels in 
MENA. HIV-related estimates in MENA are typically produced through established 
mathematical models that are applied globally such as UNAIDS SPECTRUM [40] and the Global 
Burden of Disease (GBD) models [61]. While these models provide two different approaches for 
HIV estimations, their focus is on total population-level estimates. For example, the GBD model 
uses input data from vital registration and/or antenatal care clinics, in addition to population-
based surveys [61]. However, these approaches may overlook the dynamics of infection among 
hidden KPs such as PWID and MSM. In this study, we model HIV transmission specifically among 
PWID, and use quality input data derived from this same population. Such ‘microscopic’ 
approach could potentially offer more realistic estimations since it is focused on the 
populations where HIV is actually being transmitted. The GBD model estimated 32,190 incident 
HIV infections in 2015 in the whole of MENA [61], about half of UNAIDS SPECTRUM estimates 
for this region, a result that is not surprising given that UNAIDS SPECTRUM factors in data on 
KPs, in addition to other data sources [62]. In this study, we estimated over 17,000 incident 
infections only among PWID in seven MENA countries, suggesting that GBD may have 
underestimated HIV incidence in this region, and that approaches focused on total population 
dynamics could be missing hidden epidemics among KPs.  
 
Though our estimates for HIV incidence among PWID were overall in line with UNAIDS 
estimates of total incidence in the population and with our country-specific knowledge of HIV 
epidemiology, there were some notable differences. For example, our estimated contribution 
of PWID to total incidence in Afghanistan and Pakistan was lower than expected, given that the 
epidemic is largely driven by injecting drug use in these countries [3]. This may suggest that 
UNAIDS SPECTRUM estimate for total incidence in these two countries is larger than actual 
incidence, or that we underestimated incidence among PWID given the relatively low levels of 
reported risk behavior. The potential underreporting of injecting risk behavior in Afghanistan 
and Tunisia could also explain the low estimated endemic HIV prevalence, whereas other 
prediction methods using measured levels of hepatitis C virus (HCV) suggest larger HIV epidemic 
potential in these countries [4]. In Egypt, our estimate of incident infections among PWID 
exceeded the estimated total number of infections in the population by UNAIDS. While UNAIDS 
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may have underestimated total incidence in this country (despite such a large PWID 
population), it could be also that the concentrated HIV epidemic among PWID in Egypt is limited 
to the two cities where the IBBSS studies were conducted. Careful triangulation of multiple 
sources of evidence is needed to alleviate some of these apparent contradictions, which in truth 
may reflect incomplete understanding of HIV epidemic dynamics [45].     
 
 In addition to providing estimates of incidence, our study provided insights into HIV epidemic 
dynamics among PWID. Our analyses indicated that current levels of injecting risk behavior 
could not explain observed prevalence nor the speed at which these epidemics rose. While it 
could be partially due to underreporting of risk behavior, this suggests that the epidemic was 
initially spreading among PWID sub-groups with higher levels of risk behavior. These findings 
agree with the contextual understanding of these epidemics. For example, the HIV PWID 
epidemics in Iran and Pakistan started in prisons, where they were ignited by limited access to 
clean needles/syringes and considerable levels of sharing – there are reports of syringes being 
reused 30-40 times in Iranian prisons [63]. In Libya, even assuming extreme levels of risk 
behavior at onset of epidemic, we could not retrace the course of the epidemic in this country. 
Although the data in Libya came from a quality IBBSS [41], the observed prevalence was 
extremely high (87%), one of the highest ever reported among PWID globally [41, 64].  Since 
PWID are a population characterized with relatively short injecting careers and high turnover, it 
is difficult to understand how HIV prevalence has reached such high level. Possibly, this 
prevalence may reflect a very recent HIV sub-epidemic among the PWID group that was 
sampled in Tripoli.  
  
CONCLUSION 
 
We estimated substantial HIV incidence among PWID in MENA. This is especially the case 
because some of the largest countries, such as Iran and Pakistan, are affected by large HIV 
PWID epidemics with high HIV prevalence. In several countries, PWID were found to contribute 
dominantly to HIV incidence. Concerted efforts are needed to bypass the persistent barriers 
from governments, society, and health systems to improve service delivery to PWID and their 
retention throughout the cascade [6]. Comprehensive programs that include ART, NSP, OST, 
voluntary testing and counselling, and prevention of sexually transmitted infections should be 
established and extended to include settings of vulnerability such as prisons [65].  
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We further estimated that for each currently infected PWID there is one other HIV infected 
person in the general population who acquired the infection through HIV PWID dynamics, 
either as an ex-PWID or as a sexual partner of current or ex-PWID (Figure 1). These populations 
also need to be linked to care and prevention but are usually missed by programs targeted at 
PWID. Innovative, context-sensitive approaches are needed to reach these populations, a large 
fraction of whom are women, for appropriate interventions. Recruiting sexual partners of PWID 
through their PWID partner could be a starting point [24]. Recruitment of ex-PWID remain a 
more challenging task, and service delivery models need to be explored to reach this 
population. Recruitment through peers or previous records at harm reduction centers could be 
plausible mechanisms. Also, with the availability of direct-acting antivirals, birth cohort 
screening for HCV infection, in countries considering such programs, may identify ex-PWID who 
are co-infected with HCV.   
 
Finally, HIV surveillance among PWID must be expanded in MENA. Specifically, there is an 
immediate need to continue with repeated rounds of IBBSS to provide longitudinal data in 
countries where such surveys have been initiated, and to start implementing them in countries 
who still have not established a surveillance base. Where possible, inclusion of sexual partners 
of PWID should be considered, as well as population size estimations. Generating such strategic 
epidemiological data will help monitor HIV epidemics, improve quality of input data for 
estimation studies, guide policy and programs, and track PWID through the HIV treatment 
cascade.  
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5.4. SUPPLEMENTARY ONLINE MATERIAL OUTLINE 
 
The following is the outline of the supplementary online material as cited in Research paper 4. 
The corresponding files are found in Appendix D. 
 
Additional file 1. Mathematical models description and other analyses 
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5.5. SUMMARY OF FINDINGS  
 
Overall high HIV incidence rates were estimated among PWID in most countries where 
estimations were conducted. Estimates of HIV incidence among PWID are overall consistent 
with our epidemiological understanding of the PWID HIV epidemic in each country as informed 
by Research papers 1 and 3. Injecting drug use caused a substantial number of infections among 
PWID since the start of the HIV epidemic among PWID at country-level.  
 
Injecting drug use drives incidence not only among current PWID, but also among sexual 
partners of current/ex-PWID through onward transmission. Moreover, considerable levels of 
prevalent HIV infections are found among ex-PWID. For each currently infected PWID there is 
one other HIV infected person in the general population who acquired the infection through 
HIV PWID dynamics, either as an ex-PWID or as a sexual partner of a current or ex-PWID.  
  
Increasing ART coverage, alone or in combination with harm reduction services, substantially 
reduces incidence among PWID and their sexual partners. The gaps in the HIV treatment 
cascade among PWID in MENA are enormous and call for an urgent scale up of ART and harm 
reduction services in order to be on track with global targets.   
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6. DISCUSSION 
 
The overarching aim of this thesis was to address a gap in our understanding of HIV 
epidemiology among PWID in MENA. The following main research questions were addressed: 
1) What is the status of the HIV epidemic among PWID in MENA? 
2) What is current HIV incidence among PWID in MENA and what is the role of injecting 
drug use as a driver of HIV transmission in the general population in MENA? 
3) Could HCV prevalence levels predict future endemic HIV prevalence among PWID? 
4) What is the estimated HIV epidemic potential among PWID in MENA based on existing 
HCV prevalence levels? 
5) What is the effect of select interventions on HIV incidence among PWID in MENA? 
 
The first section of this chapter brings together key findings in relation to these research 
questions from the more extensive Discussion sections of their respective chapters. The findings 
are summarized under two broad themes: HIV epidemiology among PWID in MENA, and 
theoretical and ecological explorations of the HCV-HIV association among PWID. The 
implications of the findings in terms of HIV/drug use policy and programming are discussed in 
the second section of the chapter and in Research paper 5, which also includes a summary of 
the main thesis findings in terms of HIV and HCV epidemiology among PWID in MENA. 
Recommendations for future research are discussed and, finally, the main scientific 
contributions of the thesis are summarized.    
 
6.1. SUMMARY OF FINDINGS 
 
6.1.1. HIV epidemiology among PWID in MENA  
 
A summary of some of the main findings and estimations in relation to HIV prevalence, 
incidence, epidemic state, and epidemic potential at country-level are found in Table 6.1. 
 
A large body of evidence 
Contrary to common perceptions, this thesis identified a large volume of HIV-related biological 
and behavioural data among PWID in MENA. Although the quantity and quality of data varied 
between and within countries, there is a noticeable improvement in the quality of the data over 
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time [86], with a number of IBBSS conducted in several countries in the last few years. These 
surveys used innovative sampling methodologies for hard-to-reach populations such as 
respondent-driven sampling and time location sampling, and benefited from overall large 
samples.  
 
A pattern of emerging HIV epidemics with high incidence 
There was epidemiological evidence of sufficient quality to characterize the status of the HIV 
epidemic among PWID in 13 of the 23 MENA countries (Figure 6.1 & Table 6.1). Rigorous 
methodology was used based on triangulation and synthesis of multiple sources of data and 
incorporating quality assessment of HIV biological data.  
 
Evidence for HIV epidemics was found in one-third of all MENA countries, with the most 
common pattern being that of concentrated emerging HIV epidemics. HIV prevalence was 
overall in the range of 10-15%. Most of the observed epidemics are recent and evolved only in 
the last decade. High HIV incidence rate was estimated in almost all countries with 
concentrated HIV epidemics (range: 4-25% ppy), supporting the epidemiological data and 
observed epidemic patterns. A relatively lower incidence rate of 1.2% ppy was estimated in 
Afghanistan, where the epidemic seems to be recent and mainly localized in one setting. Iran is 
the only country where the epidemic appears to be established at a national level. Although HIV 
prevalence might have saturated at stable levels, HIV incidence in this country was estimated at 
a high of 4.4% ppy (leading to 6,773 annual incident infections), sustaining an HIV prevalence of 
15%. It was estimated that injecting drug use has resulted, since HIV PWID epidemic emergence 
at country-level, in a large number of incident HIV infections among PWID ranging between 706 
in Morocco and 82,000-90,000 in each of Iran and Pakistan.  
Figure 6.1. Distribution of countries by HIV epidemic state among people who inject drugs.
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Table 6.1. Summary of key thesis findings: HIV prevalence, incidece, epidemic state, and epidemic potential among people who inject drugs at country-
level in the Middle East and North Africa.  
 Epidemiological characteristics Thesis findings and estimations 
 Reported HIV and HCV prevalence Epidemic state Incidence Epidemic potential 
Country 
HIV prevalence 
in most recent 
IBBSS  
Number of 
cities/ 
provinces 
 
Year of 
HIV 
estimate 
Mean HCV 
prevalence  
[87] 
Level of HIV 
prevalence 
Trend in 
HIV 
prevalence 
Geographical 
distribution 
Quality & 
scope of 
evidence 
Estimated 
HIV 
incidence  
HIV 
epidemic 
potentiala 
Estimated 
endemic 
HIV 
prevalence b 
 (%) n (HIV % range)  (%)     (% ppy)  (%) 
Iran 15.1 [88] 10 (2.0-32.0) 2010 47.1 Concentrated Established National Conclusive 4.4 Low 15.7-17.0 
Pakistan 25.2 (37.8c) 
[89] 
16 (3.3-49.6)  60.7 Concentrated Emerging National Conclusive 7.8 Low 19.9-26.8 
Afghanistan 4.4 [90] 5 (0.3-13.3)c 2012 34.2 Concentrated Emerging At least localized Good 1.2 Medium 5.3-12.5 
Egypt 7.2 [73] 2 (6.5-6.8)c 2010 63.0 Concentrated Emerging At least localized Good 3.8 High 15.2-22.7 
Morocco 11.5 [91] 
7.1 (3.7c) [92]d 
2 (0.4-25.1)c 
1 
2010-2 
2013-4 
57.6 Concentrated Emerging At least localized Good 3.7 Medium 14.9-20.8 
Libya 89.6 (87.1c) 
[93] 
1  2010 94.2 Concentrated Unknown At least localized Good 24.8 -- -- 
Bahrain -- -- -- -- ≥ Outbreak-type -- -- Limited -- -- -- 
Oman -- -- -- -- ≥ Outbreak-type -- -- Poor -- -- -- 
Jordan 0.0 [94] 3 2009  Low-level -- -- Good --   
Lebanon 0.0 [95] 1 2007-8 29.0 Low-level -- -- Good -- High 10.5-11.4 
OPT 0.0 [96]d 3 2013 43.8 Low-level -- -- Good -- High 14.8-15.8 
Syria -- -- -- 60.5 Low-level -- -- Limited -- High 18.8-21.8 
Tunisia 3.0  [97]  2 (0.0-2.9)c 2011 22.6 Low-level -- -- Good 0.7 Medium 3.4-10.2 
Saudi Arabia -- -- -- 60.5 Unknown -- -- Poor -- High 19.8-21.8 
aPredictions based on HCV prevalence levels 
bRange of estimates generated using different methodologies (predictions based on HCV prevalence data and/or predictions based on estimated HIV incidence rates) 
cPopulation-adjusted estimate 
dUpdated data from IBBSS conducted after research paper 1 was published 
IBBSS: Integrated bio-behavioural surveillance survey, OPT: Occupied Palestinian Territories, UAE: United Arab Emirates 
NB1: The table includes countries where the status of the HIV epidemic is known or where there was sufficient data to make estimations of HIV incidence or epidemic potential 
NB2: HIV incidence estimations were conducted in 7 countries where there is evidence for HIV transmission among PWID (HIV prevalence ≥ 1%) 
NB3: HIV epidemic potential estimations were conducted in 10 countries with HCV prevalence data among PWID
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Geographical patterns  
There was sufficient evidence that the observed HIV epidemics among PWID in two countries, 
Iran and Pakistan, are national. A large number of geographically representative settings were 
included in the IBBSS in these two countries, almost all having substantial HIV prevalence [88, 
89, 98-101]. In the other countries however, the HIV epidemic among PWID seems to be limited 
to one or two settings. For example, in Morocco, there was substantial HIV prevalence among 
PWID in Nador, but limited prevalence in the remaining cities [91, 102]. Similarly in Afghanistan, 
Herat, which is at the Iranian borders, is the only city with a large HIV epidemic among PWID 
[90, 103]. In Kabul, HIV prevalence seems to be consistently around 2-3% across consecutive 
surveys, whereas HIV prevalence in the remaining three cities was below 1% [90, 103-106]. 
Since this could be a reflection of the small number of sites covered by the IBBSS, the 
concentrated HIV epidemics in these countries was qualified as “at least localized”.   
 
Interestingly, there appears to be links between HIV epidemics among PWID of neighbouring 
countries. For example, molecular epidemiology studies have linked HIV subtypes in 
Afghanistan, Iran, and Pakistan [107]. This suggests that strains have been circulating between 
these countries following drug trade routes in the region, and probably facilitated by population 
movements across borders such as through the return of Afghani refugees from Iran following 
the fall of the Taliban [107-109].      
 
Possibility of hidden HIV epidemics 
In close to half of the MENA countries, the status of the HIV epidemic among PWID remains 
unknown due to the lack of, or poor quality of data (Figure 6.1). In these countries, there could 
be undetected HIV transmission among PWID. Previous experience in MENA has proven that 
there could be hidden HIV epidemics that are discovered, often too late, when IBBSS are 
conducted. For example, the first IBBSS among PWID in Tripoli, Libya, was implemented 
recently in 2010, revealing a major HIV epidemic with alarming prevalence of 87% [93]. 
Similarly, the first IBBSS conducted in Nador, Morocco, unveiled a hidden HIV epidemic among 
PWID with a prevalence of 37.8% in 2008 [102], which was confirmed by a subsequent survey 
that found a prevalence of 25% in 2011 [91]. As mentioned above, there could also be 
unidentified HIV sub-epidemics in countries where the IBBSS were conducted in only a few 
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settings such as in Morocco and Tunisia. The possibility of hidden HIV epidemics suggests that 
the full scale of the epidemic among PWID at the regional level could be underestimated. 
 
Role of prisons  
There is evidence that prisons played a principal role in initiating and amplifying the HIV 
epidemic among PWID in Iran, and that they may have contributed to the epidemic in other 
countries such as Pakistan [110]. In these countries, the first major outbreaks of HIV were 
identified in prisons [111-117], and some of the highest HIV prevalence measures were among 
incarcerated PWID, reaching 24% in Iran [118] and 60% in Libya [117]. The very high HIV 
incidence reported among incarcerated PWID in Iran further testifies to the vulnerability of the 
prison environment [119]. Overcrowding, availability of drugs, sharing of injecting equipment, 
unprotected sex, and poor services are some of the factors contributing to the vulnerability of 
the prison environment in MENA [110]. Overall in the region, about two-thirds of PWID have 
ever been incarcerated and as many as half have ever injected while in prison [110]. Sharing of 
injecting equipment in prisons is common in MENA [110], and it has been reported that 
syringes are used 30 to 40 times in Iranian prisons before disposal [120]. The incarcerated 
population is overall highly mobile in MENA favouring the bridging of the infection from prisons 
to the wider PWID community and vice versa. This pattern in MENA is similar to that in other 
regions where outbreaks of HIV among prisoners, driven by injecting drug use, have been 
reported in multiple countries [117, 121-123].  
 
HIV epidemic potential 
In one-fifth of MENA countries, the HIV epidemic was found to be at low-level, with multiple 
surveys consistently reporting no or very limited HIV infections among PWID (Figure 6.1 & Table 
6.1). However, the behavioural data indicates an overall high risk environment, even in 
countries at low-level. This suggests that if HIV is introduced into PWID, there could be large 
and possibly rapid HIV spread, depending on injecting networks and stochastic effects. The 
overlap of risk behaviour with other KPs who might be experiencing HIV epidemics, such as 
MSM, could also bridge the infection and ignite PWID HIV epidemics in settings with a risk 
environment that is favourable of epidemic expansion, as seems to have happened in Egypt.     
 
There have been examples in the region where HIV prevalence among PWID increased 
considerably over a short period of time, such as in Karachi – Pakistan, where HIV prevalence 
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increased from near zero to 23% in less than six months [70]. This is not surprising given that 
when HIV prevalence was still very low in Karachi, HCV prevalence was over 85% [124, 125], 
indicating substantial use of non-sterile injecting equipment and suggesting connectivity of 
injecting networks. In Iran, the substantial HCV prevalence (up to 80%) was also predictive of 
the large HIV epidemic that occurred subsequently.  
 
Within this context, this thesis made predictions of HIV epidemic potential among PWID in 
MENA countries using the results of an analysis of the association between HCV and HIV 
prevalence data (discussion in section 6.1.2 below). The main findings are summarized in figure 
6.2.  
 
 
Figure 6.2. Summary of HIV epidemic potential among people who inject drugs in the Middle 
East and North Africa as predicted using HCV prevalence levels. 
 
Based on existing HCV prevalence levels, there is predicted room for further HIV growth in most 
countries, many of whom are currently low-level HIV epidemic settings. Out of nine countries 
with HCV prevalence data, five have high and three moderate HIV epidemic potential, 
highlighting the emerging and potentially growing nature of the HIV epidemic among PWID in 
MENA. The high HIV incidence rate estimated in Egypt (3.8% ppy) and Morocco (3.7% ppy) 
suggests that the predicted HIV epidemic growth could materialize soon; whereas in 
Afghanistan and Tunisia, the lower estimated incidence of 1.2% ppy and 0.7% ppy, respectively, 
suggest that the epidemic will take longer to reach its peak, and explains why estimated 
endemic prevalence will be lower in these two countries.  
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Although HIV prevalence in Pakistan showed an increasing trend in repeated IBBSS reaching 
27% in the last round [89, 99-101], predictions based on HCV prevalence data suggest that the 
HIV epidemic could be reaching saturation with limited potential for further growth. Still, HIV 
incidence rate remains considerable in such settings of high HIV prevalence. Pakistan had the 
highest estimated HIV incidence rate at 7.8% ppy of all MENA countries where estimations were 
possible (apart from the outlier case of Libya). The limited HIV epidemic potential therefore 
should not be interpreted as low priority for prevention interventions.  
 
Injecting drug use as a driver of the HIV epidemic in the population 
In addition to the documented growing HIV prevalence and estimated substantial HIV incidence 
rate among PWID in several MENA countries, injecting drug use was found to be a source of 
substantial number of HIV infections in the general population, due to individuals who acquired 
the infection in the past through drug injection but are no longer injecting, and due to onward 
transmission to sexual partners of PWID and ex-PWID. About half of prevalent HIV infections 
and 30% of incident infections that are due to injecting drug use were estimated to be found or 
occurring among ex-PWID and/or sexual partners of current and ex-PWID, that is among 
individuals with no or no recent injecting drug use. These findings agree with recent mode of 
transmission analyses in the region that estimated a substantial number of HIV infections 
among sexual partners/spouses of persons engaging in HIV high risk behaviour such as PWID, 
clients of FSWs, and MSM [126, 127].  
 
Impact of interventions 
The impact of select interventions, each independently and in combination, on HIV incidence 
among PWID and/or their sexual partners was estimated at country-level, taking into 
consideration ART adherence and current coverage. It was estimated that increasing ART 
coverage to the 2015 unmet medium-objective of 50% under WHO’s initiative to end MENA’s 
HIV treatment crisis [78] would reduce HIV incidence among PWID and their sexual partners at 
country-level by 12-32%. Increasing ART coverage to the global target of 81% of those living 
with HIV would alone avert about half of incident HIV infections among PWID and their sexual 
partners.  
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Combining scale up of ART with harm reduction services, including NSP and condom 
distribution, as part of an optimistic intervention package scenario was estimated to avert close 
to 90% of HIV infections among PWID and close to 70% of infections among sexual partners.  
 
6.1.2. Theoretical and ecological explorations of the HCV-HIV association 
among PWID  
 
This thesis investigated and characterized the poorly-understood association between HCV and 
HIV infections among PWID using both mathematical modelling and ecological analyses of 
epidemiological data.  
 
Mathematical modelling predictions indicated a positive association between HCV and HIV 
prevalence at endemic equilibrium. The nature and magnitude of the association between HCV 
and HIV endemic prevalence varied according to six dynamical regimes depicting the 
overlapping epidemiology of the two infections among PWID (Figure 6.3).  
 
 
 
Figure 6.3. Summary of the overlapping epidemiology of HCV and HIV infections among 
people who inject drugs. The figures displays the different dynamical regimes and the HCV 
thresholds for sustainable and concentrated HIV epidemics.  
(Note: Regime 1, where the prevalence of both infections is less than 1%, is not displayed on 
the graph) 
 
 
The association was characterized by the presence of two epidemiologically and 
programmatically important thresholds: 1) the sustainability threshold which is the minimum 
HCV prevalence below which HIV will not be sustainable in a PWID population (i.e. HIV 
prevalence < 1%), estimated at 29% (95% UI: 21-40%), and 2) the concentration threshold which 
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is the minimum HCV prevalence needed for a concentrated HIV epidemic of HIV prevalence 
larger than 5%, estimated at 47% (95% CI: 37-57%) (Figure 6.3). These thresholds were largely 
insensitive to the uncertainty in biological parameters and the details of injecting risk 
behaviour, except near extreme values of mixing pattern and variation in risk behaviour among 
the different risk groups in a PWID population. 
 
These findings indicate that HCV prevalence levels in a PWID population can predict future HIV 
prevalence, and the predictive association depends on the regime existing HCV prevalence 
levels belong to in this population. It was demonstrated that HIV prevalence predictions across 
the entire spectrum of HCV prevalence are overall robust with regards to behavioural 
uncertainty, further confirming the applicability of the concept. HCV acts like a temperature 
scale of the level of risk behaviour in an injecting network and can be used as an index to 
measure the risk and severity of potential HIV epidemics among PWID  
 
The ecological analysis of the HCV-HIV prevalence data extracted from the conducted 
systematic review among PWID in MENA was in line with the above theoretical mathematical 
explorations. HCV prevalence was the only significant predictor of HIV prevalence in settings of 
established HIV epidemics where both infections are at endemic levels. Based on MENA data, a 
meta-analysis of the risk ratio of HCV to HIV endemic prevalence suggested that HIV prevalence 
will reach at endemic equilibrium about one-third of HCV prevalence in a given PWID 
population where HIV is introduced.  
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6.2. POLICY AND PROGRAMMING RECOMMENDATIONS 
 
This thesis work filled an important gap in our understanding of HIV epidemiology among PWID 
in MENA. Through its comprehensive assessment and estimations of HIV epidemic scale and 
potential at country- and regional-levels, it provided the scientific basis for evidence-informed 
and data-driven policy and programming in the region. Part of the research involved partners at 
international organizations leading HIV efforts in the region, which facilitates dissemination of 
findings to national stakeholders and improves the chances of incorporating them into policy 
and practice [128].    
   
One of the main findings of this research work is the documentation of the emerging HIV 
epidemics among PWID in several MENA countries. Since these epidemics are for the most part 
recent and still growing, there is a window of opportunity for prevention that should not be 
missed before the epidemics reach their full potential. These findings defied a general feeling of 
complacency in the region that is driven by the low HIV prevalence found in sporadic samples at 
low-risk of infection, overlooking transmission dynamics in hard to reach and stigmatized KPs 
where most HIV infections are happening. The documented rising HIV epidemics among PWID 
confront political leaders with a reality, and subsequent policy choices, that they have to face 
and may not afford to overlook. 
 
Overall, the region lags behind in responding to the emerging HIV epidemics among PWID.  
Despite some improvements in the initiation of harm reduction services in recent years, they 
remain overall limited and insufficient to meet current needs. By 2014, NSP were available in 
nine countries, and OST in five, with only four countries having both programs operational 
(Table 6.2) [37]. There is an urgent need to prioritize PWID for interventions and to scale up 
harm reduction services. Lessons could be learned from the successful experience of Iran, the 
leader in harm reduction in the region [37], and of other settings with similar socio-cultural 
background such as Malaysia and Indonesia [129, 130], to find innovative ways to integrate 
harm reduction within the prevailing socio-cultural framework. Iran has the highest coverage of 
NSP in MENA [64, 131], and appears to be the only country to provide such services in prisons 
[131, 132]. Morocco is yet another example of a MENA country that has been pioneering in its 
HIV response and that proves that harm reduction is feasible and acceptable in this region. 
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Table 6.2. State of needle and syringe programs and opioid substitution therapy programs in 
Middle East and North Africa countries, 2014 [37]. 
 NSP operational OST operational 
Afghanistan Yes Yes 
Iran Yes Yes 
Lebanon Yes Yes 
Morocco Yes Yes 
Egypt Yes No 
Jordan Yes No 
OPT Yes No 
Pakistan Yes No 
Tunisia Yes No 
UAE No Yes 
Algeria No No 
Bahrain No No 
Djibouti No No 
Iraq No No 
Kuwait No No 
Libya No No 
Oman No No 
Qatar No No 
Saudi Arabia No No 
Somalia No No 
Sudan  No No 
Sudan (South) No No 
Syria No No 
Yemen No No 
Source: Harm Reduction International. The Global State of Harm Reduction 2014. Found at 
http://www.ihra.net/files/2015/02/16/GSHR2014.pdf, Last accessed August 15, 2016. 2014. 
 
Increased political will, the integration of harm reduction in national strategies, and further 
engagement of civil society organizations are needed to advocate and implement harm 
reduction approaches among PWID in MENA. Civil society organizations play a central and 
influential role in harm reduction policy development, service delivery, and community progress 
in the region, but need to be strengthened and further supported by local and national 
governments [133]. Efforts, such as through outreach and peers, need to be made to reach 
PWID populations that may be reluctant to approach facility-based services, and those with 
multiple and overlapping risks. Programs should also be extended to settings of vulnerability 
such as prisons, which can be a catalyst of large HIV PWID epidemics [110, 117]. Programs need 
to be supported on public health and human rights grounds with a need for governments to 
move away from law enforcement which has proven ineffective globally and also regionally 
[28]. One example is Libya, where the large HIV epidemic among PWID appears to have been 
exacerbated by restrictions imposed on the sale of needles/syringes at pharmacies in the late 
1990s [63, 134].  
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Alongside prevention interventions, there is a pressing need to alleviate MENA’s “HIV treatment 
crisis”, as described by the WHO [78]. With a median ART coverage of 17% among people living 
with HIV in 2015, MENA has the lowest ART coverage of all regions globally [62]. The HIV 
treatment cascade among PWID shows an even harsher reality. According to unpublished data 
provided by the WHO, 27% of infected PWID know their status, 20% are ever enrolled in care, 
only 4% are on ART, and it is unknown how many are virally suppressed. These figures are very 
worrisome, especially in a region where the HIV epidemic is strongly driven by injecting drug 
use, and clearly indicate that MENA is far from the 90-90-90 target [135]. This thesis work 
estimated substantial reduction in HIV incidence among PWID (and their sexual partners) with 
scale up of ART as a standalone intervention, and more so if in combination with other 
prevention interventions. The punitive legal environment, stigma around HIV testing, and fear 
of discrimination are all challenges that hamper uptake of treatment by PWID in MENA [3] and 
that need to be alleviated to scale up HIV testing, access to ART, and retention in care.  
 
The recent availability of highly effective direct-acting antivirals to treat HCV offers hope for the 
almost half of PWID in MENA who are infected with HCV. The planned/ongoing manufacturing 
of generics at affordable prices will facilitate scale-up of HCV treatment among PWID, especially 
in countries affected by large HCV epidemics. HCV treatment should be integrated within 
comprehensive intervention packages for PWID that include ART, NSP, OST, voluntary testing 
and counselling, and prevention of sexual transmitted infections.  
 
In addition to PWID, this thesis highlighted the need of programs to include ex-PWID and sexual 
partners of PWID/ex-PWID. These two population groups acquired the infection through the 
dynamics of injecting drug use, but since they currently have no identifiable risk factor, are 
missed by programs targeted at PWID. It was estimated that for each currently infected PWID 
there is one other HIV infected person in the general population who acquired the infection 
through the dynamics of injecting drug use, and that needs to be linked to care and prevention. 
Innovative, context-sensitive approaches are needed to reach these populations, a large 
fraction of whom are women, for appropriate interventions. Peer recruitment for ex-PWID and 
recruitment of sexual partners/spouses through their PWID partners are plausible mechanisms.  
 
While the immediate priority should be settings already at known high incidence and with 
concentrated HIV epidemics, this thesis identified settings currently at low-level HIV PWID 
epidemics, but whose injecting risk environment, as measured by HCV prevalence, predicts that 
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they might experience further HIV epidemic growth and potentially large HIV epidemics among 
PWID. These findings highlight the need to implement intervention packages in such settings as 
well (where there could be complacency in view of the current low HIV prevalence) to prevent 
the infection from taking root in PWID.   
 
The concept that was proposed and demonstrated in this thesis to predict HIV epidemic 
potential among PWID based on existing HCV prevalence levels has important policy, 
programming, and resource allocation implications. Even though predictions may not be very 
precise, this approach can be effective in pinpointing settings that are likely to experience 
substantial HIV epidemics in the future, and accordingly need to be prioritized for prevention 
interventions. This is a simple applied tool that allows policy makers and program officers to 
predict HIV epidemic potential in PWID populations using measures of HCV-HIV association that 
enable such predictions with varying levels of precision. Using existing sources of data is 
particularly appealing in resource-limited settings with insufficient HIV surveillance, such as 
most of MENA and other regions. The application has a practical relevance which can be 
disseminated directly at the level of national stakeholders or in consultation with the 
international organizations leading the HIV/HCV response in the region (WHO, UNAIDS, and the 
World Bank). 
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6.4. RECOMMENDATIONS FOR FUTURE RESEARCH 
 
This thesis identified a large volume of HIV epidemiological data that enabled the objectives of 
the PhD to be addressed, but also identified limitations and gaps in the available literature, and 
highlighted ways to improve future research including data collection and reporting.    
 
One the most striking issues identified during the thesis is the magnitude of the gaps in the HIV 
treatment cascade among PWID in the MENA region. Generation of this cascade by WHO was 
challenging due to the scarcity of the data that quantifies the different steps of the cascade in 
the vast majority of countries. There is a need to expand data collection and routine monitoring 
along the continuum of care (HIV testing, linking to care, ART administration, and adherence), 
to implement CD4 testing and to track viral suppression (currently almost absent), and to 
improve country reporting mechanisms. There is also a need for research, at country-level, 
looking into the barriers to testing, linkage to care, and retention in care [78], to improve on the 
treatment cascade. This includes investigation of systemic and structural barriers such as 
criminalization, police practices, stigma and discrimination – even in health care settings and by 
health care providers, referral mechanisms, coordination between NGOs (points of testing) and 
care services, exclusion of active PWID from ART, drugs stock outs, among others [78, 136]. 
  
With regards to sero-surveys, there has been a recent noticeable improvement in the quality of 
HIV bio-behavioural data with the recent conduct of multiple IBBSS using state of the art 
sampling methodologies and using large samples. However, HIV surveillance in the region needs 
to be further expanded and improved. IBBSS were conducted in ten out of 23 countries, with 
repeated rounds available in six of them. Within the context of emerging HIV epidemics among 
PWID, and with over half of countries still lacking any data to inform the status of the HIV PWID 
epidemic, there is an urgent need to further develop HIV surveillance through the conduct of 
IBBSS in the region. This includes implementing subsequent rounds in countries that have 
already established their surveillance base to generate time trends, and conducting first rounds 
in settings where such surveys have not been conducted yet. 
 
A number of suggested improvements could be made to the study design and instruments of 
surveys in the region. One of the main issues encountered was the inclusion, in the sample of 
many studies, of non-injecting drug users, with results of both injectors and non-injectors being 
reported aggregately. In such cases, to maximize the number of studies included in Chapter 2 
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systematic review, while at the same time minimizing bias, only studies where over 50% of the 
sample consisted of PWID were eligible for inclusion. It is necessary that future studies restrict 
their samples to PWID or, alternatively, stratify results by injectors versus non-injectors. The 
definition of PWID also varied across studies. Some defined PWID as persons who have injected 
a non-therapeutic drug in the past month, others in the past two months, six months, or in the 
past year. These inconsistencies make comparison between studies, and synthesis of findings 
across studies, more difficult. It would be beneficial if UNAIDS/WHO can lead a process to 
harmonize risk group definitions for use of these definitions in all IBBSS. 
 
Other suggested improvements in data collection tools and/or reporting include more precise 
specification of: 1) type of behaviour (such as distinguishing between receptive and distributive 
sharing of needles/syringes and distinguishing between sharing and reuse), 2) time frame of 
behaviour (such as when sharing occurred: last act, ever, last month…), 3) denominators in 
reported proportions (such as whether the denominator is all PWID or only those sexually 
active when reporting the prevalence of condom use), and 4) missing data. It would also 
enhance the usability of data, particularly for mathematical modelling parameterization, if 
some key continuous variables (such as the frequency rate of injections, the duration of 
injecting career, the number of sexual/injecting partners…) are reported using summary 
measures of continuous data (medians, means, quartiles…) instead of using categories which 
are usually inconsistent between studies and also not optimal for modelling studies. 
 
Although the evidence suggests that injecting drug use in MENA is heavily concentrated among 
men, data on women who inject drugs are very limited. Women who inject drugs are one of the 
most stigmatized and hidden populations, and hence could be under-represented and 
underestimated in epidemiological PWID studies in MENA. A global review has identified that 
women comprise one third of PWID, with data suggesting higher HIV prevalence among women 
compared with men PWID [137]. Little is known about their risk practices, vulnerabilities, and 
HIV infection burden in MENA. Trying to reach and include women who inject drugs in future 
IBBSS in MENA is important to advocate for programs tailored for their needs [137].   
 
The thesis work identified gaps in some key indicators for monitoring, evaluation, and modelling 
studies. Although mapping exercises have been recently conducted in a few countries such as 
Pakistan [85, 138] and Morocco [84], many countries have no or no recent national estimates 
on the number and proportion of PWID. The quality and methodology used to derive some of 
 160 
 
 
the available PWID population size estimates are also unknown. PWID population size estimates 
are needed for a better estimation of HIV infection burden and for informing policy on the scale 
of PWID prevention and treatment services in the region. Other key indicators of importance 
for modelling studies and which are currently limited include the number of sharing partners 
per PWID (size of sharing network), number of acts of sharing per partner, frequency of coital 
acts within sexual partnerships (heterosexual and male same sex sex), among others. 
 
The proposed methodology of using HCV prevalence as a predictor of future HIV spreads calls 
for the need to collect quality and representative HCV prevalence data among PWID. This could 
be done by including HCV serology in HIV IBBSS among PWID. Although cost and tight budget 
are one of the main considerations when implementing IBBSS in the region, the additional 
suggested HCV test is ultimately cost-effective, as it enables predictions of future HIV epidemic 
scale, and helps prioritize most-at-risk PWID populations which significantly improves the cost-
effectiveness of interventions [139]. 
 
Finally, there is a need in MENA to complement the bio-behavioural data with qualitative 
research that focuses on the social and cultural aspects that affect exposure, risk-taking, and 
care seeking. Mapping and ethnographic studies are needed for a better understanding of the 
profile and injecting/sexual networks of PWID, and to investigate the social and structural 
determinants of the infection in this hidden KP in this region [140]. Such evidence is central to 
inform policy, and to design and implement interventions that are tailored to specific settings of 
risk and vulnerability. Mathematical modelling studies could be implemented to estimate the 
impact of social policy change on curbing the spread of the emerging HIV epidemics among 
PWID in MENA.   
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6.5. MAIN SCIENTIFIC CONTRIBUTIONS OF THESIS 
 
This thesis addressed a neglected area of research concerned with a culturally sensitive 
infection, HIV, in a hidden and stigmatized population, PWID, within the specific context of 
MENA - a region that includes about 10% of the world’s population and that has several social 
and structural vulnerabilities for HIV. Multiple methodologies were used to answer the various 
research questions, including systematic review and data synthesis, statistical analysis, and 
different mathematical modelling approaches. The research work undergone has applied, 
theoretical, and policy and programming contributions listed below:  
 
Applied epidemiology contributions 
 Challenged a widely-held misperception that there are limited data on HIV in the MENA 
region, particularly among KPs 
 Identified, analysed, and synthesised a large volume of HIV-related data among PWID in 
MENA, including unpublished key and novel national data - access to which was 
facilitated by WHO, UNAIDS and World Bank - these data appeared in the scientific 
literature for the first time (in Research paper 1) 
 Provided the first systematic review and comprehensive characterization of the status 
of the HIV epidemic among PWID at the regional level 
 Provided a detailed analysis and summary of HIV epidemiology among PWID at country-
level in MENA 
 Facilitates, through the large database of HIV biological and behavioural country-
specific data it compiled, the conduct and parameterization of mathematical modelling 
studies in the region, such as the one in Research paper 4 
 Used at country-level in MENA, a mathematical model specifically designed to estimate 
HIV transmission among PWID, unlike HIV-related estimations in the region which 
typically produce estimates through mathematical models that focus on total 
population level dynamics 
 Not only estimated HIV incidence among PWID, but also delineated and quantified the 
role of injecting drug use as a driver of HIV infection in the wider population, namely 
through history of past injection and onward transmission to sexual partners 
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 Qualified and quantified future HIV epidemic growth among PWID in MENA using HCV 
prevalence as a proxy biomarker of risk, thus complementing the behavioural data that 
suggest a high risk environment and hence potential for further growth 
 
Theoretical epidemiology contributions 
 Investigated and characterized the poorly-understood association and epidemiologic 
overlap between HCV and HIV infections among PWID, through both mathematical and 
epidemiological/statistical analyses 
 Demonstrated a powerful concept of using data on one infection, HCV, to estimate the 
future size of epidemics of another infection, HIV, among PWID, hence providing 
theoretical foundation for an innovative approach to identify PWID populations at high 
risk of future HIV epidemic expansion 
 Provided an independent estimate of the HCV to HIV infectiousness ratio, a key 
epidemiological parameter of interest in its own and also critical to the parametrization 
of HIV/HCV mathematical models 
 Provided important insights into HIV epidemic dynamics among PWID, particularly in 
relation to injecting risk behaviour dynamics and how it drives the emergence of HIV 
PWID epidemics 
 
Policy and programming contributions 
 Provided a comprehensive characterization of the status and potential future scale of 
HIV epidemics among PWID, one of the pivotal risk groups for HIV transmission in 
MENA, thus informing HIV policy and programming nationally and regionally and 
providing a strategic framework for future HIV scientific and intervention efforts  
 Highlighted a window of opportunity for prevention, given that the documented 
epidemics are recent and most often in their early phase 
 Provided baseline HIV incidence data among PWID to track progress towards the global 
and regional targets of reducing the number of new HIV infections  
 Estimated HIV infection levels among ex-PWID who are no longer injecting and HIV 
transmission to sexual partners of PWID/ex-PWID; two population groups that are 
usually missed by programs targeted at PWID but who need to be linked to care and 
prevention 
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 Provided a tool, using HCV data, for policy makers and program managers to identify 
PWID populations who should be prioritized for HIV/drug prevention and treatment 
interventions, hence improving the cost-effectiveness of interventions. 
 Maximized the use of existing sources of data (HCV prevalence data) to make future 
predictions of HIV epidemic scale, an application particularly appealing in resource-
limited settings such as most of MENA 
 Highlighted countries where the HIV epidemic among PWID is still at low-level or has 
just emerged, but where HIV prevalence is predicted to grow, highlighting the need to 
prioritize these PWID populations for prevention interventions to be ahead of the 
growing epidemics 
 Estimated the impact of select interventions on HIV incidence among PWID and their 
sexual partners, thus guiding the formulation of prevention and treatment efforts in the 
region 
 Provided a scientific basis to advocate for appropriate interventions and mobilization of 
resources targeted specifically to the needs of PWID (and their sexual partners) in 
MENA, who remain marginalized, with poor support networks, and poor access to HIV 
testing, prevention, and treatment services 
 Provided a scientific basis to advocate for more leadership and political action to 
manage the HIV epidemic and increase commitment to HIV/AIDS surveillance among 
and beyond PWID 
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8.1. APPENDIX A – RESEARCH PAPER 1 SUPPLEMENTARY ONLINE MATERIAL  
 
Outline 
 
Text S1. PRISMA checklist 
Text S2. Search criteria 
Text S3. Narrative justification for quality of the evidence and status of the epidemic at 
the country level 
Table S1. Precision and risk of bias of individual HIV prevalence measures among people 
who inject drugs in the Middle East and North Africa as extracted from eligible 
reports 
Table S2. Summary of precision and risk of bias of HIV prevalence measures as extracted 
from eligible reports 
Table S3. Subnational estimates of the number and prevalence of people who inject drugs 
in the Middle East and North Africa 
Table S4. HIV point-prevalence measures among people who inject drugs as extracted 
from various databases including the US Census Bureau database, the 
WHO/EMRO testing database, the UNAIDS epidemiological fact sheets 
databases, and other sources of data with unidentified reports 
Table S5. Measures of injecting risk behaviour among people who inject drugs in the 
Middle East and North Africa 
Table S6. Measures of sexual risk behaviour and sexually transmitted infections 
prevalence among people who inject drugs in the Middle East and North Africa 
Table S7. HIV/AIDS knowledge, perception of risk, and HIV testing among people who 
inject drugs in the Middle East and North Africa 
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Text S1 
PRISMA Checklist 
 
Section/topic # Checklist item Subsection (paragraph number) 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. All 
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number. 
All 
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known.  (1-4) 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
(5) 
METHODS 
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
NA 
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale. 
Study selection (1-3) 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
Data sources and search strategy (1-
3) 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated. 
Text S2 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
Study selection (1-3) 
Data collection 
process 
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators. 
Data extraction (1-2) 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made. 
Study selection (1) 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done 
at the study or outcome level), and how this information is to be used in any data synthesis. 
Scope and quality of the evidence (1-
2) 
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).  NA 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis. 
Analysis (1-4) 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting 
within studies).   
Scope and quality of the evidence (1, 
4) 
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Section/topic # Checklist item Subsection (paragraph number) 
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified. 
NA 
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram. 
Results of search strategy (1), Figure 2 
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations. 
Table 3 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12). Scope and quality of the evidence (2), 
Table S1 and S2 
Results of individual 
studies 
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention 
group and (b) effect estimates and confidence intervals, ideally with a forest plot. 
Tables 1-6, Tables S1-7 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. NA 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies  (see Item 15). Scope and quality of the evidence (1, 
3-4) 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). NA 
DISCUSSION 
Summary of 
evidence 
24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (e.g., health care providers, users, and policy makers). 
Injecting drug use in MENA (1), 
Emerging HIV epidemics and HIV 
epidemic potential among PWID (1-
3), Bridging of the HIV epidemic to 
other population groups (1-2) 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of 
identified research, reporting bias). 
Study limitations (1-2) 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. Conclusion (1-4) 
FUNDING 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review. 
 52 
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Text S2 
Search criteria 
 
The following criteria were used to search the different data sources. 
 
Pubmed  
 
("Drug Users"[Mesh] OR "Substance Abuse, Intravenous"[Mesh] OR "Needle Sharing"[Mesh] OR 
"Heroin Dependence"[Mesh] OR Drug use*[Text] OR Drug-use*[Text] OR Substance 
abuse*[Text] OR Drug abuse*[Text] OR Drug-abuse*[Text] OR Injecting-drug use*[Text] OR 
Intravenous-drug use*[Text] OR Injection-drug use*[Text] OR IDU*[Text] OR IVDU*[Text] OR 
Drug addict*[Text] OR Drug dependen*[Text]) AND ("Middle East"[Mesh] OR "Islam"[Mesh] OR 
"Arabs"[Mesh] OR "Arab World"[Mesh] OR "Africa, Northern"[Mesh] OR "Sudan"[Mesh] OR 
"Somalia"[Mesh] OR "Djibouti"[Mesh] OR "Pakistan"[Mesh] OR "Middle East"[Text] OR "Middle-
East"[Text] OR "North Africa"[Text] OR "North-Africa"[Text] OR "EMRO"[Text] OR "Eastern 
Mediterranean"[Text] OR “Arab”[Text] OR “Arabs”[Text] OR “Arab World”[Text] OR 
"Islam"[Text] OR "Afghanistan"[Text] OR "Algeria"[Text] OR "Bahrain"[Text] OR "Djibouti"[Text] 
OR "Egypt"[Text] OR "Jordan"[Text] OR "Kuwait"[Text] OR "Lebanon"[Text] OR "Libya"[Text] OR 
"Iran"[Text] OR "Iraq"[Text] OR "Morocco"[Text] OR "Oman"[Text] OR "Pakistan"[Text] OR 
"Qatar"[Text] OR "Saudi Arabia"[Text] OR "Somalia"[Text] OR "Sudan"[Text] OR "Syria"[Text] OR 
"Tunisia"[Text] OR "United Arab Emirates"[Text] OR "Dubai"[Text] OR "Abu Dhabi"[Text] OR 
"Abu-Dhabi"[Text] OR “Sharjah”[Text] OR "West Bank"[Text] OR "Ghaza"[Text] OR 
"Palestine"[Text] OR"Yemen"[Text])  
 
Embase  
 
(exp drug abuse/ or exp substance abuse/ or exp drug dependence/ or exp heroin dependence/ 
or (drug use* or drug abuse* or drug addict* or drug dependen* or IDU* or IVDU*).mp.) AND 
(exp Middle East/ or exp North Africa/ or exp Arab/ or exp Afghanistan/ or exp Djibouti/ or exp 
Pakistan/ or exp Somalia/ or exp Sudan/ or Middle East.mp. or North Africa.mp. or EMRO.mp. 
or Eastern Mediterranean.mp. or Arab.mp. or Arabs.mp. or Arab World.mp. or Islam.mp. or 
Afghanistan.mp. or Algeria.mp. or Bahrain.mp. or Djibouti.mp. or Egypt.mp. or Jordan.mp. or 
Kuwait.mp. or Lebanon.mp. or Libya.mp. or Iran.mp. or Iraq.mp. or Morocco.mp. or Oman.mp. 
or Pakistan.mp. or Qatar.mp. or Saudi Arabia.mp. or Somalia.mp. or Sudan.mp. or Syria.mp. or 
Tunisia.mp. or United Arab Emirates.mp. or Dubai.mp. or Abu Dhabi.mp. or Sharjah.mp. or 
West Bank.mp. or Ghaza.mp. or Palestine.mp. or Yemen.mp.)  
 
Regional databases  
 
WHO African Index Medicus: Free text search using each MENA country name 
WHO Index Medicus for the Eastern Mediterranean Region: A keyword search of “injecting” and 
a keyword search of “HIV” 
 
Conference abstracts 
 
Free text search using each MENA country name 
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Text S3 
Narrative justification for quality of the evidence and status of the epidemic at the 
country level 
 
This text relates to Table 5 in main manuscript. Countries are sorted by level of HIV prevalence, 
trend in HIV prevalence, geographical distribution, quality and scope of evidence, then 
alphabetical order. 
 
Iran 
The number of studies conducted is the largest in MENA and the number of HIV prevalence 
measures is also substantial, being the second largest after Pakistan. The geographical coverage 
of conducted studies is national, with a large number of cities/provinces represented. Two 
rounds of surveillance have also been conducted in 2006 and 2010 which included up to 10 
cities each, had a large sample size, and used the probability-based time-location sampling 
technique. In total, about half of HIV prevalence measures in Iran were from studies using 
probability-based sampling methodologies and the vast majority had high precision.  
 
The first HIV outbreaks among PWID in Iran were reported around 1996, and it is only in the 
early 2000s that HIV prevalence started increasing considerably to reach a peak by the mid-
2000s (Figure 3A). HIV transmission among PWID after 2005 is still ongoing and seemingly at 
high levels, but a trend of increasing HIV prevalence does not seem to be apparent. Injecting 
drug use remains the major mode of transmission in notified HIV cases at 60% in 2011. The 
totality of the evidence suggests that the HIV epidemic among PWID in Iran is now established 
at concentrated levels of about 15%.  
 
Pakistan 
The number of studies and of HIV prevalence measures is substantial, the latter being the 
largest in MENA. The geographical coverage of conducted studies is national, with a large 
number of cities/districts represented. Over one-third of studies conducted included multiple 
locations. The quality of HIV prevalence measures is good: two-thirds were from studies using 
probability-based sampling techniques, over half reached their target sample size, and the 
overwhelming majority had high precision. Pakistan had also four rounds of repeated 
integrated bio-behavioral surveillance surveys (IBBSS), the highest number in MENA. These 
surveys used multi-stage cluster sampling, included up to 16 cities per round, and were 
preceded and informed by ethnographic mapping.  
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The totality of the evidence indicates that after almost two decades of very limited HIV 
prevalence among PWID, a trend of increasing prevalence started to be observed after 2003 
(Figure 3B). One incidence study conducted in 2002 among PWID in three cities reported an HIV 
incidence rate of 1.7 per 100 person-years. The trend of increasing HIV prevalence seems to be 
ongoing, reaching over 40% in several studies, and with no evidence of stabilization or peak in 
the most recent studies. The trend of an emerging epidemic is also manifest in the repeated 
rounds of IBBSS using standard and state of the art methodology: HIV prevalence among PWID 
has steadily increased from 10.8% in 2005, to 15.8% in 2006, to 20.8% in 2008, and reached 
25.2% in 2011. There is conclusive evidence of a concentrated emerging HIV epidemic among 
PWID at the national level in Pakistan.  
 
Afghanistan  
A number of well-designed studies have been conducted in Afghanistan, some with respondent-
driven sampling (RDS) and others with thoughtful convenience sampling using a variant of time-
location sampling. Two round of IBBSS have been implemented in 2009 and 2012. Data are 
available from four main cities in Afghanistan and overall all studies were adequately powered.  
 
Although data from the earlier years of the epidemic are not available, the first studies 
conducted in 2005-8 reported low HIV prevalence among PWID at 0-3%. However, a substantial 
increase in HIV prevalence reaching up to 18% in one city, Herat, was reported in the IBBSS 
conducted in 2009 and confirmed in the second round at 13.3%. HIV incidence among PWID in 
Kabul in 2008 was also reported at 2.2 per 100 person-years, despite 72% reported use of harm 
reduction services among participants.  
 
The totality of the evidence suggests that the epidemic in Afghanistan is recent, emerging in the 
last few years, and has reached concentrated levels in at least some parts of Afghanistan. Herat 
is close to the Afghani-Iranian border and molecular investigations have found the same HIV 
variants among PWID in Iran and in Kabul, Afghanistan, far away from the Iranian border. This 
suggests that the virus may have been introduced by the return of Afghani refugees from Iran. 
Iran had already a large HIV epidemic among PWID since the early 2000s. More data and from 
other cities are needed to confirm the observed trends at the national level. 
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Egypt 
The number of studies conducted is small, but overall of good quality. Prominently, two rounds 
of repeated IBBSS were conducted. These were adequately powered and used the state of art 
sampling methodology of RDS. In addition, there is a large number of HIV prevalence measures 
that were extracted from databases.  
 
The totality of the evidence indicates very limited HIV prevalence among PWID for about two 
decades, including in the first round of IBBSS in 2006, but a noticeable increase reaching about 
7% in the most recent round of surveillance in 2010. Available HIV prevalence measures 
however cover mainly the two largest cities in Egypt and therefore the evidence cannot be 
generalized to the national level. Nonetheless, an emerging epidemic among PWID is also 
apparent in HIV case notification reports whereby 19.6% of notified HIV cases in 2010 were due 
to injecting drug use, compared to 1.6% of the total notified cases since the beginning of the 
epidemic until 2008. More data and from various parts of the country are needed to confirm 
the observed emerging epidemic among PWID at the national level.  
 
Morocco  
The number of studies conducted in Morocco is small, but of relatively good quality. With the 
exception of one point-prevalence measure in the 1990s with unclear methodology and quality, 
the recent studies conducted in 2008 and 2011 are well-designed, well-powered, and used RDS 
as a sampling strategy. There is also a number of HIV prevalence measures from databases, 
including voluntary counseling and treatment (VCT) data and data from sentinel surveillance. 
 
Overall, the data indicate very low HIV prevalence among PWID until recently, starting 2008, 
when both VCT data and the well-designed RDS studies started to indicate substantial 
prevalence, particularly in one city, Nador, where HIV prevalence has been reported at 25-38%. 
It is worth noting that HIV prevalence in the other cities included in the recent RDS studies is 
still at zero prevalence, suggesting that the epidemic in Morocco is only emerging and still 
highly localized. The recent nature of the epidemic is also confirmed by HIV case notifications, 
whereby the contribution of injecting drug use to notified cases in 2011 was only 1.2%. More 
data and from various parts of the country are needed to confirm the observed trends at the 
national level.  
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Libya 
Libya has just completed its first study investigating the epidemiology of HIV among PWID. This 
study is the first round of a planned IBBSS, used RDS, and had a large sample size. There is in 
addition two data points that were extracted from the various databases. Though the 
methodology of these data points is unclear, they indicated substantial HIV prevalence at 22.0% 
and 59.4%, suggesting major outbreaks of HIV among PWID in Libya possibly around the 
beginning of the last decade or even earlier. These data are now confirmed by the noted first 
round of IBBSS which reported an alarming HIV prevalence of 87.1% among PWID in Tripoli, the 
highest prevalence reported in MENA. The evidence therefore is indicative of a concentrated 
HIV epidemic among PWID in at least part of Libya. Though the epidemic in Tripoli with all 
likelihood is an established epidemic, the level of evidence overall is not enough to characterize 
whether the national epidemic is emerging, with few outbreaks in the past; or has been 
established for some time now with endemic HIV transmission among PWID. The good quality 
data is restricted to one city, Tripoli, and therefore more data are needed from various parts of 
the country to indicate whether there is a concentrated epidemic among PWID at the national 
level.  
 
Bahrain 
There is a number of HIV prevalence measures, the vast majority of which are from databases 
and therefore of unclear methodology and quality. There is only one study which was 
conducted and for which a report was available. This study had a large sample size and was 
conducted in a voluntary drug treatment center. It reported a prevalence of 21.1% in Manama 
in the early 90s. The data from the databases also indicated some HIV spread among PWID in 
Bahrain with prevalence rates reaching up to 8%. This is further reflected in HIV case 
notification reports, whereby in 2010, 37.5% of notified HIV cases were due to injecting drug 
use, suggesting ongoing transmission. The totality of the evidence suggests that there are at 
least some pockets of HIV among PWID in Bahrain, but the type and quality of available 
evidence is not enough to indicate whether there is a concentrated epidemic, even if localized.  
 
Oman 
There is a number of HIV prevalence measures, the vast majority of which are from databases 
and therefore of unclear methodology and quality. There is only one study which was 
conducted and for which a report was available, but with high risk of bias in all domains, 
including self-reported HIV prevalence. However, the reported HIV prevalence in this study, and 
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the data extracted from the databases, indicate substantial levels of HIV prevalence reaching up 
to 27%. Still, the contribution of injecting drug use to the total notified HIV cases remains small 
at 4.3% until the end of 2011. The totality of the evidence therefore suggests that there have 
been at least some pockets of HIV among PWID in Oman, but the type and quality of available 
evidence is not sufficient to indicate whether there is a concentrated epidemic, even if 
localized.  
 
Jordan 
There is a number of HIV prevalence measures from databases starting from 1990, in addition 
to one round of IBBSS in 2009 that used RDS and covered four cities. All prevalence measures 
indicated zero prevalence among PWID. This is further reflected in case notifications whereby in 
2011, 0% of the notified HIV cases were due to injecting drug use. The totality of the evidence 
therefore suggests that the HIV epidemic among PWID in Jordan is a low-level epidemic.     
 
Lebanon 
The number of HIV prevalence measures in Lebanon is small, but includes a round of IBBSS that 
used RDS and was conducted in 2007-8. The study found zero HIV prevalence among PWID. 
Although this study failed to reach its target sample size, possibly due to disconnectivity in the 
PWID networks in this country, all the other data available, whether from studies or databases, 
report very low HIV prevalence among PWID. This is also reflected in the HIV case notifications, 
whereby in 2011, 2% of notified cases were due to injecting drug use. The totality of the 
evidence therefore points towards a low-level HIV epidemic among PWID in Lebanon.  
 
Occupied Palestinian Territories (OPT) 
The number of HIV prevalence measures among PWID in the OPT is very small, but includes a 
first round of IBBSS that used RDS. The study found no infections among PWID in East 
Jerusalem, suggesting that the epidemic is at low-level. Also, only 2.8% of notified AIDS cases 
until the end of 2011 were due to injecting drug use. More data and from various parts of the 
country are needed to confirm this low-level epidemic state at the national level. 
 
Tunisia  
Two rounds of IBBSS have been conducted among PWID in Tunisia in 2009 and 2011. The 
studies had a large sample size and used RDS. They reported an HIV prevalence of 3.1% and 
2.4%, respectively. The several HIV prevalence measures extracted from databases indicate 
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limited prevalence since 1992. Still, by the end of 2009, 24.4% of all notified cases were due to 
injecting drug use, suggesting that HIV transmission is ongoing among PWID in Tunisia. The 
totality of the evidence therefore suggests that although the HIV epidemic among PWID in 
Tunisia appears to be a low-level epidemic, there could be somewhat significant ongoing HIV 
transmission among PWID. This low-intensity epidemic however does not appear to have 
reached high enough levels to be qualified as a concentrated epidemic.   
 
Syria   
A number of HIV prevalence measures among PWID in Syria are available from databases from 
1988 and until 2007. All of them indicate zero prevalence. In addition, there is one study which 
was conducted in Damascus using snow-ball sampling. The study reported a prevalence of 0.5%. 
The limited HIV prevalence among PWID is confirmed in case notifications whereby in 2011, 0% 
of the notified HIV cases were due to injecting drug use. The totality of the evidence therefore 
suggests that the HIV epidemic among PWID in Syria is a low-level epidemic. More data and 
from various parts of the country are needed to confirm this epidemic state at the national 
level. 
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Table S1. Precision and risk of bias of individual HIV prevalence measures among 
predominantly male people who inject drugs in the Middle East and North Africa as extracted 
from eligible reports 
Country Year HIV 
prevalence  
Precision Risk of bias 
  (%)  HIV 
ascertainment 
Sampling Response 
rate 
Afghanistan 2012 13.3 [1] Good precision Low ROB Low ROB Low ROB 
 2012 2.4 [1] Good precision Low ROB Low ROB Low ROB 
 2012 0.3 [1] Good precision Low ROB Low ROB Low ROB 
 2012 1.0 [1] Good precision Low ROB Low ROB Low ROB 
 2012 0.9 [1] Good precision Low ROB Low ROB High ROB 
 2009 18.2 [2] Good precision Low ROB Low ROB High ROB 
 2009 3.2 [2] Good precision Low ROB Low ROB Low ROB 
 2009 1.0 [2] Good precision Low ROB Low ROB High ROB 
 2007-9 2.1 [3] Good precision Low ROB Low ROB Unclear 
 2006-8 3.2 [4] Good precision Low ROB Low ROB Unclear 
 2006-8 0.0 [4] Low precision Low ROB Low ROB Unclear 
 2006-8 0.0 [4] Good precision Low ROB Low ROB Unclear 
 2005-6 3.0 [5] Good precision Low ROB Low ROB Unclear 
Bahrain 1991 21.1 [6] Good precision Low ROB High ROB Low ROB 
Egypt 2010 6.5 [7] Good precision Low ROB Low ROB Low ROB 
 2010 6.8 [7] Good precision Low ROB Low ROB Low ROB 
 2008-11 1.4 [8] Good precision Low ROB High ROB Unclear 
 2006 0.6 [9] Good precision Low ROB Low ROB Low ROB 
 1994 0.0 [10] Good precision Low ROB High ROB Unclear 
 -- 0.0 [11] Low precision Low ROB High ROB Unclear 
 -- 7·6 [12] Low precision Low ROB High ROB Unclear 
 -- 0·0 [13] Low precision Low ROB High ROB Unclear 
Iran 2012-3 7.7 [14] Good precision Low ROB High ROB Unclear 
 2011 2.9 [15] Good precision High ROB High ROB Unclear 
 2010 31.9 [16] Good precision Low ROB High ROB Unclear 
 2010 26.4 [16] Good precision Low ROB High ROB Unclear 
 2010 23.9 [16] Good precision Low ROB High ROB Unclear 
 2010 18.3 [16] Good precision Low ROB High ROB Unclear 
 2010 16.8 [16] Good precision Low ROB High ROB Unclear 
 2010 9.4 [16] Good precision Low ROB High ROB Unclear 
 2010 7.0 [16] Good precision Low ROB High ROB Unclear 
 2010 6.2 [16] Good precision Low ROB High ROB Unclear 
 2010 3.6 [16] Good precision Low ROB High ROB Unclear 
 2010 2.2 [16] Good precision Low ROB High ROB Unclear 
 2010 9.4 [17] Good precision Low ROB High ROB Low ROB 
 2009-10 9.9 [18] Good precision Low ROB High ROB Unclear 
 2009 1.2 [19] Low precision Low ROB High ROB Unclear 
 2009 1.0 [19] Good precision Low ROB High ROB Unclear 
 2009 1.7 [19] Good precision Low ROB High ROB Unclear 
 2009 3.5 [19] Good precision Low ROB High ROB Unclear 
 2009 1.5 [19] Good precision Low ROB High ROB Unclear 
 2008-9 1.1 [20] Good precision Low ROB High ROB Unclear 
 2008-9 6.4 [21] Good precision Low ROB High ROB Unclear 
 2008 18.8 [22] Good precision Low ROB High ROB Unclear 
 2008 0.7 [23] Good precision Low ROB Low ROB Low ROB 
 2007-8 3.7 [24] Good precision Low ROB High ROB Unclear 
 2007-8 2.4 [25] Good precision Low ROB High ROB Unclear 
 2007-9 18.2 [26] Low precision Low ROB High ROB Unclear 
 2007 6.6 [27] Good precision Low ROB Low ROB Unclear 
 2007 30.0 [28] Low precision Low ROB High ROB Unclear 
 2006-7 10.7 [29] Good precision Low ROB High ROB Unclear 
 2006 24.4 [30] Good precision Low ROB High ROB Low ROB 
 2006-7 8.2 [31] Good precision Low ROB Low ROB Unclear 
 2006-7 24.7 [31] Good precision Low ROB Low ROB Unclear 
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Country Year HIV 
prevalence  
Precision Risk of bias 
  (%)  HIV 
ascertainment 
Sampling Response 
rate 
 2006-7 20.8 [31] Good precision Low ROB Low ROB Unclear 
 2006-7 30.5 [31] Good precision Low ROB Low ROB Unclear 
 2006-7 6.5 [31] Good precision Low ROB Low ROB Unclear 
 2006-7 4.2 [31] Good precision Low ROB Low ROB Unclear 
 2006-7 35.7 [31] Good precision Low ROB Low ROB Unclear 
 2006-7 11.6 [31] Good precision Low ROB Low ROB Unclear 
 2006-7 2.1 [31] Good precision Low ROB Low ROB Unclear 
 2006-7 14.4 [31] Good precision Low ROB Low ROB Unclear 
 2006-7 25.0 [32] Good precision Low ROB Low ROB Unclear 
 2005-6 47.7 [33] Good precision Low ROB High ROB Unclear 
 2004 6.3 [34] Good precision Low ROB High ROB Unclear 
 2004 0.8 [35] Good precision Low ROB High ROB Low ROB 
 2004-5 72.1 [36] Low precision Low ROB High ROB Low ROB 
 2004 23.2 [37] Good precision Low ROB High ROB Low ROB 
 2003-6 45.7 [38] Low precision Low ROB High ROB Unclear 
 2003 14.0 [39] Good precision Low ROB High ROB Unclear 
 2003-4 15.2 [40] Good precision Low ROB High ROB Unclear 
 2003 24.0 [41] Good precision Low ROB High ROB Low ROB 
 2003 22.0 [41] Good precision Low ROB High ROB Low ROB 
 2003 9.7 [42] Low precision Low ROB High ROB Unclear 
 2002-6 18.0 [43] Good precision Low ROB High ROB Unclear 
 2002 15.1 [44] Good precision Low ROB Low ROB Unclear 
 2002-3 18.2 [45] Low precision Low ROB Low ROB Unclear 
 2002-4 35. 7[46] Good precision Low ROB High ROB Unclear 
 2002 0.7 [47] Good precision Low ROB Low ROB Unclear 
 2001-2 7.8 [48] Low precision Low ROB High ROB Unclear 
 2001-2 17.0 [48] Good precision Low ROB Low ROB Unclear 
 2001-6 1.6 [49] Good precision Low ROB High ROB Unclear 
 2001-6 12.7 [50] Good precision Low ROB High ROB Unclear 
 2001-3 67.5 [51] Good precision Low ROB High ROB Unclear 
 2001-2 0.0 [52] Good precision Low ROB High ROB Unclear 
 2001-2 6.9 [52] Good precision Low ROB High ROB Low ROB 
 2001 19.2 [53] Good precision Low ROB High ROB Unclear 
 2000-5 25.8 [54] Low precision Low ROB High ROB Unclear 
 1998 1.2 [55] Good precision Low ROB High ROB Unclear 
 1996 0.0 [56] Good precision Low ROB Low ROB Unclear 
  41.7 [57] Good precision Low ROB High ROB Unclear 
 -- 0.0 [58] Low precision Low ROB Low ROB Unclear 
 -- 20.5 [59] Good precision Low ROB Low ROB Unclear 
 -- 8.8 [60] Low precision Low ROB High ROB Unclear 
Jordan 2009 0. 0 [61] Good precision Low ROB Low ROB Unclear 
 2009 0.0 [61] Low precision Low ROB Low ROB Unclear 
 2009 0.0 [61] Low precision Low ROB Low ROB Unclear 
Lebanon 2007-8 0.0 [62] Low precision Low ROB Low ROB High ROB 
 2000-2 0.0 [63] Low precision Low ROB High ROB Unclear 
Libya 2010 87.1 [64] Good precision Low ROB Low ROB Low ROB 
Morocco 2011-12 25.1 [65] Good precision Low ROB Low ROB Low ROB 
 2010-11 0·4 [65]  Good precision Low ROB Low ROB Low ROB 
 2008 0.0 [66]  Unclear Low ROB Unclear Unclear 
 2008 37.8 [66] Good precision Low ROB Low ROB Unclear 
 1991-9 33.0 [67] Good precision Low ROB High ROB Unclear 
Oman -- 12.0 [68] Low precision High ROB High ROB High ROB 
 -- 27.0 [68] Low precision High ROB High ROB High ROB 
 -- 18.0 [68] Low precision High ROB High ROB High ROB 
OPT 2010 0.0 [69] Good precision Low ROB Low ROB Unclear 
Pakistan 2011 49.6 [70] Good precision Low ROB Low ROB Low ROB 
 2011 52.5 [70] Good precision Low ROB Low ROB Low ROB 
 2011 46.2 [70] Good precision Low ROB Low ROB High ROB 
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Country Year HIV 
prevalence  
Precision Risk of bias 
  (%)  HIV 
ascertainment 
Sampling Response 
rate 
 2011 30.8 [70] Good precision Low ROB Low ROB Low ROB 
 2011 24.9 [70] Good precision Low ROB Low ROB Low ROB 
 2011 3.3 [70] Good precision Low ROB Low ROB Low ROB 
 2011 14.9 [70] Good precision Low ROB Low ROB High ROB 
 2011 40.6 [70] Good precision Low ROB Low ROB Low ROB 
 2011 16.0 [70] Good precision Low ROB Low ROB High ROB 
 2011 42.2 [70] Good precision Low ROB Low ROB Low ROB 
 2011 18.6 [70] Good precision Low ROB Low ROB Low ROB 
 2011 19.2 [70] Good precision Low ROB Low ROB Low ROB 
 2011 7.9 [70] Low precision Low ROB Low ROB High ROB 
 2011 20.0 [70] Good precision Low ROB Low ROB High ROB 
 2011 7.1 [70] Good precision Low ROB Low ROB Low ROB 
 2011 21.4 [70] Good precision Low ROB Low ROB Low ROB 
 2009 8 [71] Good precision Low ROB High ROB Low ROB 
 2009 52 [71] Good precision Low ROB High ROB Low ROB 
 2009 23 [71] Good precision Low ROB High ROB Low ROB 
 2009 21 [71] Good precision Low ROB High ROB Low ROB 
 2008 13 [72] Good precision Low ROB High ROB Low ROB 
 2008 10 [72] Good precision Low ROB High ROB Low ROB 
 2008 41 [72] Good precision Low ROB High ROB Low ROB 
 2008 18.6 [73] Good precision Low ROB Low ROB Low ROB 
 2008 12.3 [73] Good precision Low ROB Low ROB Low ROB 
 2008 30.5 [73] Good precision Low ROB Low ROB Low ROB 
 2008 23.1 [73] Good precision Low ROB Low ROB Low ROB 
 2008 14.5 [73] Good precision Low ROB Low ROB Low ROB 
 2008 28.5 [73] Good precision Low ROB Low ROB Low ROB 
 2008 12.8 [73] Good precision Low ROB Low ROB High ROB 
 2008 22.8 [73] Good precision Low ROB Low ROB Low ROB 
 2007 2.6 [74] Good precision Low ROB Low ROB Unclear 
 2007 0.0 [74] Good precision Low ROB Low ROB Unclear 
 2006-7 1.4 [75] Low precision Low ROB Low ROB High ROB 
 2006-7 13.3 [75] Good precision Low ROB Low ROB Low ROB 
 2006-7 1.0 [75] Good precision Low ROB Low ROB Low ROB 
 2006-7 29.8 [75] Good precision Low ROB Low ROB Low ROB 
 2006-7 30.1 [75] Good precision Low ROB Low ROB Low ROB 
 2006-7 6.5 [75] Good precision Low ROB Low ROB Low ROB 
 2006-7 16.5 [75] Good precision Low ROB Low ROB Low ROB 
 2006-7 0.0 [75] Good precision Low ROB Low ROB Low ROB 
 2006-7 2.2 [75] Good precision Low ROB Low ROB High ROB 
 2006-7 9.5 [75] Good precision Low ROB Low ROB High ROB 
 2006-7 51.3 [75] Good precision Low ROB Low ROB Low ROB 
 2006-7 5.3 [75] Good precision Low ROB Low ROB Low ROB 
 2005 0.0 [76] Unclear Low ROB High ROB Unclear 
 2005 9.5 [77] Good precision Low ROB Low ROB Unclear 
 2005 2.5 [77] Good precision Low ROB Low ROB Unclear 
 2005 12.0 [77] Good precision Low ROB Low ROB Unclear 
 2005 1.0 [77] Good precision Low ROB Low ROB Unclear 
 2005 13.3 [78] Good precision Low ROB Low ROB Low ROB 
 2005 25.3 [78] Good precision Low ROB Low ROB Low ROB 
 2005 3.8 [78] Good precision Low ROB Low ROB Low ROB 
 2005 0.3 [78] Good precision Low ROB Low ROB Low ROB 
 2005 0.4 [78] Good precision Low ROB Low ROB High ROB 
 2005 9.5 [78] Good precision Low ROB Low ROB High ROB 
 2005 19.2 [78] Good precision Low ROB Low ROB Low ROB 
 2004 23.1 [79] Good precision Low ROB Low ROB Low ROB 
 2004 0.5 [79] Good precision Low ROB Low ROB Low ROB 
 2004 24.0 [80] Low precision Low ROB High ROB Unclear 
 2004-5 26.0 [81] Good precision Low ROB Low ROB Unclear 
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Country Year HIV 
prevalence  
Precision Risk of bias 
  (%)  HIV 
ascertainment 
Sampling Response 
rate 
 2004-5 0.5 [81] Good precision Low ROB High ROB Unclear 
 2004 8.3 [82] Good precision Low ROB High ROB Unclear 
 2003 0.3 [83] Good precision Low ROB High ROB Unclear 
 2003 0.6 [84] Good precision Low ROB High ROB Low ROB 
 2003 0.0 [85] Good precision Low ROB High ROB Unclear 
 2003 0.0 [85] Low precision Low ROB High ROB Unclear 
 2003 9.7 [86] Good precision Low ROB High ROB Unclear 
 2002 0.0 [87] Low precision Low ROB High ROB Unclear 
 2002 3.4 [88] Good precision Low ROB High ROB Unclear 
 2002 0.0 [89] Good precision Low ROB High ROB Unclear 
 1999 0.0 [90] Good precision Low ROB High ROB Unclear 
 1996 0.4 [91] Good precision Low ROB High ROB High ROB 
 1994 0.0 [92] Good precision Low ROB High ROB Unclear 
 1987-4 0.0 [93] Low precision Low ROB High ROB Unclear 
 -- 37.2 [94] Low precision Low ROB High ROB Unclear 
 -- 0.0 [95] Good precision Low ROB Unclear Unclear 
Syria 2006 0. 5 [96] Good precision Low ROB High ROB Unclear 
Tunisia 2011 2.9 [97] Good precision Low ROB Low ROB Low ROB 
 2011 0.0 [97] Good precision Low ROB Low ROB High ROB 
 2009 3.1 [98] Good precision Low ROB Low ROB Unclear 
OPT: Occupied Palestinian Territories, ROB: Risk of Bias 
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Table S2. Summary of precision and risk of bias of HIV prevalence measures as extracted from 
eligible reports 
 n %* 
Precision of estimates    
High precision 159 83.7 
Low precision 29 15.3 
Missing 2 1.1 
Risk of bias quality domains    
HIV ascertainment   
Low risk of bias 186 97.9 
High risk of bias 4 2.1 
Unclear -- -- 
Sampling methodology   
Low risk of bias 100 52.6 
High risk of bias 88 46.3 
Unclear 2 1.1 
Response rate   
Low risk of bias 64 33.7 
High risk of bias 20 10.5 
Unclear 106 55.8 
Total 190* 100.0 
   
 n % 
Low risk of bias   
In at least one quality domain 186 97.9 
In at least two quality domains 117 61.6 
In all three quality domains 47 24.7 
High risk of bias   
In at least one quality domain 104 54.7 
In at least two quality domains 5 2.6 
In all three quality domains 3 1.6 
* Out of a total of 190 HIV prevalence measures among predominantly male PWID 
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Table S3. Subnational estimates of the number and prevalence of people who inject drugs in 
the Middle East and North Africa 
Country City/province Year N (range) % (range) Source 
Afghanistan Mazar-i-Sharif, Kabul, 
Jalalabad 
2006-7 1,465 (55-1,251) 0.22 (0.15-0.24) [1] 
 Herat 2012 1,211  [2] 
 Jalalabad 2012 1,471  [2] 
 Kabul 2012 12,541  [2] 
 Mazar-i-Sharif 2012 1,496  [2] 
Egypt Greater Cairo -- 85,000  [3] 
Iran Hamadan 2012 11,333  [4] 
 Hormozgan 2006  0.1 [5] 
 Kerman city -- 1,640 (1,368-1,911)  [6] 
 Kerman city -- 3,805 (57-11,254)  [6] 
 Kermanshah 2006  0.7 [7] 
 Khoshropdpey 2003  0.0 [8] 
 Tehran 2006  1.0 [5] 
Pakistan 19 cities 2011 46,351 (39,793-52,896) 0.37 [9] 
 8 cities 2005 24,390 (20,770-28,010) 0.47 [10]  
 Bannu 2006 250 0.08 [11] 
 Faisalabad 2005  (2,400-2,550)  [12] 
 Faisalabad 2006 8030 1.07 [11] 
 Gujranwala 2005  (466-607)  [12] 
 Gujranwala 2006 2650 0.62 [11] 
 Hyderabad 2006 2600 0.66 [11] 
 Islamabad 2006  5.9 [13] 
 Karachi 2006 9000 0.25 [11] 
 Kech 2007  0.4 [14] 
 Lahore 2005  (1,754-2,110)  [12] 
 Lahore 2006 3350 0.18 [11] 
 Larkana 2006 800 0.65 [11] 
 Mandi Bahauddin 2005  (713-928)  [12] 
 Multan 2006 900 0.21 [11] 
 Peshawar 2006 150 0.04 [11] 
 Quetta 2006 150 0.07 [11] 
 Rawalpindi 2005  (348-451)  [12] 
 Rawalpindi 2006 123 0.02 [11] 
 Sarghoda 2005  (1,000-1,100)  [12] 
 Sarghoda 2006 2450 0.87 [11] 
 Sheikhukupura 2005  (367-460)  [12] 
 Sialkot 2005  (600-800)  [12] 
 Sukkur 2006 1350 0.59 [11] 
Tunisia Bizerte 2112 654  [15] 
 Tunis 2012 1,573  [15] 
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Table S4. HIV point-prevalence measures among people who inject drugs as extracted from various databases including the US Census Bureau database, the 
WHO/EMRO testing database, the UNAIDS epidemiological fact sheets databases, and other sources of data with unidentified reports  
 Afg Bah Dji Egy Irn Irq Jor Kuw Leb Lib Mor Oma OPT Pak SA Sud Syr Tun Yem 
Year n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
1984                    
1987                    
1988         103 (3.9)        51 (0.0)   
1989  728 (7.8)  1932 
(0.2) 
         97 (0.0)      
1990  1436 
(2.9) 
  135 (0.0)  240 (0.4)             
       24 (4.2)             
1991  609 (2.1)  122 (0.0) 579 (0.2)   840 (0.4)      18 (0.0)      
    72 (0.0)                
    50 (0.0)                
1992  393 (1.0)  266 (0.8) 2098 
(0.1) 
 4 (100.0)       24 (0.0)   963 (0.1) 801 
(1.6) 
 
    106 (2.8)                
     4 (0.0)                
1993  139 (1.4)  75 (1.3) 1295 
(0.2) 
(0.0) 26 (0.0) 208 (1.0) 46 (2.2)     698 
(0.3) 
  157 (0.0) 822 
(1.1) 
 
    616 (0.0)                
    214 (0.0)                
1994  191 (1.6)  385 (0.0) 349 (0.3) (0.0)  59 (0.0) 32 (3.1)     342 
(0.0) 
  1419 
(0.1) 
1224 
(0.9) 
 
    102 (0.0)             1379 
(0.3) 
  
1995  183 (0.0)  1085 
(0.0) 
1232 
(0.0) 
(0.0)  110 (0.0) 15 (0.0)     703 
(5.4) 
  834 (0.0) 1571 
(0.7) 
 
                 165 (0.0)   
1996  439 (1.1) (0.0) 96 (0.0) 2747 
(5.7) 
(0.0)  172 (0.6)      19 (0.0)   153 (0.0) 1518 
(1.0) 
 
              113 
(1.8) 
     
              242 
(0.4) 
     
              19 (0.0)      
1997  350 (0.0)  138 (0.0) 34120 
(1.8) 
(0.0)  94 (0.0)      32 (0.0)  (0.1) 314 (0.0) 584 
(0.3) 
 
    438 (0.0)                
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 Afg Bah Dji Egy Irn Irq Jor Kuw Leb Lib Mor Oma OPT Pak SA Sud Syr Tun Yem 
Year n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
1998  336 (0.9) (0.0) 96 (0.0) 8202 
(0.5) 
(0.0)  181 (0.0)  400 (0.5)   28 (0.0) 25 (0.0)   1299 
(0.0) 
 13 
(0.0) 
  128 (2.3)   2827 
(12.6) 
              
1999  78 (0.0) (0.0) 88 (0.0) 8000 
(0.1) 
(0.0)  74 (0.0)    135 (5.2) 1 (0.0) 37 (0.0)   595 (0.0)  3 (0.0) 
  334 (0.0)  176 (0.0)    (0.0)    (5.0)     301 (0.0)   
2000  291 (0.3) (0.0) 369 (0.0) 7200 
(0.2) 
  (0.0)    58 (5.5)  207 
(0.0) 
  525 (0.0)  2 (0.0) 
2001  158 (1.3) (0.0) 580 (0.0) 3714 
(1.6) 
  166 (0.6)  (59.4)  73 (5.5)  1516 
(0.0) 
  375 (0.0)  2 (0.0) 
              (1.0)      
2002  124 (7.3) (0.0) 488 (0.0) 76 (19.7)  54 (0.0) 126 (0.0)    34 (8.8)  423 
(0.0) 
  120 (0.8)   
     (29.9)       (5.0)        
            (11.8)        
            (18.6)        
2003  203 (1.5)  512 (0.0) 1688 
(14.2) 
 160 (0.6) 31 (0.0)    93 (1.1)  641 
(3.3) 
(0.0)  237 (0.0)   
2004  309 (1.3)  342 (0.0) 1705 
(7.4) 
 93 (0.0) 191 (1.6)  (22.0) 19 (5.3) 155 (1.9)  87 (0.0)   258 (0.0)   
    353 (0.0) (18.0)         395 
(26.3) 
     
              3154 
(8.3) 
     
2005 338 (3.6) 265 (1.1)  293 (0.0) 761 
(13.7) 
 217 (0.0)    133 (0.0) 194 (1.0)  (12.1)   456 (0.0)   
 (1.7)          111 (0.0)   (10.8)      
 (3.4)          22 (0.0)   (9.6)      
 (5.1)                   
2006  238 (0.4)  (0.6) 310 
(11.6) 
 326 (0.0)    (6.5) 191 (0.5)     444 (0.0) 187 
(0.0) 
 
    (2.6) 426 
(25.0) 
     147 (0.0)         
    (4.5)       146 (0.0)         
    281 (0.0)       1 (0.0)         
2007  197 (1.5)         30 (0.0) 224 (0.9)   750 
(0.8) 
 388 (0.0)  1 (0.0) 
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 Afg Bah Dji Egy Irn Irq Jor Kuw Leb Lib Mor Oma OPT Pak SA Sud Syr Tun Yem 
Year n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
           22 (0.0)         
           8 (0.0)         
2008 127 (11.0)          61 (1.6)         
           77 (1.3)         
2009        255 (0.0) 109 (0.9)  66 (0.0)    (0.3)     
           16 (6.3)         
2010  181 (3.9)      454 (0.2)       2925 
(0.4) 
    
               (0.8)     
               (1.6)     
2011 4681 (0.9)      304 (0.0) 373 (0.0)   173 (2.3) 929 (1.4) 65 (0.0)  3441 
(0.6) 
 478 (0.0)   
         (7.8)           
Afg: Afghanistan, Bah: Bahrain, Dji: Djibouti, Egy: Egypt, Irn: Iran, Irq: Iraq, Jor: Jordan, Kuw: Kuwait, Leb: Lebanon, Lib: Libya, Mor: Morocco, Oma: Oman, OPT: Occupied Palestinian Territories, Pak: Pakistan, SA: Saudi Arabia, 
Sud: Sudan, Syr: Sria, Tun: Tunisia, Yem: Yemen 
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Table S5. Measures of injecting risk behavior among people who inject drugs in the Middle East and North Africa 
 Afghanistan Algeria Bahrain Egypt Iran Jordan Lebanon Libya Morocco Oman OPT Pakistan Syria Tunisia 
Shared needles or 
syringes (%) 
              
Ever 8 [1], 11 [2], 
17 [3], 27 [2], 
34 [2], 50 [4] 
  59 [5] 12 [6], 12 [7] 14 
[8], 18 [9] 20 
[10], 25 [11] 28 
[12], 31 [13] 31 
[14], 32 [15] 32 
[16], 34 [17], 35 
[18], 36 [19], 36 
[20], 37 [21], 48 
[22] 49 [9], 49 
[18] 50 [23], 66 
[23] 76 [24], 70 
[25], 71 [25], 95 
[26,27] 
63 [28], 
64 [28], 
71 [29] 
41 [30], 
65 [31]  
85 [32] 47 [33] 90 [34], 
94 [34], 
97 [34] 
 14 [35], 17 [36], 
41 [35], 46 [37], 
50 [38], 53 [39], 
56 [38], 56 [38], 
58 [40], 63 [38], 
63 [38], 64 [41], 
67 [36], 74 [38], 
68 [41], 69 [39], 
70 [39], 79 [39],  
46 [42]  
Last 6 months 16 [43], 28 
[44], 29 [44], 
34 [43], 45 
[43] 
   47 [45], 64        47 [46]   
Last 3 months 6 [3]              
Last month    23 [47], 32 
[48], 41 [47], 
53 [48], 55 
[5], 86 [49] 
8 [13], 12 [50], 13 
[51], 14 [50], 14 
[52], 18 [50], 21 
[25], 40 [25], 73 
[53], 100 [54] 
   30 [55], 
33 [55], 
36 [55], 
36 [55] 
  54 [56] 28 [42]  
Last week     9 [57], 23 [57]          
Last injection    25 [49] 6 [26], 11 [22] 61 [29] 17 [31], 
21 [58]  
18 [32]   11 [59], 
19 [60] 
18 [61], 18 [62], 
18 [62], 22 [63], 
23 [61], 23 [64], 
23 [65], 24 [62], 
24 [62], 25 [65], 
28 [63], 30 [65], 
31 [64], 35 [66], 
47 [66], 82 [65]   
  
Currently          44 [34], 
65 [34], 
70 [34] 
 48 [67], 57 [68], 
66 [69], 72 [67] 
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Unspecified  41 [70] 79 [71] 11 [72], 15 
[73], 40 [74], 
43 [75], 
0 [76], 29 [77], 31 
[78], 33 [79], 36 
[80], 48 [81], 50 
[82], 59 [83], 70 
[84] 
     39 [85], 
47 [85] 
8 [86], 46 [87], 
52 [88], 80 [38], 
86 [89], 88 [38], 
90 [90], 95 [91] 
  
Clean used needle 
before use (%) 
              
Always 14 [5]    14 [45] 34 [29]  86 [32] 70 [55], 
85 [55] 
  43 [92], 64 [36]  60%[42]  
In the last month 34 [47], 83 
[47] 
             
Last injection           54 [59] 49 [93]     
Unspecified      83 [28]     36 [85]    
Method of cleaning (%)               
Water    72 [5]  79 [28]  82 [32] 89 [55], 
97 [55] 
 68 [59] 
84 [85] 
34 [36], 39 [65], 
54 [93], 78 [46], 
84 [92], 100 [65] 
40 [42] 82 [94]  
Bleach        9 [32] 4 [55], 7 
[55] 
  0 [46], 5 [93] 3 [42] 8 [94] 
Last time injected with 
(%) 
              
Friends/acquaintances            56 [65], 64 [63], 
64 [61], 67 [66], 
72 [65], 81 [64] 
  
Strangers            0 [64], 0 [66], 0 
[61], 1 [63], 2 
[65], 3 [65]  
  
Alone           45 [85], 
61 [59] 
15 [65], 18 [36], 
18 [64], 27 [66], 
32 [63], 34 [61], 
36 [65], 42 [93] 
  
Place of last injection 
(%) 
              
Public place         21 [33], 
46 [55], 
51 [55] 
 47 [85] 25 [40], 66 [63], 
78 [66], 79 [65], 
82 [61], 89 [65], 
91 [64] 
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Home         33 [55], 
41 [33], 
46 [55] 
 54 [85] 3 [65], 5 [64], 9 
[61], 11 [65], 11 
[66], 14 [63], 68 
[40] 
74 [42]  
Used “street doctors” 
(%) 
              
Ever            26 [63], 42 [38], 
77 [65], 84 [38], 
99 [38], 100 [38] 
  
Last injection            247 [66], 32 [61], 
44 [64] 
  
Unspecified            11 [67], 11 [67], 
19 [93], 46 [39], 
58 [39], 59 [69], 
61 [39], 71 [39], 
73 [36], 85 [36]  
  
Average # of injections               
/day 5.7 [3]    3.3 [95]       1.1 [36], 2 [69], 2 
[56], 2.2 [65], 2.2 
[63], 2.2 [61], 2.3 
[96], 2.3 [65], 2.3 
[66] 
  
/week     7.7 [97], 21.1 
[98], 21.3 [97],  
         
/last month     54.0 [19], 92.6 
[25], 104.3 [99], 
110.3 [25] 
      20 [100], 63 
[101], 67 [101]  
41 [42]  
Age at first injection                
Mean (years) 25.8 [3], 26.4 
[4]  
  23.1 [47], 
23.3 [5], 27.0 
[47] 
23.6 [13], 23.7 
[102], 23.9 [103], 
24.0 [79], 24.0 
[15], 25.0 [18], 
25.9 [51], 26.0 
[50], 26.3 [50], 
26.5 [50], 27.0 
[104], 27.3 [76], 
27.4 [104], 28.1 
[18] 
   32.9 [33]  20 [34], 
22 [34], 
22 [34] 
28.8 
[59]  
25.0 [39], 25.2 
[38], 25.6 [64], 
27.0 [105], 27.0 
[63], 27.2 [36], 
27.9 [66], 28.1 
[38], 28.3 [38], 
28.5 [61], 29.1 
[38], 31.6 [36]  
27.0 [42]  
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Median (years) 26.0 [43]    25.0 [22], 25.0 
[14] 
   21.0 [55], 
28.0 [55] 
  25.0 [46]   
Duration of injecting               
Mean (years) 1.3 [106], 1.4 
[106], 1.7 [2], 
2.1 [2], 2.3 
[106], 2.4 
[106], 2.5 [2], 
2.9 [106], 3.3 
[43], 4.0 [3], 
4.4 [4] 
  6.4 [47], 9.3 
[47] 
1.6 [76], 2.0 [18], 
2.6 [18], 3.8 [23], 
4.1 [107], 4.5 
[79], 4.5 [15], 4.8 
[23], 4.8 [25], 4.9 
[25], 5.4 [13], 5.8 
[95], 6.7 [98], 7.4 
[26], 8.4 [27], 12 
[99] 
      2.1 [105], 4.2 
[65], 4.4 [36], 4.6 
[65], 4.6 [61], 4.9 
[64], 5.3 [63], 5.9 
[66], 6.1 [35], 7.6 
[35], 7.7 [36] 
  
Median (years)     6 [22]     8.0 [55], 
8.7 [55] 
  3 [41], 7 [41]   
Re-injecting own blood 
(%) 
              
Ever 69 [43], 70 
[3], 73 [43], 
81 [43], 83 
[44]  
          70 [38], 91 [41], 
92 [41], 92 [38], 
94 [38], 96 [38] 
  
Selling or donating 
blood (%) 
              
Ever 5 [4]    30 [5] 56 [108]       3 [35], 8 [46], 12 
[105], 23 [69], 27 
[35], 28 [96], 31 
[36], 44 [68]   
23 [42]  
Last 12 months            1 [62], 2 [62]   
Last 6 months            1 [38], 5 [61], 5 
[38], 9 [38], 11 
[38]  
  
OPT: Occupied Palestinian Territories 
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Table S6. Measures of sexual risk behavior and sexually transmitted infections prevalence among people who inject drugs in MENA 
 Afghanistan Bahrain Egypt Iran Jordan Lebanon Libya Morocco Oman OPT Pakistan Syria Tunisia 
Sexually active (%)              
Currently   30 [1], 73 [2] 95 [3]          
Ever 83 [4], 86 [4], 92 [5], 
93 [4], 94 [4] 
91 [6] 95 [7], 96 
[7], 96 [8] 
75 [9], 77 [10], 
81 [11], 84 [12], 
85 [13], 86 [14], 
87 [14], 88 [14] 
  77 [15]  91 [16], 94 
[16], 100 [16] 
 77 [17], 79 [17], 84 
[18], 89 [19], 89 
[20], 93 [21], 94 
[19], 95 [22] 
 96 [23], 
97 [24] 
Last year   71 [8], 76 
[7], 80 [7] 
39 [25], 54 [25] 64 [26] 73 [27]     52 [28] 78 [29]  
Last 12 months        55 [30], 
61 [30] 
    87 [24] 
Last 6 months 58 [31], 76 [31], 78 
[31], 80 [31], 85 [31] 
         22 [32], 91 [33]   
Last month   54 [2]    23 [15]    63 [34]  68 [29]  
Married (%)              
Currently 30 [35], 34 [35], 37 
[31], 39 [31], 42 
[31], 43 [35], 52 
[36], 53 [31], 61 
[31], 68 [37] 
  
27 [6] 29 [7], 38 
[38], 39 [8], 
49 [7] 
9 [39], 26 [40], 
28 [14], 29 [41], 
33 [42], 33 [43], 
33 [25], 33 [14], 
33 [25], 35 [44], 
36 [14], 39 [45], 
45 [46], 45 [47], 
45 [48], 48 [49], 
48 [50], 52 [51], 
54 [52], 56 [53], 
64 [47], 67 [54], 
79 [54], 89 [55] 
49 [26] 21 [56] 12 [15] 19 [57], 
20 [30], 
21 [30] 
3 [16], 26 
[16], 28 [16] 
67 [58] 24 [59], 26 [60], 26 
[17], 28 [61], 30 
[32], 30 [62], 31 
[28], 33 [63], 34 
[21], 35 [64], 41 
[22], 42 [65], 
45[20], 45 [63], 45 
[63], 45 [18], 48 
[63], 53 [66], 53 
[66], 55 [33], 68 
[19], 73 [67], 77 
[19]  
44 [29] 16 [24] 
Ever 38 [68], 46 [5], 52 
[68], 64 [69] 
 34 [7], 56 
[8], 56 [7] 
19 [70], 35 [12], 
43 [71], 44 [13], 
52 [72], 54 [14], 
54 [39], 55 [14], 
55 [73], 56 [14], 
57 [11], 65 [73] 
 33 [56]     26 [74], 43 [74]  20 [24] 
Had sex with regular 
female partners (%) 
             
Last year   83 [7], 86 
[7], 89 [8] 
43 [14], 57 [14], 
58 [14] 
 66 [56]        
Last 6 months           26 [21], 38 [22], 42 
[20], 46 [18] 
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 Afghanistan Bahrain Egypt Iran Jordan Lebanon Libya Morocco Oman OPT Pakistan Syria Tunisia 
Last month      62 [75] 73 [15]      77 [24]  
Had sex with non-regular 
female partners (%) 
             
Last year   29 [8], 34 
[7], 42 [7] 
27 [14], 31 [14], 
34 [14]  
 40 [56]  18 [30], 
36 [30] 
    42 [24]   
Last month      34 [75] 28 [15]       
Unspecified    73 [54]          
Had sex with men (%)              
Ever 2 [31], 10 [5], 10 
[31], 10 [4], 14 [35], 
15 [35], 19 [31], 19 
[31], 25 [4], 26 [35], 
26 [4], 29 [31], 36 
[4] 
 9 [2], 18 [38]  5 [45], 8 [39], 8 
[11], 11 [12], 13 
[76], 14 [14], 17 
[14], 17 [14], 
18, [49], 24 
[43], 27 [51], 30 
[52], 36 [9], 39 
[76]  
12 [26] 25 [27]   6 [16], 12 
[16], 15 [16], 
28 [16], 42 
[16], 35 [16] 
25 [58] 37 [19], 50 [19]    
Last 5 years           7 [32]   
Last 12 months   8 [7], 9 [8], 
14 [7] 
2 [25], 2 [25], 7 
[14], 8 [14], 10 
[14] 
7 [26]      2 [77], 14 [77] 4 [29]  
Last 6 months           18 [17], 27 [17]   
Last month    19 [44]  10 [27]        
Unknown/unspecified  9 [6]  12 [3], 14 [78]    14 [57]   24 [28]   
Had sex with a sex worker 
(%) 
             
Ever 23 [4], 37 [5], 38 [4], 
47 [35] 56 [35], 64 
[35], 67 [4], 72 [4] 
 13 [8]  23 [45], 25 [12], 
32 [13], 41 [39]  
 50 [56]   31 [16], 40 
[16], 54 [16], 
60 [16], 65 
[16], 97 [16] 
18 [34] 41 [79], 43 [62], 68 
[19], 71 [19], 81 
[17], 18 [17]  
47 [29]  
Last 12 months    9 [25], 15 [25] 30 [26]      21 [77], 18 [74], 23 
[74], 24 [77], 30 
[74], 34 [74]  
  
Last 6 months 5 [68], 6 [68], 19 
[68] 
         7 [21], 8 [61], 
13[18], 13 [61], 13 
[61], 14 [21], 14 
[22], 15 [20], 18 
[22], 27 [18] 27 
[61], 28 [61]     
   
Last month      33 [75] 20 [15]    11 [67], 47 [67] 40 [29]  
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 Afghanistan Bahrain Egypt Iran Jordan Lebanon Libya Morocco Oman OPT Pakistan Syria Tunisia 
Unknown/unspecified           3 [28], 96 [28]    
Sold sex (%)              
Ever    8 [39], 36 [14], 
43 [14], 45 [14] 
 12 [56], 
25 [27] 
       
Last 12 months   26 [38] 18 [14], 22 [14] 
26 [14], 29 [78]  
   18 [30], 
24 [30] 
 8 [34] 5 [74], 11 [74]   
Last 6 months           15 [21], 17 [22], 20 
[18] 
  
Last month    19 [80]          
Unknown/unspecified           9 [66], 14 [61], 19 
[28], 20 [61] 
  
Sold or bought sex (%)              
Ever   51 [2]           
Last 12 months   11 [7], 13 [7]       25 [58]   26 [24] 
Unknown/unspecified        68 [57]      
Have multiple partners (%)              
Lifetime    54 [11], 57 [14], 
59 [14], 62 [14] 
         
Last 12 months   39 [7], 45 [7]  46 [26]   51 [57]  29 [58] 51 [28]  60 [24] 
Last 6 months           18 [33]   
Last month   49 [2]    23 [15]       
Unknown/unspecified    41 [47]          
Overall condom use (%)              
Ever 10 [4],16 [4], 19 
[4],30 [4], 33 [4] 
 41 [2] 24 [51], 24 [25], 
29 [25], 53 [11], 
53 [13], 57 [9] 
 88 [27]  55 [57] 53 [16], 
63[16], 
69[16] 
 14 [19], 16 [79], 18 
[28], 21 [62], 36 
[67], 37 [17], 38 
[19] 
60 [29]  
Last 12 months         24 [30], 
36 [30] 
     
Last 6 months           33 [32]   
Last act 4 [31], 15 [31], 17 
[35],18 [31], 20 
[31], 26 [35], 27 
[31], 32 [35] 
  38 [80] 7 [81]  66 [15]   34 [58]   24 [24], 
34 [23]  
Unknown/unspecified   9 [82] 68 [55]          
Consistent condom use (%)              
Last 12 months   14 [2]      12 [16], 19 
[16], 25 [16] 
  19 [29]  
Last 6 months           7 [32]   
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 Afghanistan Bahrain Egypt Iran Jordan Lebanon Libya Morocco Oman OPT Pakistan Syria Tunisia 
Last month          30 [58]    
Unknown/unspecified           9 [32]   
Condom use with 
commercial sex workers 
(%) 
             
Ever 18 [4], 19 [4], 34 [4], 
39 [4] 
   65 [26]         
Last 12 months   34 [8] 24 [25], 24 [25]          
Last 6 months           7 [61], 49 [61]   
Last month         67 [16], 75 
[16], 75 [16] 
  49 [29]  
Last act       80 [15]   48 [34] 17 [20], 17 [74], 21 
[18], 28 [21], 31 
[22], 32 [74] 
 29 [24], 
37 [23] 
Condom use during anal 
sex with male (%) 
             
Ever 3 [4], 4 [83], 13 [83], 
13 [83] 
            
Last 12 months    0 [25], 33 [25]     0 [16], 40 
[16], 42 [16] 
  0 [29]  
Last act    6 [14], 8 [14], 
15 [14] 
         
Prevalence of:              
Syphilis (%) 0.0 [4], 1.2 [5], 1.2 
[4], 1.9 [35], 2.2 [4], 
3.3 [31], 3.5 [35], 
3.8 [31], 4.0 [31], 
4.0 [31], 6.2 [31], 
6.9 [31], 13.9 [4], 
16.7 [35] 
 3.0 [84] 0.0 [85], 8.0 
[86] 
      1.2 [87], 3.9 [77], 
7.6 [77], 13.1 [67], 
14.0 [88], 16.9 [17], 
18.2 [88]  
   
HSV-2 (%) 4.4 [35], 7.7 [35], 
20.6 [35]  
         6.0 [77], 11.0 [77], 
19.0 [87]  
  
Gonorrhea (%)            0.0 [77], 1.0 [88], 
1.3 [77], 1.8 [88], 
12.8 [87]  
  
Chlamydia (%)           0.0 [77], 0.2 [88], 
0.5 [88], 0.7 [77] 
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 Afghanistan Bahrain Egypt Iran Jordan Lebanon Libya Morocco Oman OPT Pakistan Syria Tunisia 
Self-reported history of 
sexually transmitted 
disease (%) 
  11.0 [82] 7.6 [45], 22.8 
[47] 
      6.8 [20], 10.0 [17], 
10.4 [18], 11.4 [22], 
12.1 [79], 18.8 [17], 
23.0 [89], 54.1 [19], 
65.9 [19]  
   
OPT: Occupied Palestinian Territories. NB: The denominator in some studies corresponds to sexual active PWID while in other studies the denominator corresponds to the total sample of PWID in the study. 
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Table S7. HIV/AIDS knowledge, perception of risk, and HIV testing among people who inject drugs in the Middle East and North Africa 
 Afghanistan Egypt Iran  Jordan Lebanon Morocco Oman OPT Pakistan Syria Tunisia 
Ever heard of HIV/AIDS 
(%) 
43 [1], 83 [2], 
97 [2], 98 [2], 
100 [3], 100 [3], 
100 [3], 100 [3], 
100 [3] 
9 [4], 96 [5], 99 
[6], 100 [6] 
73 [7], 82 [8], 93 [9], 
94 [9], 96 [9], 100 [10] 
     29 [11], 52 [12], 54 [13], 
59 [14], 65 [15], 66 [16], 
67 [17], 72 [18], 74 [19], 
82 [20], 86 [20], 87 [21], 
88 [16], 89 [22], 93 [23], 
96 [24], 97 [25]  
99 [26] 100 [27], 
100 [28] 
Knowledge of injecting 
drug use as a mode of 
transmission (%) 
51 [1], 81 [2], 
94 [2], 97[2] 
5 [4], 22 [29], 
33 [5], 98 [6], 
98 [6] 
63 [7], 85 [9], 91 [9], 
96 [30], 96 [9], 100 
[31] 
43 [32], 
96 [33] 
97 [34] 54 [35], 
90 [36], 
97 [36] 
 96 [37] 15 [38], 46 [16], 53 [16], 
65 [24], 68 [19], 71 [18], 
72 [23], 77 [17], 80 [15], 
81 [39], 82 [14], 87 [21], 
88 [22] 
47 [26] 80 [27], 
93 [28] 
Knowledge of sex as a 
mode of transmission 
(%) 
78 [40]  88 [5]   65 [32]  80 [35]   19 [38], 41 [39], 41 [16], 
42 [16], 50 [24], 72 [19], 
72 [23], 82 [22], 84 [21], 
91 [17]  
94 [26]  
Self-perception of risk 
(%) 
 20 [5], 29 [41] 43 [9], 47 [9], 54 [9]  45 [42], 
50 [34] 
69 [35]  73 [37]  13 [16], 30 [24], 31 [19], 
33 [16], 34 [17], 58 [18], 
63 [25], 64 [21] 
27 [26] 63 [27] 
Ever tested for HIV (%) 3 [3], 13 [3], 16 
[3], 24 [2], 24 
[2], 33[2], 58 
[3], 60 [3] 
1 [5], 6 [43], 10 
[6], 10 [6] 
28 [44], 29 [8], 39 [9], 
44 [31], 45 [10], 45 [9], 
47 [45], 47 [46], 48 [9], 
60 [30], 66 [47] 
15 [32] 
27 [33] 
61 [34], 
80 [42] 
13 [35], 
33 [36], 
48 [36] 
73 [48], 
94 [48], 
97 [48] 
66 [37] 2 [12], 6 [19], 21 [22], 25 
[21], 55 [25] 
36 [26] 29 [27], 
30 [28] 
OPT: Occupied Palestinian Territories 
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8.2. APPENDIX B – RESEARCH PAPER 2 SUPPLEMENTARY ONLINE MATERIAL  
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Additional file 2. Models assumptions in terms of parameter values 
Additional file 3. Trend of HIV prevalence among PWID in Iran as described by available 
HIV point-prevalence measures 1990-2013 
Additional file 4. Effect of stochasticity (purple) and of behavioural (blue) and biological 
(red) uncertainty on the modeling predictions of the endemic HIV 
prevalence, /HCV HIVRR  and /HCV HIVOR  at 59.4% HCV prevalence in Iran 
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Additional file 1 
Mathematical models description 
 
1. HIV model structure  
We developed a deterministic/stochastic compartmental mathematical model that describes 
the parenteral transmission of HIV through sharing unsterile needles/syringes among people 
who inject drugs (PWID) (Figure 1). Other methods of HIV transmission (e.g. sexual) are not 
considered in the model. The model stratifies the PWID population into compartments 
according to HIV status, stage of HIV infection, and level of injecting risk behavior.  
 
 
Figure S1. HIV model structure 
 
The model was solved both deterministically and stochastically. The deterministic version of the 
model was expressed with the below system of coupled nonlinear differential equations for 
each risk group. For the stochastic version, we used the same transition rates in this 
deterministic system of equations to generate the stochastic process.  
0, ( )     
i
i i ii
dS
N S S
dt
       (1) 
,1
,1 1 ,1( )     
i
i i i i
dI
S I I
dt
       (2) 
,2
1 ,1 ,2 2 ,2( )    
i
i i i
dI
I I I
dt
       (3)   
,3
2 ,2 ,3 3 ,3( )    
i
i i i
dI
I I I
dt
       (4)  
 
To accommodate heterogeneity of injecting risk behavior, we stratified the population into 7 
injecting risk groups, defined with the index i  ( 1,2,...,7i  representing the low to high risk 
groups). Here iS  
is the HIV susceptible population in the i –risk group, and ,iI  
is the HIV 
infected population in the i –risk group. The index   marks the stage of HIV pathogenesis; 
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1,2,3   represent the acute, latent, and advanced stages, respectively. 0,iN is the initial 
population size of each i -risk group.  is the natural mortality rate, and   is the leaving 
injecting career rate. The rate of progression from one HIV stage to the next is described by 1  
and 2 , while 3  
is the rate of HIV/AIDS disease mortality. The rate  i  is the HIV force of 
infection (incidence rate of infection) experienced by the iS  susceptible population.  is given 
by: 
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where 
iP
describes the effective new partner acquisition rate for any population variable iP   (
iS or iI )  (note further discussion in section 3.2 below). 
 
The parameter 
, j iI S
t  defines the HIV transmission probability per partnership between a 
member of the susceptible population  and a member of the HIV infected population : 
  ,
, ,
1 1

 

   
I Sj i
j i j i
n
HIV
I S I St p        (6)  
It is expressed in terms of HIV transmission probability per needle/syringe sharing act per HIV 
stage in this partnership (
, j i
HIV
I Sp ) and the number of needle/syringe sharing acts per 
partnership (
, j iI S
n ). 
 
The mixing among the different risk groups is dictated by the injecting-mixing matrix ,i jG . This 
matrix provides the probability that an individual in risk group i  would choose a partner in risk 
group j . It is given by: 
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Here, ,i j  is the identity matrix and the parameter  0,1e  measures the degree of 
assortativeness in the mixing. At the extreme 0e , the mixing is proportionate (choosing 
partners with no preferential bias based on the kind of risk group) while at the other extreme 
i
iS ,jI 
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1e , the mixing is fully assortative as individuals choose partners only from within their own 
risk group [1].  
 
2. HCV Model structure  
We developed a deterministic/stochastic compartmental mathematical model that describes 
the parenteral transmission of HCV through sharing unsterile needles/syringes among PWID 
(Figure 2). The model is similar in structure to the HIV model described above, and also stratifies 
the PWID population into compartments according to HCV status and stage of infection, and 
level of injecting risk behavior.  
 
Figure S2. HCV model structure 
 
The model was solved both deterministically and stochastically. The deterministic version of the 
model was expressed in terms of a system of coupled nonlinear differential equations for each 
risk group:   
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The index i  defines the seven injecting risk groups, ( 1,2,...,7i  representing the low to high 
risk groups). Here 1iX  
is the HCV susceptible population in the i –risk group, and ,iY  
is the HCV 
infected population in the i –risk group. The index   marks the stage of HCV pathogenesis; 
1,2,3    represent the acute, chronic, and secondary acute stages, respectively. 2iX  
is the 
population, in the i –risk group, that was previously exposed to HCV infection but cleared it and 
is now susceptible for HCV reinfection. 0,iN  is the initial population size of each i -risk group.   
is the natural mortality rate, and ƞ is the leaving injecting career rate.  The rates of progression 
from primary and secondary acute HCV infections are 1  and 2 , respectively. 1  is the 
percentage of primary HCV infections that clear,
 
and 2  the percentage of HCV reinfections 
that clear.  
 
The rate 1
iX
 is the HCV force of infection experienced by the 1iX  
susceptible population and is 
given by: 
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We assume here that the susceptible population 2iX  
experiences the same force of infection as 
the 1iX  
 population (no acquired immunity): 
2 1 
i iX X
         (14) 
 
iP
 describes the effective new partner acquisition rate for any population variable iP  ( iX or iY
)  (note further discussion in section 3.2 below). 
 
The parameter 1
, j iY X
R  defines the HCV transmission probability per partnership between a 
member of the susceptible population 1iX  and a member of the HCV infected population ,iY : 
 
1
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1 1
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1 1
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 
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 
  
Y Xj i
j i j i
n
HCV
Y X Y X
R p        (15)  
It is expressed in terms of HCV transmission probability per needle/syringe sharing act per HCV 
stage in this partnership 1
, j i
HCV
Y X
p  and the number of needle/syringe sharing acts per partnership 
( 1
, j iY X
n ), 
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The mixing among the different risk groups is dictated by the mixing matrix ,i jH . This matrix 
provides the probability that an individual in risk group i  would choose a partner in risk group 
j . It is given by: 
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Here, ,i j  is the identity matrix and the parameter  0,1e  measures the degree of 
assortativeness in the mixing. At the extreme 0e , the mixing is proportionate while at the 
other extreme 1e , the mixing is fully assortative [1].  
 
3. Injecting risk behavior 
3.1. Distribution of injecting risk behavior in the population 
The PWID population was stratified into a number of risk groups. In the absence of direct 
empirical data to inform on the exact distribution of injecting risk behavior in a given PWID 
population, we assumed that the proportion of the PWID population initially in each risk group 
i   follows a gamma distribution. This assumption was informed by previous theoretical work [2-
5] and mathematical modeling of HIV sexual transmission [6, 7], and accommodates wider 
flexibility [4]. The gamma distribution of the population size across the risk groups is given by: 
11( )
( )



i
a b
a
p i i e
b a
 (17)  
Here a  is the shape parameter determined through normalization of the distribution, and b  is 
the scale parameter in the gamma distribution.   
 
3.2. The effective new injecting partner acquisition rate 
The 
iP
 parameter describes the number of new injecting partners an individual in a specified 
risk group acquires, but also effectively other factors that enhance the risk of exposure to the 
infection such as concurrency and clustering within injecting networks, and variability in 
injecting risk behavior in the population. Since the exact nature of injecting behavior and 
injecting networks is not well-understood and varies within and across communities, 
iP  
is 
effectively a summary measure of the population-specific level of injecting risk behavior, and 
captures the distribution and strength of the risk of exposure to HIV (or HCV) infection. The 
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form of the 
iP  
distribution across different risk groups was defined through a power law 
function as: 
  
iP
Ci          (18) 
where   is the exponent in the power-law function and C   is an overall constant.   
This form is motivated by simulations using an individual-based network model developed to 
explore the diversity of risk in risk networks [8], and also by analyses of the architecture of 
complex weighted networks [9, 10], and by an analysis of the average separation between 
individuals in a network or a sub-network [11, 12]. The latter can be seen as a proxy of the size 
of the “ecology” through which an individual can acquire an infection. Here C is a constant 
determined by the average risk behavior and 
 
is the exponent parameter that determines the 
level of variability in the effective new injecting partner acquisition rate [8].  
 
4. Parameter values  
The parameters of the model were derived using current empirical data on HIV/HCV 
epidemiology and natural history, and are listed in Table S1 along with their references.  
 
We assumed that the transmission probability of HIV per sharing needle/syringe is 10 times 
higher than the probability of transmission per coital act in each HIV stage [13]. The latter were 
based on recent re-analyses of the Rakai Study data [14-17].  The durations of the acute, latent, 
and advanced stages of HIV infection were assumed to be 49 days, 9 years, and 2 years, 
respectively. These choices were based on compilation of data by UNAIDS indicating that the 
average duration from HIV acquisition to death, in absence of antiretroviral therapy, is about 11 
years [18], and based on the classification in Wawer et al. [17], re-analysis of the Rakai data for 
acute infection [14], and measured time from seroconversion to death in several cohort studies 
[19, 20].  
 
The transmission probability of HCV in the chronic stage was calculated based on the 
transmission probability of HIV in the latent stage [14-17]. Based on model fitting to empirical 
data (please see main text), we found HCV transmission probability in the chronic stage to be 
7.8 times greater than that of HIV. HCV transmission probability in the primary acute infection 
was estimated earlier at 2.7 times HCV transmission probability in the chronic stage [21]. We 
also assumed that HCV transmission probability in the secondary acute stage is half of that in 
the primary acute stage, based on the 50% reduction in viral load following reinfection 
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compared to primary infection, as estimated in a cohort study by Obsurn et al. [22]. The 
durations of primary and secondary HCV acute stages were assumed to be 16.5 weeks and 4.1 
weeks, respectively, based on direct measurement in recent prospective cohort studies [22, 23]. 
The percentage of primary HCV infections and HCV reinfections that clear were assumed to be 
25% and 83%, respectively, based on cohort studies data [22, 23].  
  
As for the parameters of injecting risk behavior, the degree of assortativeness ( e ) was fixed at 
0.3; a representative value informed by earlier modeling work on HIV [16]. Meanwhile, the 
scale ( b ), and shape ( a ) parameters (in the gamma distribution of the population across the 
different risk groups) were fixed at 0.5 and 0.28, respectively, based on our model fitting to a 
statistical model summarizing the HCV/HIV empirical data [24]. The exponent parameter in the 
power law function of the distribution of injecting risk behavior ( ) was fixed at 2.0, based also 
on our model fitting to HCV/HIV empirical data [24]. The duration of the injecting career was 
assumed to be 10 years as informed by empirical data [13].  
 
5. Effect of ART - sensitivity analysis  
We assessed the sensitivity of the HCV thresholds for HIV epidemic expansion to antiretroviral 
therapy (ART) scale up. We assumed that the efficacy of ART in reducing HIV transmission 
among PWID is 100%, based on clinical trials of treatment for prevention and other 
observational data [25, 26]. Accordingly, the probability of HIV transmission per needle/syringe 
sharing act (
, j i
HIV
I S
p ) in a population with ART coverage of   among those eligible for treatment 
is reduced by a factor of (1 ) . We assumed that with ART scale up, all infected PWID in the 
advanced stage and half of those in the latent stage would be eligible for ART treatment, which 
corresponds roughly to an eligibility treatment criteria of CD4 cell count < 500 cells/μl [27].  
 
We also assumed that ART slows disease progression from onset of infection to death. The 
average duration of latent infection in the HIV infected population up to treatment initiation 
was assumed to be 4.5 4.5(1 ) years . The average duration from treatment initiation to 
death was assumed to be 2 15.5years . Accordingly, 100% coverage among those eligible will 
double the average duration from onset of infection to death in the HIV infected population 
from 11 years to 22 years.  
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Additional file 2 
 
Table S1. Models assumptions in terms of parameter values 
Parameter Symbol Value Range of 
values* 
Reference 
HIV Biological parameters     
HIV Infectiousness ratio for 
injecting/sexual transmission  
R   10 N/A [1] 
Probability of transmission per 
shared injection in each HIV stage: 
    
Acute  
,1j i
HIV
I Sp  R 0.03604 = 0.360   N/A Calculation using R  
and reference [2] 
Latent  
,2 j i
HIV
I Sp  R 0.0008 = 0.008  N/A Calculation using R  
and reference [2] 
Advanced  
,3j i
HIV
I Sp  R 0.0042 = 0.042  N/A Calculation using R  
and reference [2] 
Duration of each HIV stage:     
Acute  
11/   49 days N/A [3-8] 
Latent  
21/   9 years N/A [3-8] 
Advanced  
31/   2 years N/A [3-8] 
HCV Biological parameters     
Infectiousness ratio of HCV to HIV F   7.8 1-15 Model fitting 
Probability of transmission per 
shared injection in each HCV stage: 
    
Acute  
,1j i
HCV
Y Sp  ,2j i
HCV
Y Sp2.7 × = 0.168  N/A [1] 
Chronic 
,2 j i
HCV
Y Sp  ,2 j
HIV
IF P = 0.062  N/A Calculation using F   
Secondary acute  
,3j i
HCV
Y Sp  ,1j i
HCV
Y Sp0.5 × = 0.084  N/A [9] 
Duration of each HCV stage:     
Acute  
11/   16.5 weeks N/A [10] 
Secondary acute  
21/   4.1 weeks N/A [9] 
Proportion of virus clearance 
among: 
    
Primary HCV infections  
1   25% N/A [10] 
HCV reinfections  
2  83% N/A [9] 
Behavioral and demographic parameters    
Death rate       1 / 70 years = 0.014   N/A [11] 
Duration of injection career     10 years N/A [1] 
Degree of assortative mixing  e   0.3 0-1 [1] 
Scale parameter in the gamma 
distribution of the population across 
risk groups 
b   0.5 0.4-0.6 Model fitting 
Shape parameter in the gamma 
distribution of the population across 
risk groups  
a   0.28 0.05-
0.45 
Model fitting 
Exponent parameter in the power 
law function of the risk behavior 
distribution  
   2.0 1.0-2.6 Model fitting 
Number of sharing acts per 
partnership 
, j iI S
n  50 N/A Representative 
value 
* In the sensitivity analyses  
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8.3. APPENDIX C – RESEARCH PAPER 3 SUPPLEMENTARY ONLINE MATERIAL 
 
Outline 
 
Table S1. HIV epidemic states among people who inject drugs in select Middle 
East and North Africa countries with sufficient data to explore the 
HCV-HIV association 
Table S2. Summary of the 54 paired HCV-HIV prevalence data among people 
who inject drugs in the Middle East and North Africa 
Figure S1. Forest plot for the meta-analysis of the risk ratio of HCV to HIV 
prevalence among people who inject drugs in Middle East and North 
Africa settings of low-level HIV epidemics 
Figure S2. Forest plot for the meta-analysis of the risk ratio of HCV to HIV 
prevalence among people who inject drugs in Middle East and North 
Africa settings of emerging HIV epidemics 
Figure S1. Forest plot for the meta-analysis of the risk ratio of HCV to HIV 
prevalence among people who inject drugs in Middle East and North 
Africa settings of established HIV epidemics 
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Table S1 
 
 
Table S1. HIV epidemic states among people who inject drugs in select Middle East and North 
Africa countries with sufficient data to explore the HCV-HIV association*  
 Low level Emerging  Established 
Afghanistan Before 2009 2009 and after NA 
Iran Before 2001 2001-2006 After 2006 
Morocco Before 2008 2008 and after NA 
Pakistan Before 2004 2004 and after NA 
Tunisia All N/A N/A 
*Based on findings by Mumtaz et al, 2014 [1] 
N/A: Not applicable 
 
 
 
Reference of Table S1 
 
1. Mumtaz GR, Weiss HA, Thomas SL, Riome S, Setayesh H, Riedner G, et al. HIV among 
people who inject drugs in the Middle East and North Africa: systematic review and 
data synthesis. PLoS Med 2014,11:e1001663. 
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Table S2 
 
Table S2. Summary of the 54 paired HCV-HIV prevalence data among people who inject drugs in the Middle East and North Africa  
Country Year City Sampling Site HIV epidemic state Sample size HCV HIV 
Afghanistan [1]  2005-6 Kabul Convenience sampling Voluntary counseling and testing Low level 463 36.7% 3.0% 
Afghanistan [2] 2006-8 Herat Convenience sampling Voluntary counseling and testing Low level 340 49.1% 3.2% 
Afghanistan [3] 2007-9 Kabul Targeted sampling Mixed Low level 483 36.0% 2.1% 
Afghanistan [4] 2009 Herat Respondent driven sampling N/A Emerging 159 57.9% 18.2% 
Afghanistan [4] 2009 Kabul Respondent driven sampling N/A Low level 286 37.1% 3.1% 
Afghanistan [4] 2009 Mazar-i-Sharif Respondent driven sampling N/A Low level 102 25.5% 1.0% 
Afghanistan [5] 2012 Herat Respondent driven sampling N/A Emerging 185 70.8% 15.7% 
Afghanistan [5] 2012 Jalalabad Respondent driven sampling N/A Low level 236 15.3% 2.5% 
Afghanistan [5] 2012 Kabul Respondent driven sampling N/A Low level 369 27.6% 2.4% 
Afghanistan [5] 2012 Mazar-i-Sharif Respondent driven sampling N/A Low level 254 23.6% 2.4% 
Afghanistan [5] 2012 Charikar Respondent driven sampling N/A Low level 117 28.2% 0.9% 
Iran [6] 1998 Shiraz Convenience sampling Voluntary drug treatment center Low level 464 80.2% 1.3% 
Iran [7] 2001-2 Tehran Convenience sampling Voluntary drug treatment center Emerging 90 36.4% 7.8% 
Iran [7] 2001-2 Tehran Simple random sampling Prison Emerging 371 80.6% 17.0% 
Iran [8] 2001-2 Mashhad Convenience sampling Prison Emerging 101 59.4% 6.9% 
Iran [9] 2002 Hormozgan Simple random sampling Prison Emerging 249 65.5% 15.3% 
Iran [10] 2002 Tehran Convenience sampling Voluntary drug treatment center Emerging 34 64.7% 8.8% 
Iran [11] 2002 Hamadan Simple random sampling Prison Emerging 149 31.5% 0.7% 
Iran [12] 2002-3 Gorgan Simple random sampling Prison Emerging 22 95.5% 18.2% 
Iran [13] 2000-5 Zahedan Convenience sampling Clinical setting Emerging 31 22.6% 25.8% 
Iran [14] 2003 Rafsanjan Convenience sampling Clinical setting Emerging 31 16.1% 9.7% 
Iran [14] 2003 mix of cities Convenience sampling Prison Emerging 401 76.8% 14.0% 
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Country Year City Sampling Site HIV epidemic state Sample size HCV HIV 
Iran [15] 2001-6 Kashan Convenience sampling Clinical setting Emerging 177 11.9% 1.7% 
Iran [16] 2001-6 Ahfaz Convenience sampling Clinical setting Emerging 142 52.1% 12.7% 
Iran [17] 2002-6 Ahfaz Convenience sampling Clinical setting Emerging 333 30.9% 18.0% 
Iran [18] 2004 Shahr-e-Kord Convenience sampling Voluntary drug treatment center Emerging 133 11.3% 0.8% 
Iran [19] 2004 Tehran Convenience sampling Mixed Emerging 202 52.0% 23.8% 
Iran [20] 2006 Tehran Convenience sampling Mandatory drug treatment center Established 454 80.0% 24.7% 
Iran [21] 2006 mix of cities Random cluster sampling National Established 936 43.4% 20.5% 
Iran [22] 2006-7 Tehran Convenience sampling Mixed Established 38 44.4% 10.5% 
Iran [22] 2006-7 Tehran Convenience sampling Mixed Established 861 34.1% 10.7% 
Iran [23] 2007 Tehran Convenience sampling Clinical setting Established 70 35.7% 30.0% 
Iran [24] 2008 Tehran Convenience sampling Mandatory drug treatment center Established 258 65.1% 19.4% 
Iran [25] 2007-9 Sari Convenience sampling Clinical setting Established 88 37.5% 18.2% 
Iran [26] 2008 Foulad-Shahr Respondent driven sampling N/A Emerging 117 60.7% 1.7% 
Iran [27] 2008- Isfahan Convenience sampling Harm reduction center Low level 531 47.1% 1.1% 
Iran [28] 2008-9 Isfahan Convenience sampling Prison Low level 943 41.6% 6.6% 
Iran [29] 2009-10 mix of cities Convenience sampling  Established 158 42.4% 10.1% 
Iran [30] 2010 mix of cities Convenience sampling Harm reduction center Established 42 35.7% 7.1% 
Iran [30] 2010 mix of cities Convenience sampling Harm reduction center Established 226 38.1% 9.3% 
Iran [31] 2010 Shiraz Convenience sampling Voluntary drug treatment center Established 144 50.0% 41.7% 
Iran [32] 2012-3 Shiraz Convenience sampling Voluntary drug treatment center Established 233 40.3% 7.7% 
Morocco [33] 2010-1 Tanger Respondent driven sampling N/A Low level 261 42.1% 0.4% 
Morocco [33] 2011-2 Nador Respondent driven sampling N/A Emerging 277 73.0% 22.0% 
Pakistan [34] 2002 mix of cities Convenience sampling Mixed Low level 500 42.0% 3.4% 
Pakistan [35] 2003 Quetta Convenience sampling Voluntary drug treatment center Low level 300 44.7% 0.3% 
Pakistan [36] 2003 Karachi Convenience sampling Harm reduction center Low level 161 93.8% 0.6% 
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Country Year City Sampling Site HIV epidemic state Sample size HCV HIV 
Pakistan [37] 2004 Karachi Time location sampling Community Emerging 402 87.0% 23.1% 
Pakistan [37] 2004 Lahore Time location sampling Community Low level 397 91.8% 0.5% 
Pakistan [38] 2004 Quetta Convenience sampling Community Emerging 50 60.0% 24.0% 
Pakistan [39] 2007 Karachi Convenience sampling Clinical setting Emerging 42 45.2% 19.0% 
Pakistan [40] 2007 Rawalpindi Respondent driven sampling N/A Low level 302 17.2% 2.6% 
Tunisia [41] 2009 mix of cities Respondent driven sampling N/A Low level 715 29.1% 3.1% 
Tunisia [42] 2011 Tunis Respondent driven sampling N/A Low level 506 32.8% 4.7% 
N/A: Not applicable  
Note 1: In studies using respondent driven sampling, unadjusted sample estimates of HIV and HCV prevalence are displayed 
Note 2: The sample size displayed refers to the total number of PWID tested for HIV. In some studies, the sample size used for HCV testing might vary slightly.  
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Figure S2 
 
  
Research paper 3 supplementary online material 
 
254 
 
 
Figure S3 
Research paper 4 supplementary online material 
 
255 
 
 
8.4. APPENDIX D – RESEARCH PAPER 4 SUPPLEMENTARY ONLINE MATERIAL 
 
Outline 
 
Additional file 1. Mathematical models description and other analyses 
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Additional file 1 
Description of mathematical model and other analyses  
 
A. Original Kwon et al model  
 
Below is the derivation of the original model developed by Kwon et al [1], which we used and 
further adapted for estimating HIV incidence among people who inject drugs (PWID) in the 
Middle East and North Africa (MENA). The model is a static mathematical model of HIV 
transmission among PWID who share needles/syringes. The model assumes that sharing of 
needles/syringes occurs in sharing groups of specific average size, where PWID share 
needles/syringes in a random order, and where each PWID injects once per sharing event.  
  
Table 1. Parameters used in the original Kwon et al model [1] 
Parameter Description 
N  Total number of PWID 
m  Average number of PWID in a sharing group 
n  Average number of injections per PWID per year 
s  Proportion of PWID who share injections 
0q  Proportion of the injections that are shared 
r  Number of PWID infected in the sharing group 
0p  HIV prevalence among PWID  
  Probability of transmission from a contaminated needle/syringe 
 c  Effectiveness of needle/syringe cleaning 
cP  Proportion of shared injections that are cleaned 
 s  Average number of times a shared needle/syringe is used before disposal 
 
The following series of equations describe the Kwon et al model: 
 
 Total number of shared injections per year:  
S Nnsq  
 Average number of sharing events per year:  

Nnsq
SE
m
 
 Total number of transmissions per year for all PWID (incidence): 
*I SE T  
where T  is the average number of transmissions per sharing event 
 
Deriving T, the average number of transmissions per sharing event:  
Research paper 4 supplementary online material 
 
257 
 
 
 
 Probability of having r  infected people in a sharing group of size m  using binomial theory: 
 
 r/ 0 0 0 0
!
P (1 ) (1 )
! !
    

m r m r r m r
m r
m
p p p p
r m r
 
 Average number of uninfected who will inject before the first infected in a sharing event: 
 
1



b
m r
U
r
 
 Average number of uninfected who will inject after an infected person in a sharing event: 
2
1

   

a b
mr r
U m r U
r
 
 Average number of needles/syringes used per sharing event: 


s
m
Sy  
 Average number of uninfected who will use the same needle/syringe after an infected 
person in a sharing event: 
2
1

 

a s
s
U mr r
U
Sy r m
 
 Probability of transmission per shared injection: 
(1 ) (1 ) (1 )          c c c c c cp p p  
 Number of transmissions in the sharing group (per sharing event): 
 
21 1
r/ 0 0
1 1
P * (1 )* (1 )
1

  
 

 

   

 
m m
m r m rs
s c m c c r
r r
mr r
T U p p p
r m
  
 
21
0 0
1
(1 )
(1 )
1
    

 
 


m
m r m rs c c
r
r
p mr r
T p p
m r
  
 Total number of transmissions per year for all PWID (incidence): 
*I SE T  
 
21
0 02
1
(1 )
(1 )
1
    

 
 


m
m r m rs c c
r
r
Nnsq p mr r
I p p
m r
  
 Incidence rate:  
0(1 )
 

I
N p
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B. Modifications to the original Kwon et al model  
 
We further adapted the above model by Kwon et al [1] using the following extensions: 
 
1) Antiretroviral therapy (ART) 
 
We adjusted for the use of antiretroviral therapy (ART) on HIV incidence by incorporating ART 
effect into the transmission probability per shared injection/coital act: 
 
' (1 )  ART   
Where: 
' = ART-adjusted transmission probability per unprotected exposure  
 = Original/unadjusted (for ART) transmission probability per unprotected exposure 
 = Reduction in HIV transmission per exposure due to ART 
ART = Proportion of the population on ART (ART coverage) 
 
2) Heterogeneity in risk behavior 
 
The original Kwon et al model [1] uses a fixed level of injecting risk behavior for all PWID. To 
account for heterogeneity in risk behavior, we accommodated different sizes of the sharing 
group m . Specifically, we assumed that m  follows a gamma distribution with a mean equal to 
averagem . The gamma distribution is right skewed, and therefore assumes that the majority of the 
PWID population shares injections in smaller groups whereas a small fraction shares in larger 
groups (such as at shooting galleries). Therefore m  is gamma distributed with shape ( )k  and 
scale ( )  parameters:  
11( )
( )





m
k
k
P m m e
m
  
In absence of clear data to parameterize the variability in injecting risk behavior in a given PWID 
population, the structure of the model was informed by data on the variability in sexual risk 
behavior and networking, where we assumed that the variance of the gamma distribution is 
equal to its mean [2].  Accordingly, the scale parameter 1   and the shape parameter 
 averagek m .  
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averagem  was estimated using a deterministic compartmental model [3] to fit the trend in HIV 
prevalence in two countries with sufficient available trend data (Pakistan and Iran), and then 
using the estimated incidence rate and the present adapted Kwon et al model to predict using 
fitting the value of the sharing group size in our model. The fitting was implemented by 
minimizing the residual sum of squares between all data points and model predictions [4]. 
Based on the fitting, a value of 2averagem  was found for Pakistan and of 3averagem  for Iran.   
 
In the remaining countries, we did not have sufficient data to inform a country-specific 
estimation of averagem . Based on the range of 2-3 obtained for Iran and Pakistan, and as 
informed by epidemiological data from Iran [5, 6], we used a value of 3averagem  in the 
remaining countries.  
  
3) Needle/Syringe reuse  
In the original Kwon et al model [1], the number of times a needle/syringe is reused before 
disposal ( s ) is fixed and is independent of the size of the sharing group m . Since the model 
also assumes a fixed total number of injections in the population, fixing  s  will constrain the 
transmission system after a certain value of m  leading to smaller HIV incidence with larger 
sharing groups. This was a fair assumption in the study setting of Australia where there are 
effective needle and syringe exchange programs (NSPs) leading to less needle/syringe reuse, 
where the size of the sharing group is small ( 2m  ), and where HIV incidence among PWID is 
low [1].  
 
In the MENA context of emerging HIV epidemics among PWID [7], high levels of needle/syringe 
reuse, and weak interventions including NSPs among PWIDs, we have modified the above 
assumption by relating the number of times a needle/syringe is reused before disposal ( s ) to 
the size of the sharing group ( m ). We assumed that if 10m  , then 10 s ; that is all the 
PWID in the sharing group will use the same needle/syringe. If 10m , then  s m ; that is a 
needle/syringe is reused for a maximum of ten times in any sharing event.  
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C. Additional analyses  
 
1) Estimating HIV prevalence at endemic equilibrium 
 
To estimate HIV prevalence at endemic equilibrium ( eP ) using the estimated HIV incidence rate, 
the following generic model was used: 
  
The above deterministic compartmental mathematical model describes the parenteral 
transmission of HIV through sharing unsterile needles/syringes among PWID. Individuals 
become PWID, and hence enter into the PWID population, at a rate b . .  . is the natural 
mortality rate,   is the leaving injecting career rate, and   is the HIV/AIDS disease mortality 
rate.  is the incidence rate (or force of infection) experienced by the susceptible population S
. The model is expressed with the below system of coupled differential equations: 
 
dS
b S S S
dt
           
dI
S I I I
dt
            
 
At endemic equilibrium: 
0
dI
dt
 , and hence eP

   

  
  
 
  
 
Susceptible 
 
 
Infected 
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2) Past exposures in PWID 
 
To estimate the total number of HIV infections that occurred in PWID since the start of the HIV 
epidemic among PWID, we retraced the course of the HIV epidemic among PWID at country-
level starting from epidemic emergence. The year of epidemic emergence was informed by 
epidemiological data from each country [7]. We ran, in each country, the model x  number of 
times, where x  is the number of years since HIV epidemic emergence. We assumed that at year 
0, HIV prevalence is 1% (
0
0.01yp  ). 
 
The total number of infected PWID in year 1 includes both prevalent infections from the 
previous year and incident infections in this year, and is given by: 
1 1 0y y y
Inf Incident prevalent    
1 1 0y y y
Inf I Np    
 
Assuming that the incident infections occur in the middle of the year, the number of HIV 
infected PWID who will leave the PWID population in year 1 due to leaving injection (  ), 
natural mortality (  ), or disease mortality ( ) is given by: 
1
0
1
( ) ( )
2
yy
out y
I
n Np          
 
Therefore, HIV prevalence at the end of year 1 will be given by: 
1
1
1
y
y out
y
Inf n
p
N

  (Note: we assume a fixed total PWID population size ‘ N ’) 
 
The model is then run for year 2 starting with HIV prevalence 
1y
p . The same calculations and 
processes are repeated x  times.  
 
It bears notice that the number of HIV infected PWID who will leave the PWID population in 
year 1 due only to leaving injection is given by: 
 1
0
1
( )
2
yy
past y
I
n Np     
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Accordingly, the number of HIV infected PWID who left the PWID population due to leaving 
injection in each subsequent year is calculated the same way.  
 
Iterating this process until the last (current) year will provide an estimate for HIV prevalence in 
the last year. However, in the runs for countries, we were not often able to reach observed HIV 
prevalence, with the last year estimated prevalence being lower than observed prevalence. We 
therefore increased the level of risk behavior at year 0, to account for higher risk behavior in 
earlier years of the epidemic, and used linear interpolation for the level of injecting risk 
behavior from year 0 to the last year, in order to reach observed levels of risk behavior and HIV 
prevalence at the last (current) year.   
 
In Libya, the measured HIV prevalence (87% [8]) was not consistent with reported levels of 
current risk behavior. With such levels of risk behavior, the maximum current HIV prevalence 
the model could reach was 52%; and hence, estimations of past exposures were not possible in 
Libya.   
 
3) HIV incidence in PWID sexual partners  
 
In a sero-discordant partnership where the PWID is HIV-infected and the sexual partner 
(opposite sex; only heterosexual transmission was considered) is seronegative, the probability 
of HIV transmission after one year is given by: 
(1 )1 (1 )y csz 
     
where: 
s = HIV transmission probability per unprotected coital act 
y = Number of coital acts per year 
c = Proportion of the coital acts that are protected (condom use at last sex)     
 
The number of sero-discordant partnerships is given by: 
0(1 )disc pn Nvp p    
where: 
N = Total number of PWID  
v  = Proportion of PWID who had a sexual partner in the last year 
0p = HIV prevalence among PWID 
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pp = HIV prevalence among sexual partners of PWID (which was assumed to be equal to one 
third of HIV prevalence among PWID) 
 
HIV incidence among PWID sexual partners is therefore given by: 
fsp discI n z   
(1 )
0 (1 )(1 (1 ) )
y c
fsp p sI Nvp p 
      
 
4) Past exposures in PWID sexual partners  
 
HIV incidence in PWID heterosexual sex partners was calculated for each year since start of the 
HIV PWID epidemic in each MENA country using the year-specific HIV prevalence measures in 
PWID (
xy
P ) as estimated in section C2 above (Past exposures in PWID).  
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